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Tenosynovial Giant Cell Tumour (TGCT) is an orphan, mono-articular disease, arising from 
the synovial lining of joints, bursae or tendon sheaths1, 2. TGCT is divided into a lobulated 
well circumscribed lesion (localized-type) and a more locally aggressive lesion (diffuse-type) 
(figure 1). In general, the disease is considered a benign entity, but the diffuse-type can invade 
surrounding tissues and is regarded as locally invasive1, 2. The best treatment modality for this 
disease is a highly discussed topic. Literature about this disease is scarce. However, the impact 
of the disease can be severe: a deteriorated joint function threatens the quality of life in the 
relatively young patient population3-5. Therefore, it is of upmost importance to gain insight in 
the pathophysiology and severity of the disease to improve treatment strategies. 
Historical vignette
In the 2013 WHO classification, giant cell tumour of the tendon sheath and pigmented villonodular 
synovitis (PVNS) were unified in one overarching name: tenosynovial giant cell tumours (TGCT) 
(table 1)1, 2. Historically, different terms have been used for this entity, including synovial 
xanthoma, xanthogranuloma, synovial fibroendothelioma or endothelioma, xanthomatous 
giant cell tumour of the tendon sheath, myeloplaxoma, chronic haemorrhagic villous synovitis, 
giant cell  fibrohaemangioma, fibrohaemosideric sarcoma, sarcoma fusigiganocellulare, benign 
or malignant polymorphocellular tumour of the synovial membrane, and fibrous xanthoma of 
the synovial membrane6-9.
In 1852, Chassaignac reported a nodular lesion of the synovial membrane affecting the flexor 
tendons of the fingers10. Simon was the first to describe the localized form11 and Moser the 
first to define the diffuse form affecting the knee12. At that time, the disorder was considered a 
malignant condition. Dowd was the first person to question this13. Jaffe elucidated the clinical, 
radiological and pathological characteristics of the yellow-brown tumor-like tenosynovial 
lesions and suggested a reactive or inflammatory origin of the disease as both nodular 
synovitis and pigmented villonodular synovitis (PVNS) showed similar histological features 
and both showed a benign course6. The authors also merged both localized- and diffuse-forms 
to PVNS. However, the condition was considered neoplastic after the discovery of numerical 
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Figure 1  A 65-year-old female patient with a large medical history, consisting of multiple mutilating 
diffuse-type TGCT-related surgeries of her right knee. a. Swollen right knee in bonnet position. On the 
posterior, medial side is TGCT growing outside the operation-scar (arrow-head). b. Sagittal Short-TI 
Inversion Recovery metal clear MR image, revealing extensive tumour growth, also extending superficially 
into the skin (arrow-head). Characteristic TGCT blooming effect is seen attributed to scattered areas of low 
signal intensity, typical for iron deposition. c. Positron emission tomography–computed tomography (PET-
CT): enhancement around total knee replacement, suspect for recurrent TGCT. d. Macroscopic aspect of 
this tumour after surgical removal, including the typical red-brownish colours and villous appearance. This 





and structural chromosomal aberrations14-20. At present, an inflammatory disease component 
remains, as only a small part of TGCT encompassing cells are considered neoplastic or tumour 
cells (2-16%). These neoplastic cells express elevated levels of CSF1, resulting in an increase of 
neoplastic cells by an autocrine-loop as well as the recruitment of multiple non-neoplastic cells 
by a paracrine Ioop. This phenomenon is coined as ‘the landscape effect’21, 22.
aetiology
Chromosomal aberrations, in both localized- and 
diffuse-TGCT, include trisomy for chromosomes 5 
and 7 and translocations involving 1p11-13, most 
commonly partnering with 2q37 emerging in a 
t(1;2)(p13,q37) translocation (figure 2). At the 1p13 
breakpoint, the Colony Stimulating Factor 1 (CSF1) 
gene is located. In both TGCT subtypes, CSF1 is 
fused to the collagen 6A3 (COL6A3) promotor. As 
a result, the fusion leads to deregulated expression 




Figure 2  Systemic partial karyotype showing 
characteristic TGCT translocation t(1;2)(p13;q37). 
Source: CyDAS Online Analysis Site, 
http://www.cydas.org/OnlineAnalysis/
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Figure 3  Etiopathogenesis of 
TGCT, neoplastic cells carrying 
the translocation (t(1;2)
(p13;q37)), express elevated 
levels of CSF1 (red triangles). 
This results in an increase of 
neoplastic cells through an 
autocrine loop. In addition, the 
recruitment of inflammatory cells 
of the monocyte/macrophage 
lineage expressing the CSF1 
receptor (paracrine loop), results 
in the tumour-landscape effect. 
Source: permission obtained from 
designer drs. D.M. Hoek
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Chapter one
Table 1  Chronological literature overview on acquaintance of Tenosynovial Giant Cell Tumours
Study Jaffe (1941)6 Fletcher (1992)14 Cin (1994)15 West (2006)21 Cupp (2007)22 WHO (2013)1, 2 Panagopoulos (2014)56
Name Pigmented Villonodular 
Synovititis (PVNS)
Tenosynovial Giant Cell 
Tumour (TGCT)
Types Circumscribed form
affected membrane ≥1 yellow-




membrane, covered by villous 
and coarse nodular outgrowths
Localized-type
well circumscribed, small 
(0.5-4 cm) and lobulated 
tumour
Diffuse-type
Large (>5 cm) firm or 
sponge-like tumour, 
typical villous pattern and 
multi-nodular appearance 
with variegated colours
Definition Mono-articular, regarded 




Multinuclear giant cells, 
hemosiderinladen
macrophages and lipophages,
alternate with areas of 
intercellular collagen and hyalin
Mononuclear and 
multinucleated cells, 
both showing high 
levels of CSF1R
Perinuclear CSF1 protein 
expression within 
mononuclear cells in a 
diffuse, punctate pattern
Synovial like mononuclear 
cells, multinucleated 
osteoclast-like giant cells, 
foam cells, siderophages, 
inflammatory cells
Tumourigenesis Inflammatory response, 
unknown to what agent
Numerical changes 
(trisomy) in 







COL6A3 gene) and 
non-neoplastic
Central mechanism 
of tumorigenesis is 
the signaling pathway 




Different parts of individual 
lesions vary widely. A 
considerable number of blood 
vessels and much blood 
pigment
Landscape effect; 
a minority of 
neoplastic cells (CSF1 
overexpression) create 




1: both CSF1 
translocation and high 
expression of CSF1 RNA 
(61%). 
2: no detectable 
translocation, but high 
expression of CSF1 RNA 




fusion gene, indicates 
replacement of 3’-UTR 
of CSF1 in abirritations 
targeting CSF1 gene
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Definite diagnosis of TGCT is established on microscopy.
Macroscopically, localized-TGCT is an encapsulated or pedunculated, small (<5 cm) lesion 
with a white to grey aspect and alternating yellow and brown areas. In contrast, diffuse-TGCT 
involves a large part or all of the synovial lining with either a typical villous pattern (intra-
articular) or a multi-nodular appearance (extra-articular), including a diverse colour pattern, 
varying from white-yellow to brown-red areas. The diffuse-type shows an infiltrative growth 
pattern. Microscopically, both types contain an admixture of mononuclear cells (histiocyte-like 
and larger cells) and multinucleated giant cells, lipid-laden foamy macrophages (also known as 
xanthoma cells), siderophages (macrophages including hemosiderin-depositions), stroma with 
lymphocytic infiltrate and some degree of collagenization (figure 4)1, 2.
Figure 4  Tenosynovial Giant Cell Tumours contain an admixture of mononuclear cells, multinucleated giant 









TGCT affecting small joints, both fingers and toes, usually presents as localized-TGCT. In large 
joints, excluding digits, both localized- and diffuse-TGCT are seen. The diffuse-type mainly 
affects weight-bearing joints, predominantly the knee (75%)1, 2, 4. TGCT incidence is based on one 
single US-county study in 1980, that reported an incidence of 9 and 2 per million person-years 
for localized- (including digits) and diffuse-TGCT, respectively23. Male:female ratio is about 1:1.5 
for both types. The mean age at the time of diagnosis lies between 30 and 50 years1, 2, 4. Typically, 
patients primarily present with pain and swelling of the associated joint (figure 1a). Additional 
symptoms might be limited range of motion, stiffness, instability, giving way and locking 
complaints5. Time to definitive diagnosis is often prolonged, on average 4.4 years, due to these 
unspecific symptoms and the rarity of the disease4, 24, 25. As TGCT is not lethal, overall survival 
is similar to the general population. Diffuse-TGCT frequently becomes a debilitating chronic 
illness; therefore joint function and quality of life should be assessed as disease-outcome3, 5, 26, 27.
radiology
In daily practice, an X-ray imaging of the affected joint is frequently performed as a first line 
imaging. Degenerative changes and effusion may be present but are nonspecific, and could 
also be noticed on computed tomography (CT). Magnetic resonance (MR) imaging is the most 
distinctive imaging technique7, 8, 28-30. MR imaging reveals nodular (localized-type) or villous 
(diffuse-type) proliferation of synovium, including associated joint effusion. On T1- and T2-
weighted fast spin echo and other fluid sensitive sequences, lesions demonstrate predominantly 
intermediate to low signal intensity (dark). After intravenous administration of Gadolinium-
chelate, TGCT shows heterogeneous enhancement. Hemosiderin deposits are frequently seen, 
but occur also in other entities31. This degraded hemoglobin deposits cause local changes in 
susceptibility (‘blooming effect’) on gradient echo sequences, resulting in low signal intensity 
areas that are larger than the anatomical substrate (figure 1b). No substantial change in signal 
intensity is detected when comparing the localized- and diffuse-types7, 28. Differential diagnosis 
based on MR imaging includes hemophilia, synovial hemangioma, rheumatoid pannus, amyloid 




The current standard of care is still surgical resection of the tumour, either arthroscopically 
or with an open resection (figure 5), in order to: 1. reduce pain, stiffness, and joint destruction 
caused by the disease process; 2. improve function; and 3. minimize the risk of recurrence. 
Depending on the extensiveness of the disease, complete resection is frequently impossible, 
especially in diffuse-TGCT. Some reports consider arthroscopic management of TGCT superior to 
open surgery, because of less morbidity and a shorter recovery period32-36. Standard arthroscopy 
of the knee using the anteromedial and anterolateral approaches however, does not allow 
surgical access to all areas where diseased tissue could be present. A systematic review showed 
lower recurrence rates for open synovectomy (average 14%, maximum 67%) compared to 
arthroscopic synovectomy (average 40%, maximum 92%) in diffuse-TGCT37. A randomized 
controlled trial for arthroscopic synovectomy versus open synovectomy or surgical treatment 
versus targeted therapy is not (yet) performed.
Figure 5 (right page)  Example of the surgical technique of an open synovectomy in localized-
TGCT. An 8-year-old boy presented at the outpatient clinic with intermittent complaints of pain and 
swelling of his left knee of more than 12 months. These progressive debilitating symptoms were 
not sufficiently reduced by paracetamol and have led to school absenteeism. In the outpatient 
clinic, swelling was not objectified without limitation in range of motion and palpation was diffusely 
pressure painful. X-ray imaging did not show abnormalities.  a. A sagittal T1-weighted MR imaging 
after intravenous administration of Gadolinium-chelate, revealed a well-circumscribed lesion 
on the posterior knee compartment. The T1-weighted and Proton Density MR scan (not shown 
here) revealed a lesion of low intensity. Despite the young age of the boy, a localized-TGCT was 
suspected. An open resection was planned, because of debilitating symptoms.  b. A small lazy-C-
incision was performed on the posterior, lateral side of the left knee. This approach and surgical 
window was chosen because of the lateral tumour localization. After opening the crural fascia, 
the saphena parva vene, the suralis cutaneous medius nerve, the tibialis nerve and the peroneus 
nerve were identified. Lateral gastrocnemius muscle was partially released, because of lateral 
localization of the tumour, without compromising the neurovascular bundle. c & d. The capsule 
overlying the tumour was partially released.  A yellow-brown tumourous aspect showed and 
could be resected en bloc from the posterior cruciate ligament where it generally pedicles from. 
e. The entire localized-TGCT was excised. f. Minimal invasive techniques can be used to prevent post-
operative complaints such as stiffness. After histological examination, TGCT diagnosis was confirmed.








In patients with extensive and/or recurrent TGCT, other available treatment modalities include 
radiation synovectomy with 90yttrium38, external beam radiation therapy39-41, and cryosurgery42. 
Their therapeutic value has only been assessed in retrospective, mostly single center series and 
their long-term side effects and complications are poorly described.
Discovery of the CSF1-CSF1R pathway in the pathogenesis of the tumour contributed to trials 
with targeted therapy. At present extensive or recurrent diffuse-TGCT is also treated with non-
selective CSF1 inhibitors such as nilotinib and imatinib43, 44; selective CSF1 inhibitors such as 
pexidartinib, emactuzumab, cabrilazimab; or monoclonal antibody such as MSC11045-48. Long-
term efficacy data have not yet been reported with these newer agents. Emactuzumab showed 
an overall response rate of 86% and a rate of disease control of 96%, including a significant 
functional and symptomatic improvement (median follow up 12 months)45. The preliminary 
results for cabiralizumab are consistent, with radiographic response and improvement in 
pain and function in five out of 11 patients (45%)46. Pexidartinib had an overall response rate 
of 52% (all patients had a partial response) and a rate of disease control of 83%. Responses 
were associated with an improved joint function (median duration of response exceeded eight 
months)48.
tgct in animals
TGCT affects both humans and animals. Case-reports of cats, dogs, horses, a European lynx and 
a reticulated giraffe are described49-55. Adequate diagnosis is animals is even more challenging, 
due to its rarity, unspecific symptoms and the absence of a verbal patient history. MR scans 
are infrequently performed. When animals present with debilitating symptoms of this tumour, 
extreme measures as joint amputation or euthanasia are more common. 




Treatment of the often debilitating chronic illness, tenosynovial giant cell tumours (TGCT) of 
large joints, is challenging. This thesis aims to find better treatment modalities for this disease 
by evaluating the pathophysiology, biological behavior, diagnosis and quality of life. Sufficient 
data for evaluation of the rare disease TGCT was established through collaboration with the 
RadboudUMC and additionally with 31 international sarcoma centers.
Foremost, this thesis aims to create awareness for TGCT and to improve medical care. It evaluates 
different aspects of this heterogeneous neoplasm and addresses currently existing lacunas 
concerning disease incidence, histopathologic- and hormonal characteristics, disease severity 
stratification and pediatric disease burden. Moreover, this thesis addresses long-term effects 
of systemic targeted treatment and assessment of health-related quality of life after treatment 
in TGCT patients. Lastly, this thesis presents the largest global individual data study of TGCT for 
both localized- and diffuse-type TGCT.
outline of thesis
In chapter 2 we performed nationwide incidence calculations upon TGCT, since no incidence 
study was reported past 1980. Radiologically and clinically, localized- and diffuse-TGCT are two 
different entities. However, genetically and histopathologically they are identical. Chapter 3 
correlates the biological behaviour of TGCT in the knee at a molecular level.
In the patient-population of localized- and diffuse-TGCT, different disease extent exist. Therefore, 
chapter 4 focuses on the establishment of a TGCT severity classification, sub-classifying both 
localized- and diffuse-type TGCT into two more distinct subtypes. 
The clinical behaviour between TGCT patients differs greatly. In chapter 5 we explore the 
influence of female sex hormones on the experienced TGCT-related symptoms.
Many case-series of TGCT in adults are described, whereas TGCT is only incidentally reported in 
children. Chapter 6 evaluates differences in TGCT presentation between adults and children.
Relatively small and heterogeneous case-series emphasize the importance of a large-scaled study. 
In chapter 7 and chapter 8, an international multicentre study in 31 international sarcoma 
centres is described. This study explores risk factors for TGCT of large joints in 941 localized- and 
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Chapter one
1192 diffuse-type TGCT patients. Results of this study are crucial to the treatment possibilities 
and prognosis of this rare entity. 
Since a decade, targeted therapies are used in TGCT; however long-term results are still lacking. 
In chapter 9, we evaluated the long-term efficacy of imatinib mesylate, a targeted therapy 
blocking the Colony Stimulating Factor 1 (CSF1) receptor, in patients with advanced TGCT.
In a benign disease, not only oncologic outcomes are of interest. Of utmost importance is quality 
of life for patients bearing this chronic disease. Chapter 10 evaluates the quality of life and joint 
function after surgical treatment and chapter 11 assesses the patient perspective on daily life 
with TGCT by crowdsourcing.
To emphasize the impact of a disease considered benign, extreme measures like above knee 
amputation are described in chapter 12 as final treatment for TGCT.
Finally, a summary of this thesis is provided in chapter 13. Conclusions, clinical implications and 
future perspectives for the subject of this thesis are discussed in chapter 14. 
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Tenosynovial Giant Cell Tumours (TGCT) are rare, benign tumours, arising in synovial lining of 
joints, tendon sheaths or bursae. 2 Types are distinguished: localized-, either digits or extremity, 
and diffuse lesions. Current TGCT incidence is based on 1 single US-county study in 1980, with 
an incidence of 9 and 2 per million person-year in localized- (including digits) and diffuse-
TGCT, respectively. We aim to determine nationwide and worldwide incidence rates (IR) in TGCT 
affecting digits, TGCT localized-extremity and TGCT diffuse-type.
Material and methods
Over a 5-year period, the Dutch Pathology Registry (PALGA) identified 4503 pathology reports on 
TGCT. Reports affecting digits were solely used for IR-calculations. Reports affecting extremities, 
were clinically evaluated. Dutch IRs were converted to world population IRs.
Results
2815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type TGCT were identified. 
Dutch IR in digits, localized extremity and diffuse-type was 34 (95% CI 33-35), 11 (95% CI 11-
12) and 5 (95% CI 4-5) per million person-years, respectively. All 3 groups showed a female 
predilection and highest number of new cases in age-category 40-59 years. Knee-joint was 
most often affected: localized-extremity (46%) and diffuse-type (64%), mostly treated with 
open-resection: localized (65%) and diffuse (49%). Reoperation rate due to local recurrence for 
localized-extremity was 9%, diffuse-TGCT 23%.
Interpretation
This first nationwide study and detailed analyses of IRs in TGCT estimated a worldwide IR in 
digits, localized-extremity and diffuse-TGCT of 29, 10 and 4 per million person-years, respectively. 
Recurrence rate in diffuse-type is 2.6 times higher, compared with localized-extremity. TGCT is 




Tenosynovial Giant Cell Tumours (TGCT) are a rare entity, affecting generally young patients 
(below the age of 40 years), with an equal sex distribution. The World Health Organisation (WHO) 
classification of Tumours of Soft Tissue and Bone (2013) distinguishes 2 TGCT-types: localized and 
diffuse lesions1, 13. Microscopically the 2 types show no clear difference. However, on Magnetic 
Resonance Imaging (MRI) discrimination between these types is made2. 
The localized-type was previously  described as Giant Cell Tumour of Tendon Sheath, nodular synovitis 
or localized Pigmented VilloNodular Synovitis (PVNS). The typical macroscopic aspect is a well 
circumscribed, small (among 0.5 to 4 centimetres) usually lobulated lesion, with white to grey, yellow 
and brown mottled areas1. Based on anatomical site of the localized-type tumour, differentiation is 
made into a group affecting digits and a group occurring in and around larger joints3, 4. TGCT affecting 
digits is defined as a localization distal to metacarpal or metatarsal bones; localized TGCT-extremity is 
defined as all sites near joints proximal and including metacarpal- and metatarsal-joints.
In localized-TGCT, most lesions are found in the digits of hand and feet (Figure 1). The majority 
of these lesions arise from the tendon sheath and less frequently from synovial lining of digital 
joints. Common treatment is marginal excision5, 6. A systematic review showed a recurrence rate 
of 15%, after an average follow-up of 37 to 79 months7. Fewer localized TGCT lesions are found 
around larger joints, they originate from synovial lining, tendon sheaths or bursae (Figure 2). The 
preferred treatment of these lesions is marginal excision by an arthroscopic or by open approach5, 
6. A systematic review reported an average recurrence rate of 6% after arthroscopic resection and 
4% after open resection (with variable follow-up)8. 
The diffuse-type TGCT; previously called diffuse Pigmented VilloNodular Synovitis (PVNS) or 
Synovitis (Villo)nodularis Pigmentosa (SVP), is a more destructive and locally aggressive tumour 
(figure 3). Diffuse-TGCT is defined by the presence of an infiltrative soft tissue mass along synovial 
lining, showing villous projections of the proliferated synovial membrane, with or without 
involvement of the adjacent joint or other structures. Macroscopically, the diffuse-type affects a 
large part of synovial lining and has a multinodular, multi-coloured appearance, including white, 
yellow and rust-coloured areas1. 75% are located around the knee-joint8. Current treatment 
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Figure 1  MRI of TGCT localized-type, affecting digits - A 43 year old male patient with a well circumscribed 
tumour in the proximal phalanx of the third digit of the right hand. a. A coronal T1-weighted MRI after 
intravenous contrast injection. b. A clear coronal T1 weighted MRI without intravenous contrast injection. 
a b
Figure 2  MRI of TGCT localized-type, extremity - Sagittal T1 weighted turbo spin echo MRI of a 47 year old 
female patient, affecting her right knee. A well circumscribed lesion in Hoffa’s fat pad is seen.  a. Proton density 




is surgical excision5, 6, 9. However, it is often difficult to perform a marginal excision. Average 
recurrence rates after arthroscopy are 40% and after open resection 14%, with variable follow-up 
times8. In extensive disease, peri-operative radiotherapy might reduce recurrence rate10, 11. Patients 
with (multiple) recurrences experience impaired quality of life12. 
According to the WHO-classification of 2002 and 2013, the Incidence Rate (IR) in TGCT is not exactly 
known1, 13. Current TGCT IRs are based on 1 single US-county study completed in 1980, with an IR 
of 9 and 2 per million person-year in localized- (including digits) and diffuse-TGCT, respectively14. 
Verschoor et al. (2015) performed the initial nationwide registry based study on giant cell 
containing tumours and calculated an overall IR for TGCT of 50 per million per year. Discrimination 
between localized and diffuse disease was not possible as additional clinical information was 
lacking. The difference in biological behaviour, however, demands for further stratification of this 
general IR in the 3 different TGCT-groups. Therefore, we aimed to estimate the worldwide (WHO-
standardized) TGCT IR by investigating clinical data of affected joints, sex differences, 10 year age 
specific categories, initial treatments, follow-up and recurrences rate at individual patient level 
through extensive additional data collection at participating hospitals. 
Figure 3  MRI of TGCT diffuse-type. A 23 year old male patient with an extensive proliferative synovial process 
around both cruciate ligaments, dominating the anterior and posterior knee compartments, intra- and extra-
articular. Inside suprapatellar pouch and Baker’s cyst a blooming villonodular aspect shows typical iron 
depositions. a. Sagittal proton density weighted turbo spin echo MRI. b. Sagittal T2 weighted fast field echo MRI.
a b




A search in PALGA, the non-profit nationwide network and registry of histo- and cytopathology 
in The Netherlands was performed15. To find all patients with Tenosynovial Giant Cell Tumours, 
between January 2009 and January 2014, search terms ‘Tenosynovial Giant Cell Tumour’, ‘Pigmented 
Villonodular Synovitis’ and a variety of synonyms were used, either as a code or as free text16, see 
supplementary data. Received pathology-reports provided limited and anonymous information 
on sex, age, date of tissue removal and conclusion of the pathology report. In these reports, 
definitive diagnosis was frequently provided, however information on (localized/diffuse) type and 
affected joint was only sparsely available. Therefore, further investigation of additional clinical and 
radiological data was necessary. Reports with TGCT affecting digits were solely used for calculating 
incidence rate (for TGCT-digits) and not further investigated clinically. PALGA interlinked 1941 
pathology-reports to 95 original Dutch hospitals. Departments of pathology received a request to 
collaborate in this nationwide study. After approval, personal hospital identifiers were obtained and 
concerned departments (mostly orthopaedics and general surgery) were invited to confirm TGCT 
diagnosis and add detailed information on TGCT-type, affected joint, sex, age at first histologically 
proven TGCT, primary treatment, total surgeries related to TGCT, date of last follow-up and follow-up 
status. Clinical and radiographic data were derived from medical files. Data were kept anonymously. 
75 of 95 attributed hospitals collaborated, including all specialized and academic centres. 
Clinical evaluation started with 1941 eligible TGCT cases. In 1576 (81%) cases, diagnosis was 
confirmed. 253 Reports were determined to be in digits and amended in digits-group. For included 
TGCT extremity cases (n 1323), incomplete evaluated clinical data were imputed for unknown 
data on TGCT-type (n=393), affected joint (n=101), sex (n=52), age (n=54) and treatment (n=484), 
using multiple imputation techniques. 10 Datasets were imputed, results were pooled according 
to standard Rubin’s rules17. All imputed data were checked for errors. Finally, 1323 patients with 
histological proven TGCT were included (figure 4).
In addition to the 2562 patients with TGCT affecting digits which were already identified based on 
the pathology reports, 253 additional patients with TGCT affecting digits were discovered during 
clinical data evaluation. 2815 TGCT patients affecting digits were identified (2649 fingers, 119 toes, 
47 finger or toe), but not investigated in detail. 
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Reoperation rate due to local recurrence was defined as surgery for recurrent TGCT, based on 
additional pathology reports in the same patient, at least 6 months after initial surgery until 
January 2015 (date of PALGA-search).
Statistics
The Statistical Package for Social Sciences statistics (SPSS) version 23 was used for analyses. 
The IR was separately estimated for TGCT localized-, either digits or extremity, and diffuse-type 
TGCT per year, by using the number of histologically proven TGCT as numerator and the sum 
of individual person-years for The Netherlands as the denominator. IRs were reported for the 
overall study period, by calendar year, and stratified on type, affected joints, sex and 10-years age 
categories (age at TGCT diagnosis). The Central Bureau of Statistics (CBS) provided information 
on Dutch population during the examined period. 
Overall worldwide IRs were obtained by standardizing Dutch IRs to global IRs by using the 
direct method, applying age-specific IRs in each 10-year age group to the world WHO standard 
population (http://seer.cancer.gov). Estimates of IRs were reported with 95% Confidence 
Intervals (CI). Patient demographics were reported as counts and percentages for categorical 
variables and as medians and interquartile ranges (IQR) for continuous variables. The Kaplan 
Meier method was used to evaluate reoperation due to local recurrence free survival at 2- and 
at 5-year. 
Ethics, funding, and potential conflict of interest
Research is performed in accordance with the ethical standards in the 1964 Declaration of 
Helsinki. As this study does not involve subject-related research, it is not covered by Dutch law on 
human subjects research. This study is approved by the Institutional review board (CME) from our 
institution (registration number G16.024, 22 April 2016). In collaboration of physicians of the TGCT 
study group, and in special collaboration with Radboud University Medical Centre and Medical 
Spectrum Twente, data collection was performed. Data capturing and analyses was performed 
in the Leiden University Medical Centre. No funding or benefits were received, by none of the 
authors. There is no conflict of interest by any of the authors regarding this manuscript.  
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Figure 4  Inclusion flowchart 









2815 digits-TGCT 933 localized-TGCT* 390 diffuse-TGCT*
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Table 1  Incidence rates (IRs) of localized- and diffuse-type TGCT in The Netherlands: 
overall, by calendar year 2009-2013, sex and age-categories. 
  
Person-years
Localized TGCT – digits Localized TGCT – extremity Diffuse TGCT
 New cases* IR** New cases* IR** New cases* IR**
Overall 83,226,498 2815 33.8 (33 - 35) 933 11.2 (11 - 12) 390 4.7 (4 - 5)
Calendar year       
2009 16,485,787 578 35.1 (32 - 38) 192 11.7 (10 - 13) 73 4.4 (4 - 6)
2010 16,574,989 561 33.8 (31 - 37) 183 11.0 (10 - 13) 82 5.0 (4 - 6)
2011 16,655,799 580 34.8 (32 - 38) 176 10.6 (9 - 12) 78 4.7 (4 - 6)
2012 16,730,348 563 33.6 (31 - 37) 188 11.2 (10 - 13) 77 4.6 (4 - 6)
2013 16,779,575 533 31.8 (29 - 35) 194 11.6 (10 - 13) 80 4.8 (4 - 6)
Sex       
Female 42,032,934 1698 (60) 40.4 (39 - 42) 544 (58) 12.9 (12 - 14) 236 (61) 5.6 (5 - 6)
Male 41,193,564 1117 (40) 27.1 (26 - 29) 389 (42) 9.4 (9 - 10) 154 (39) 3.7 (3 - 4)
Age at diagnosis       
0-9 9,528,271 13 (0) 1.4 (1 - 2) 6 (1) 0.6 (0 - 1) 2 (0) 0.2 (0 - 1)
10-19 10,012,994 98 (3) 9.8 (8 - 12) 57 (6) 5.7 (4 - 7) 26 (7) 2.6 (2 - 4)
20-29 10,178,289 259 (9) 25.4 (23 - 29) 108 (11) 10.6 (9 - 13) 49 (13) 4.8 (4 - 6)
30-39 10,673,194 411 (15) 38.5 (35 - 42) 169 (18) 15.8 (14 - 18) 62 (16) 5.8 (5 - 7)
40-49 12,894,743 650 (23) 50.4 (47 - 54) 211 (23) 16.4 (14 - 19) 70 (18) 5.4 (4 - 7)
50-59 11,456,662 704 (25) 61.5 (57 - 66) 193 (21) 16.9 (15 - 19) 71 (18) 6.2 (5 - 8)
60-69 9,466,681 503 (18) 53.1 (49 - 58) 133 (14) 14.0 (12 - 17) 58 (15) 6.1 (5 - 8)
70-79 5,680,080 155 (6) 27.3 (23 - 32) 41 (4) 7.2 (5 - 10) 37 (9) 6.5 (5 - 9)
80-89 2,860,556 22 (1) 7.7 (5 - 12) 15 (2) 5.2 (3 - 9) 15 (4) 5.2 (3 - 9)
*New cases: number of cases, %. **IR: Incidence rate per million person-years (95% CI).
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Table 1  Incidence rates (IRs) of localized- and diffuse-type TGCT in The Netherlands: 
overall, by calendar year 2009-2013, sex and age-categories. 
  
Person-years
Localized TGCT – digits Localized TGCT – extremity Diffuse TGCT
 New cases* IR** New cases* IR** New cases* IR**
Overall 83,226,498 2815 33.8 (33 - 35) 933 11.2 (11 - 12) 390 4.7 (4 - 5)
Calendar year       
2009 16,485,787 578 35.1 (32 - 38) 192 11.7 (10 - 13) 73 4.4 (4 - 6)
2010 16,574,989 561 33.8 (31 - 37) 183 11.0 (10 - 13) 82 5.0 (4 - 6)
2011 16,655,799 580 34.8 (32 - 38) 176 10.6 (9 - 12) 78 4.7 (4 - 6)
2012 16,730,348 563 33.6 (31 - 37) 188 11.2 (10 - 13) 77 4.6 (4 - 6)
2013 16,779,575 533 31.8 (29 - 35) 194 11.6 (10 - 13) 80 4.8 (4 - 6)
Sex       
Female 42,032,934 1698 (60) 40.4 (39 - 42) 544 (58) 12.9 (12 - 14) 236 (61) 5.6 (5 - 6)
Male 41,193,564 1117 (40) 27.1 (26 - 29) 389 (42) 9.4 (9 - 10) 154 (39) 3.7 (3 - 4)
Age at diagnosis       
0-9 9,528,271 13 (0) 1.4 (1 - 2) 6 (1) 0.6 (0 - 1) 2 (0) 0.2 (0 - 1)
10-19 10,012,994 98 (3) 9.8 (8 - 12) 57 (6) 5.7 (4 - 7) 26 (7) 2.6 (2 - 4)
20-29 10,178,289 259 (9) 25.4 (23 - 29) 108 (11) 10.6 (9 - 13) 49 (13) 4.8 (4 - 6)
30-39 10,673,194 411 (15) 38.5 (35 - 42) 169 (18) 15.8 (14 - 18) 62 (16) 5.8 (5 - 7)
40-49 12,894,743 650 (23) 50.4 (47 - 54) 211 (23) 16.4 (14 - 19) 70 (18) 5.4 (4 - 7)
50-59 11,456,662 704 (25) 61.5 (57 - 66) 193 (21) 16.9 (15 - 19) 71 (18) 6.2 (5 - 8)
60-69 9,466,681 503 (18) 53.1 (49 - 58) 133 (14) 14.0 (12 - 17) 58 (15) 6.1 (5 - 8)
70-79 5,680,080 155 (6) 27.3 (23 - 32) 41 (4) 7.2 (5 - 10) 37 (9) 6.5 (5 - 9)
80-89 2,860,556 22 (1) 7.7 (5 - 12) 15 (2) 5.2 (3 - 9) 15 (4) 5.2 (3 - 9)




During a 5-year period; 2815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type 
TGCT were identified. TGCT affected digits 3 and 7 times more often compared to localized-extremity 
and diffuse-TGCT, respectively. Dutch TGCT IRs were 34 (CI 33 - 35) in TGCT affecting digits, 11 (CI 11 
- 12) in localized-type extremity TGCT and 5 (CI 4 - 5) in diffuse-type TGCT per million person-years. 
Median age for TGCT affecting digits was 49 (IQR 38-59) years, for localized-extremity type 45 (IQR 
34-56) years and diffuse-TGCT 47 (IQR 32-61) years. Male-female ratio was about 1:1.5 for any type.
Table 1 shows IRs per million person-years by calendar years 2009 up to and including 2013, sex 
and 10 year age-specific categories of the 3 different TGCT-groups. In these 3 groups: IRs over 
disaggregated years were quiet similar, female IR were slightly higher compared to male IRs and the 
majority of new cases were seen in age-categories 40-49 and 50-59 years.  
In 2015, The Netherlands counted 16,900,726 inhabitants. According to calculated IR; 571 new TGCT 
affecting digits, 189 new localized-extremity and 79 new diffuse-TGCT patients were diagnosed 
in 2015. The estimated standardized worldwide IRs were 29, 10 and 4 per million person-years for 
respectively localized-digits, localized-extremity and diffuse-TGCT.
As TGCT affecting digits were not clinically investigated, following results were based on localized-
extremity and diffuse-type. The majority of TGCT cases affected the knee-joint; 46% and 64% in localized- 
and diffuse-TGCT respectively (figure 5), followed by the hand- and wrist-joint in localized-type and the 
ankle- and hip-joint in diffuse-type TGCT. Sex distribution per affected joint was comparable. 
The initial TGCT treatment plan was open resection in 65% and 49% in localized- and diffuse-
lesions, respectively (figure 6). TGCT was reported as an incidental finding during endoprosthetic 
replacement in 60 procedures.
According to the clinical charts, the majority of patients were lost to follow-up in both types (71% 
in localized- and 55% in diffuse-TGCT). Therefore, we decided to base recurrence rates on additional 
surgeries (defined by a second pathology report documenting recurrence of TGCT in PALGA). By 
evaluating the municipal personal records database (Gemeentelijke BasisAdministratie (GBA)) for 
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2all patients, 8 patients (7 localized- and 1 diffuse-TGCT) deceased at time of evaluation and were 
censored at time of death when no second surgery was performed.
Reoperation rate due to local recurrence, calculated as a percentage from all TGCT patients, in localized-
TGCT was 9% and in diffuse-TGCT 23%. Reoperation free survival curves for localized- and diffuse-TGCT are 
shown in figure 7. In localized-extremity, reoperation free survival at 2- and at 5-years was 90% and 83%, 
respectively. In diffuse-type, reoperation free survival at 2- and at 5-years was 77% and 49%, respectively. 
Only a minority (12%) of TGCT patients were primarily treated in a tertiary oncology centre: 9% of 


















Figure 5  Skeleton, showing affected TGCT localization (fingers and toes excluded).  
3% in localized-type and 1% in diffuse-type is classified as ‘other’ .
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Figure 7  Reoperation due to local recurrence free survival curve in localized-extremity and diffuse-TGCT 
(Kaplan Meier), excluding digits. Time zero is time of primary surgery. 8 Patients died and were censored at 
time of death if a reoperation had not occurred.



































Microscopically localized-extremity and diffuse-TGCT are identical1. A distinction is made 
between localized-digits and localized-extremity, based on anatomical location and histological 
differences3, 4. TGCT affecting digits are characterized as multiple, small (average 1 centimetres) 
nodules surrounded by a thin fibrous capsule, originating in synovial tissue of tendon sheaths or 
small joints of digits, with a small number of cleft-like spaces and thick bundles of collagenous 
tissue, showing rarely inflammatory cells. On the contrary, TGCT localized-extremity lesions are 
typically single, relatively large (average 2 centimetres) lesions covered by 1 or more layers of 
synovial cells, intra-articular, showing large or numerous pseudoglandular spaces sometimes 
filled with foam cells and showing more inflammatory cells than digits3.
Because of the rarity of the disease, current TGCT literature contains predominantly retrospective, 
relatively small cohort studies, including heterogeneous data4. 2 previous studies described 
TGCT incidence: Myers and Masi (1980) reported 117 new cases of localized- (including digits) 
and 49 new cases of diffuse-type TGCT between 1960 and 1976, resulting in an IR of 9 per million 
person-years for localized- and 2 per million person years for diffuse-type TGCT. A single hospital 
study was performed by Monoghan et al. (2001) and showed an IR of 20 new cases per million 
per year between 1990 and 1997 for localized-type TGCT (including digits). Compared to the 
initial US-county study14, our study showed a 5-fold higher IR in localized-type (combining 
localized-digits and localized-extremity), and a more than 2.6 fold higher IR in diffuse-type. This 
difference could be attributed to our nationwide coverage, our registry based-clinically verified 
character and because of increased knowledge about the disease.
Localized- and diffuse-lesions are distinguished clinically and on MRI. To investigate these 
lesions separately, clinical and radiological confirmation is of utmost importance. Treatment 
in localized-TGCT affecting digits or extremity is mostly 1 single excision. In contrast, multiple 
mutilating surgeries are often required for diffuse-type TGCT, with a continuous risk of 
recurrences. In an effort to find all TGCT patients, our search included specific pathology codes 
for TGCT and both TGCT and synonyms of TGCT as free text (Appendix). Therefore, cases with 
‘synovitis’ or differential diagnostic TGCT were represented in our search. In addition, PALGA 
data is based on input of physicians and sometimes lacks specificity. For instance affected joint: 
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‘upper extremity’, ‘hand’ or ‘wrist’ could all turn out, after clinical evaluation, to be affected digits. 
In our search, 1941 patients were clinically evaluated and 1323 ascertained histologically proven 
TGCT extremity cases were included. Consequently, only 68% of eligible TGCT patients had 
histologically proven TGCT of the large joints. Without clinical TGCT-confirmation, the estimated 
IR would have been much higher.
Despite our large number of patients with lack of follow-up, reoperation rates due to local 
recurrence were described, based on additional surgeries, defined by a second pathology 
report documenting recurrence of TGCT in PALGA (up to January 2015, date PALGA-search 
was performed). Recurrences without treatment (no additional pathology report) were not 
included, therefore reoperation rate due to recurrence is not identical to recurrence rate. 
However, compared to literature, we found comparable average recurrence rates for localized-
TGCT-extremity (9%) and for diffuse-type (23%)8. As local recurrence might develop years after 
initial surgery18, and PALGA provided pathology reports with a maximum of 7 years after initial 
surgery, underestimation of the true recurrence free survival is likely.
There are some limitations to this study. Determined IR may be exposed to under- or 
overestimation. Primarily, our calculated IR could be slightly underestimated, because our study 
is based on a search in PALGA, the nationwide network and registry of histo- and cytopathology 
in The Netherlands15. TGCT patients without a biopsy or treatment are not represented in this 
pathology based cohort. 
Second, our IR in localized-extremity and diffuse-type could be marginally over- or 
underestimated, because 21% of eligible TGCT patients was not clinically evaluated and 
therefore imputed. Analyses with and without imputed data were comparable. PALGA identified 
1941 eligible TGCT patients, scattered over 95 Dutch hospitals. Regarding different hospital-
boards, different concerning departments (pathology, orthopaedics, general surgery) and 
different local legislations, it was challenging to evaluate all eligible TGCT patients. 
Third, clinical distinction between localized-extremity and diffuse-type TGCT is difficult, 
especially for clinicians not familiar with this rare disease19. 
Subsequently, an overestimation of IR in TGCT localized-digits might be present. IR of digits is 
solely based on PALGA-registry numbers, in contrast to localized-extremity and diffuse-TGCT IRs 
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2which were clinically evaluated.
Global IRs were estimated by using a direct standardization approach (http://seer.cancer.gov). 
Even though this is a widely accepted method, there is no adjustment for other influences in 
global structure or possible risk factors in TGCT.
To calculate prevalence rates, follow-up time and status is important. Majority of our investigated 
patients lacked in clinical chart follow-up. It seemed unfair to estimate TGCT prevalence rates as 
the proportion of TGCT patients alive at the end of 2013 and diagnosed with TGCT: this assumes 
TGCT to not resolve and not to be cured.
In The Netherlands, traditionally, larger orthopaedic clinics have been treating TGCT or diagnosed 
TGCT as an incidental finding during arthroscopy or endoprosthetic replacement. When (severe) 
complaints occur, patients are commonly referred to specialized tertiary sarcoma centres. In this 
study, we investigated primary patients to calculate incidence rate. No centralization of care 
of TGCT in these primary patients is shown, with only a minority of 12% primarily treated in a 
tertiary oncology centre. Remarkably, only 18% of diffuse-TGCT was primarily treated in tertiary 
oncology centres.
In summary, this study is the first nationwide study and detailed analyses of IRs in TGCT. IRs 
for TGCT of digits, localized-type-extremity and diffuse-type were calculated using additional 
hospital record evaluation of patients originally selected from a nationwide pathology registry. 
The worldwide estimated incidence rate in digits, localized-extremity and diffuse-TGCT is 29, 
10 and 4 per million person-years, respectively. Despite high clinical variability in localized-
extremity and diffuse-lesions, both types show a predilection for the knee-joint, slight 
predisposition in female patients, median age around 47 years at first treatment and primarily 
treated with an open resection. Recurrence rate in diffuse-type is 2.6 times higher, compared to 
localized-type extremity. TGCT is still considered a rare disease, however, more common than 
previously understood.
Supplementary data 
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Localized- and diffuse-type tenosynovial giant cell tumours (TGCT) are regarded different 
clinical and radiological TGCT-types. However, genetically and histopathologically they seem 
indistinguishable. We aimed to correlate CSF1-expression and CSF1-rearrangement with the 
biological behaviour of different TGCT-types with clinical outcome (recurrence).
Methods
Along a continuum of extremes, therapy naïve knee TGCT patients with >3 year follow-up, mean 
age 43(range 6-71)years and 56% female were selected. Nine localized-(two recurrences), 16 
diffuse-type(nine recurrences) and four synovitis as control were included. Rearrangement of 
the CSF1-locus was evaluated with split-apart Fluorescence In Situ Hybridization (FISH) probes. 
Regions were selected to score after identifying CSF1-expressing regions, using mRNA ISH with 
the help of digital correlative microscopy. CSF1-rearrangement was considered positive in samples 
containing >2 split signals/100 nuclei.
Results
Irrespective of TGCT-subtype, all cases showed CSF1-expression and in 76% CSF1-rearrangement 
was detected. Quantification of CSF1-expressing cells was not informative, due to the extensive 
intra tumour heterogeneity. Of the four synovitis cases, two also showed CSF1-expression, without 
CSF1-rearrangement. No correlation between CSF1-expression or rearrangement with clinical 
subtype and local recurrence was detected. Both localized- and diffuse-TGCT cases showed a 
scattered distribution in the tissue of CSF1-expressing cells.
Conclusion
In diagnosing TGCT, CSF1 mRNA-ISH in combination with CSF1 split-apart FISH; using digital 
correlative microscopy, is an auxiliary diagnostic tool to identify rarely occurring neoplastic cells. 
This combined approach allowed us to detect CSF1-rearrangement in 76% of the TGCT-cases. 
Neither CSF1-expression nor presence of CSF1-rearrangement could be associated with the 




Tenosynovial giant cell tumour (TGCT), previously known as pigmented villonodular synovitis (PVNS) 
and giant cell tumour of tendon sheath, is a rare, neoplastic lesion arising from the synovial lining of 
joints, bursae or tendon sheaths in predominantly young adults. Excluding digits, this mono-articular 
disease is most commonly diagnosed around the knee or other weight bearing joints1-3. 
Initially, TGCT was believed to be an inflammatory disease4. After genomic aberrations were 
discovered, TGCT was evidently considered neoplastic5-10. Chromosomal aberrations include 
trisomy for chromosomes 5 and 7 and translocations involving the short arm of chromosome 1p11-
13, most commonly translocated to chromosome 2q37 region. At the 1p13 breakpoint, Colony 
Stimulating Factor 1 (CSF1) gene is located. The translocation leads to a classical promoter fusion 
event in which collagen 6A3 (COL6A3) promoter element is fused to CSF1. As a result, the fusion 
leads to deregulated expression of CSF111. The excessive CSF1 secretion attracts inflammatory cells 
that express the CSF1 receptor (CSF1R) (i.e. monocytes and macrophages). Consequently, in TGCT 
tissue, only a small percentage of cells (2-16%) are neoplastic, carrying the t(1;2) translocation. 
This phenomenon is coined as “the landscape effect”11, 12. Based on CSF1 rearrangements 
(translocation), two groups are described. The first group is defined by both CSF1 over-expression 
and CSF1 translocation, whereas the second group lacks the classical translocation. The latter 
group likely carries other rearrangements altering CSF1 regulation leading to high CSF1 mRNA 
and CSF1 protein levels12. 
According to the 2013 WHO classification, TGCT is subdivided in a lobulated well circumscribed 
lesion (localized-type) and a more locally aggressive lesion, involving a large part or all of the 
synovial lining (diffuse-type)1, 2, 13 (figure 1). Standard choice of treatment was surgical resection of 
the lesional tissue, either arthroscopically or with an open resection14-17. The localized-type TGCT is 
known with a favourable course after resection (average recurrence rates <6%), while the diffuse-
type TGCT generally causes significant morbidity due to the high risk of local recurrence (>50% 
depending on surgical procedure and follow-up time)15, 18, 19. Therefore, at present diffuse-type 
TGCT is also treated with CSF1 inhibitors, such as nilotinib, imatinib, pexidartinib, emactuzumab, 
cabrilazimab and MSC11020. Long term efficacy data have not yet been reported with these newer 
agents.
CSF1 in tenosynovial giant cell tumours
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Recurrent TGCT is rarely lethal, but a chronic illness with substantial morbidity to the joint leading 
to functional and quality of life impairment, caused by the course of the disease itself and multiple 
treatments21. Clinically, localized- and diffuse-TGCT are clearly two very different diseases. However, 
histopathologically they seem indistinguishable with both subtypes containing an admixture of 
mononuclear cells (histiocyte-like and larger cells) and multinucleated giant cells, lipid-laden foamy 
macrophages (also known as xanthoma cells), siderophages (macrophages including hemosiderin-
depositions), stroma with lymphocytic infiltrate and some degree of collagenisation1, 2.
It remains unclear why localized- and diffuse-TGCT are microscopically and genetically identical, 
but clinically distinct. Moreover, predictors for progressive disease or local recurrence are lacking. 
In this study, we investigate whether CSF1 over-expression and rearrangement are correlated 
with tumour characteristics (localized-/diffuse-TGCT) and clinical outcome (recurrence). We 
hypothesize that diffuse-type TGCT, compared with localized-type TGCT, would have a higher load 
of neoplastic cells. We expect that a higher tumour load is associated with recurrent disease. 
Figure 1  Localized- and diffuse-TGCT sagittal T1-weighted MR image after intravenous contrast injection with 
fat suppression. Tumour region enhances by contrast injection. a. A localized-TGCT involving Hoffa’s fat pad 
in the anterior part of the left knee in a 55-year-old female patient (L4835). b. Left knee in a 61-year-old male 
patient with extensive recurrent diffuse-TGCT located intra- and extra-articular with an additional posterior 




Case acquisition and study design 
Subtypes of TGCT (localized- or diffuse) were defined based on clinical features and radiological 
imaging according to 2013 WHO1, 2. Along a continuum of extremes, 25 patients with TGCT 
affecting the knee were carefully selected: patients with small or very large localized or diffuse 
lesions, with and without recurrent disease. All cases showed all characteristic histological features 
of TGCT (mononuclear cells, giant cells, macrophages, siderophages, foam cells or lymphocyte-
clusters). Included patients were therapy naïve (one diagnostic arthroscopy elsewhere was 
allowed) and treated with open synovectomy at the Leiden University Medical Centre (LUMC). 
A clinical follow-up of at least three years was required for inclusion. For comparison, we used 
tissue specimens of four patients with non-TGCT synovitis. Written informed consent was 
obtained from all patients. This study was performed in accordance with the Code of Conduct 
for responsible use in The Netherlands (Dutch Federation of Medical Scientific Societies) and 
approved by the local medical ethical committee (P13.029).
Inclusion selected cases and tissue specimens
Nine localized- and 16 diffuse-type TGCT patients were included, mean age at surgery of 43 
(range 6-71) years, mean follow-up of 57 (range 36-121) months (table 1), with a slight female 
predominance (56%). Two localized- and nine diffuse-type TGCT patients had recurrent disease, 
after mean 26 (range 14-53) months. The mean age at surgery of the four patients with non-TGCT 
synovitis was 53 (range 44-65) years, including two (50%) females.
For each patient, multiple formalin-fixed paraffin-embedded (FFPE) tissue blocks and 
corresponding Haematoxylin and Eosin stained (H&E) 4 μm slides of the primary resected 
specimen were reviewed by an expert bone and soft tissue pathologist (JVMGB) to confirm TGCT 
diagnosis and to select representative areas of the tumour with highest proportion of suspected 
neoplastic cells. 
A large tissue heterogeneity was observed between the different blocks. As a control for the 
landscaped CSF1 mRNA expression, multiple blocks were selected for three cases (L4046, L3496 
and L4954) representing various tissue compositions.




The RNAscope 2.5 High Definition(HD)-RED assay (Advanced Cell Diagnostics, 322350) was 
used to detect CSF1 mRNA expression. This assay visualizes single RNA molecules per cell by a 
novel method of in situ hybridization (ISH). The double Z probe design allowed simultaneous 
signal amplification and background suppression22. Positive (PPIB (Cyclophilin B)) and negative 
controls (bacillus subtilis strain SMY) ensured reliable results. mRNA hybridisation were performed 
according to manufacturer’s protocols.
CSF1 rearrangement
To identify the presence of CSF1 rearrangements at region 1p13, DNA Fluorescence In Situ 
Hybridisation (FISH) analysis was performed on all tissue specimens using bacterial artificial 
chromosome (BAC) clones: RP11-354C7 (centromeric to CSF1) and RP11-96F24 (telomeric to 
CSF1)) bracketing CSF1 locus, to identify both translocation and inversion. Probe labelling and 
hybridisation were done according to previously described protocols23. An index case outside 
of the study population (L4018) was included with a COBRA-FISH molecular karyotyping proven 
inv(1)(p13;q23) as reference for the detection of the chromosome inversion in tissue section24. 
Detailed description of mRNA ISH and FISH procedures are presented in supplementary material.
Table 1  Descriptives of study population
Localized Localized recurrence Diffuse
Diffuse 
recurrence No TGCT
Total number 7 2 7 9 4
Mean age at surgery (R), y 33 (6-55) 41 (20-62) 54 (33-71) 42 (17-63) 53 (44-65)
Male:female 5:2 0:2 2:5 4:5 2:2
Mean time to recurrence (R), m na 31 (18;44) na 24 (14-53) na
Mean follow up (R), m 61 (39-100) 81 (40;121) 54 (39-97) 51 (36-70) na
Localized: localized-TGCT; Diffuse: diffuse-TGCT; R: range; y: years; m: months
58
Chapter three
Scoring and correlative analysis 
All slides were scanned in brightfield and/or fluorescence on a Pannoramic P250 or MIDI digital scanner 
(3DHistech, Budapest, Hungary). Scanned images were visualized using the Pannoramic Viewer (V2.1; 
3DHistech). Interpretation was performed manually by a senior FISH expert (KS), blinded towards TGCT-
type and clinical outcome. Because CSF1 expressing regions were expected to contain neoplastic cells, 
three of these regions were selected. With the use of digital correlative microscopy, regions with CSF1 
mRNA expressing (supposed neoplastic) cells were identified and the same areas were scored after 
FISH analysis. If the distance between the two signals was larger than the size of a single hybridization 
signal, cells were recorded CSF1 split positive. All nuclei within the selected area with a complete set of 
signals were evaluated. Nuclei with an incomplete set of signals were excluded from counting. Samples 
containing >2/100 nuclei with a CSF1 split were considered CSF1 split positive.
results
CSF1 mRNA expression 
Specimens of all localized- and diffuse-TGCT cases showed a scattered, tissue infiltrating distribution of 
CSF1 expressing cells (figure 2). Corresponding to the landscape effect, heterogeneous distribution of 
CSF1 expressing cells were observed when sections from multiple bock were analysed, meaning that 
regions completely devoid CSF1 expressing cells were seen in regions containing large proportion of 
foam cells or regions with lymphocytic infiltrates. CSF1 mRNA pattern expression was not observed in 
multinucleate giant cells, siderophages or foam cells. Consequently, due to the great heterogeneity 
between different blocks derived from one tumour and within regions in one section, quantification 
of CSF1 expressing cells, meaning the expression of the proportion of CSF1 positive cells, was not 
informative and was not further analysed (supplementary material figure 1). Selecting the block with 
the highest possible neoplastic cell component, we did not observe a clear difference in distribution 
of CSF1 between different TGCT cases. Cells with CSF1 mRNA expression were distributed diffusely 
and showed an infiltrating scattered pattern throughout the sections with some clustering at various 
regions within a tissue element (figure 2, supplementary material figure 2 and 3). 
For the control cases, two of the four cases with synovitis showed expression of CSF1 (L5619, L5620). 
However, in these two cases CSF1 expression was restricted to cells localised in the synovial lining, 
which was different from the scattered distribution seen in TGCT (figure 3). The other two cases with 
synovitis showed no expression of CSF1 (L3715, L5622).
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Figure 2  Conventional histology and mRNA ISH from 61-year-old male patient (L3496), with extensive recurrent 
diffuse-TGCT. This is the same patient as figure 1 right. Left panel H&E stained section (A; C) with matching CSF1 
mRNA ISH (B; D) on the right panel. White box in panel A and B show regions at higher resolution in panel C 
and D. Heterogeneous cellular composition of TGCT is visible including foam cells, inflammatory cells, synovial-
like cells, siderophages and characteristic giant cells (A; C). mRNA ISH shows a scattered distribution of CSF1 
expressing cells with granular cytoplasmic signals (red signal), identifying CSF1 expressing cell-nuclei (blue 
signal after DAPI staining). Green arrowheads shows giant cells without CSF1 expression. Scale bars are in the 






The CSF1 probe set showed a clear split-apart signal even for detection of chromosome inversion 
using our molecular karyotyping proven index case with an inv(1)(p13;q23) indicating that cases with 
no split signal are unlikely to have similar inversion. Due to great heterogeneity, CSF1 split scoring 
was done on selected areas based on presence of CSF1 expressing cells identified by mRNA ISH using 
correlative digital microscopy. Using this approach, CSF1-gene rearrangement was detected in 76% 
of all TGCT cases: in localized-type 77% and in diffuse-type 75% (figure 4, supplementary material 
figure 2). Further stratification of positive cases, rearrangement of the CSF1 locus was present in 78% 
of localized-TGCT without recurrence, 100% of localized-TGCT with recurrent disease, 86% of diffuse-
TGCT without recurrence and 67% of diffuse-TGCT including recurrent disease (table 2, supplementary 
material table 1 patient and tumour characteristics). There was no CSF1 gene rearrangement in all four 
synovitis control cases. 
a b
Figure 3  Distribution of synovial lining CSF1 mRNA ISH positive cells in TGCT and reactive synovitis. 
a. 61-year-old male patient (L3496) with diffuse-type TGCT. Cells with red cytoplasmic staining after mRNA 
ISH, show a deep infiltrating pattern in synovial villi with rare occurrence at the synovial lining parts. This is the 
same patient as figure 1 right and figure 2. b. 45-year-old female patient (L5620) with synovitis, showing CSF1 
expressing cells (red cytoplasmic signal) restricted to cells localised in the synovial lining. Nuclei are displayed 
in blue after DAPI staining, scale bars are in the right top corner (100µm).
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Table 2  Proportion of cases with CSF1 mRNA expression and CSF1 gene rearrangement*
N CSF1 over-expression CSF1 gene rearrangement 
Localized 7 7 (100%) 5 (78%) 
Localized recurrence 2 2 (100%) 2 (100%)
Diffuse 7 7 (100%) 6 (86%) 
Diffuse recurrence 9 9 (100%) 6 (67%) 
Synovitis 4 2 (50%) 0 (0%) 
Localized: Localized-TGCT; Diffuse: Diffuse-TGCT
*Comprehensive patient and tumour characteristics are shown in supplementary material table 1.
Figure 4  Correlative microscopy used to identify neoplastic cells. a. mRNA ISH helps to identify regions 
with cells overexpressing CSF1 mRNA (red signal), blue nuclei after DAPI staining. b. CSF1 locus specific split-
apart probe set using BAC probes: centromeric (red) and telomeric (green) probes. Yellow signal represent 
co-localization of the signal meaning no rearrangement. White arrowheads indicate cells with split-apart 
signal, indicating rearrangement of the CSF1 gene. Samples are from a 61-year-old male patient (L3496), with 
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Localized- and diffuse-type TGCT are histopathologically identical and carry the same chromosomal 
translocation, leading to uncontrolled over-expression of CSF1 due to a gene fusion between 
COL6A3 and CSF1 genes. Undeniably, localized- and diffuse-type TGCT are clinically different 
diseases. In a well-defined TGCT population with >3 years follow-up, molecular differences in 
primary resected tissue between both subtypes and clinical outcome (recurrence) were evaluated. 
We were unable to find a clear association between CSF1 over-expression or CSF1 rearrangement 
and the biological behaviour in TGCT of the knee.
In this study, 76% CSF1 rearrangement was detected when lumping all our 25 cases together, 
compared with 61% of the evaluated cases by Cupp et al.12. Further subdivided, our study revealed 
no difference in CSF1 rearrangement for localized-TGCT (77%) and diffuse-TGCT (75%). On the 
contrary, West et al. reported a large difference between these two types; 87% rearrangement 
in localized- and 35% in diffuse-TGCT11. The relatively high percentage of rearrangement in our 
study, could be attributed to our scoring on preselected areas, based on high CSF1 expression. 
In addition, our DNA FISH analysis, using bacterial artificial chromosome (BAC) clones (RP11-
354C7 and RP11-96F24) bracketing CSF1 locus, identifies not only a translocation, but also an 
inversion for CSF1 rearrangements. Panagopoulous et al. revealed a CSF1-S100A10 fusion gene, 
with translocation t(1;1)(q21;p11) as the sole karyotypic abnormality25. Nilsson et al. found that 
30% of the TGCT specimens did not have a rearrangement involving the 1p13 locus, where CSF1 
is located using split-apart interphase FISH approach, similar to ours8. Next to the translocation, 
Panagopoulos et al. reported the replacement of the 3’-UTR of CSF1, resulting in over-expression 
or a longer lifetime of CSF1 mRNA due to loss of the 3-UTR controlling region25. Similar cryptic 
changes leading to loss of smaller gene region involving the 3’-UTR segment of CSF1 are beyond 
the detection level of our FISH probes. Next to this, other, yet not identified alterations leading to 
deregulated CSF1 expression cannot be ruled out in cases with CSF1 mRNA expression without 
CSF1 rearrangement of the CSF1 locus.
Up to date, clinically reliable antibodies working on FFPE tissue sections to detect CSF1 or CSF1R 
are lacking. Therefore, mRNA ISH was the best regarded option to identify CSF1 over-expressing 
cells. Consistent with previous reports, all 25 evaluated cases showed CSF1 up-regulation11. Exact 
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determination of the proportion of CSF1 expressing cells was considered not meaningful, since in 
all tumours considerable intratumoural heterogeneity was observed between selected blocks and 
with individual tissue sections, reflecting the “landscape effect”11. This heterogeneity prevents any 
conclusion on the true neoplastic cell load in the tumour and a possible correlation to clinical outcome.
Deregulated CSF1 expression is believed to be the central mechanism of tumourigenesis for TGCT. 
CSF1, also called macrophage colony-stimulating factor, is a cytokine, produced by many different 
cell types including macrophages, fibroblasts, endothelial cells and osteoblasts (and other cancer 
types, especially in bone metastasis)26. CSF1 is expressed in neoplastic cells infiltrating throughout 
the lesion. Secreted CSF1 recruits non-neoplastic macrophages into the tumour. By binding to 
its receptor CSF1R (type III receptor tyrosine kinase), CSF1 promotes survival, proliferation and 
differentiation of cells of the mononuclear phagocyte lineage (e.g. monocytes, macrophages and 
osteoclasts)27, 28. Besides its general biological function, CSF1 is also involved in inflammatory or 
reactive synovitis (rheumatoid arthritis, chronic artritis) and cancer (breast, endometrial, ovarian, 
lung, kidney)12, 27. When CSF1 is expressed in reactive synovitis, its expression is restricted to cells in 
the synovial lining12, 29, as was confirmed in our synovitis control cases.
Inhibition of signalling between CSF1 and CSF1R targets the underlying cause of the disease29, 
30. The involvement of this pathway contributed to the introduction of systemic therapies for 
extensive diffuse-TGCT20. Primarily, imatinib31 or related drugs as nilotinib32 showed efficacy 
in the treatment. Recently, new CSF1R blockers were developed and are investigated in clinical 
trials; Emactuzumab and Cabiralizumab (FPA008) both monoclonal antibodies directed against 
CSF1R33-35; Pexidartinib (PLX3397; retains CSF1R in inactive state)29, and MSC110 (an antagonist of 
the CSF1 ligand)35. Emactuzumab (N=29) showed an overall response rate of 86% (two patients 
with a complete response) and a rate of disease control of 96%, including a significant functional 
and symptomatic improvement (median follow up 12 months)33. The preliminary results for 
cabiralizumab (N=22) are consistent, with radiographic response and improvement in pain and 
function in five out of 11 patients (45%)34. In a randomized, placebo-controlled phase 3 study, 
pexidartinib showed an improved overall response rate by RECIST: 39% in the pexidartinib-group 
(N=61) and 0% of placebo-group (N=59), after median six months follow-up36. However, long term 
results still need to be evaluated with these newer agents.
CSF1 in tenosynovial giant cell tumours
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Within our well-defined patient cohort, all patients had a minimum follow-up of three years. 
However, patients without recurrent disease at the time of analysis could still develop this in due 
course, since it is known that local recurrence might develop years after initial surgery1, 2, 15, 19, 37. 
Verspoor et al. calculated an overall recurrence rate of 72% in 75 patients with diffuse-TGCT of the 
knee with a mean follow-up from index treatment of 13.9 years. They suggested a trend towards 
the longer the follow-up, the greater the number of recurrences19.
In conclusion, DNA FISH analysis, using bacterial artificial chromosome (BAC) clones (RP11-354C7 
and RP11-96F24) bracketing CSF1 locus, can identify both chromosomal rearrangement caused 
translocation or inversion of the CSF1 locus. Figure 5 summarizes the workflow in the current 
study and the proposed workflow for molecular pathology work up of TGCT cases. The use of CSF1 
mRNA ISH in combination with CSF1 split-apart FISH is an auxiliary diagnostic tool to confirm the 
diagnosis of TGCT. This combined approach allowed us to detect CSF1-gene rearrangement in 76% 
of the TGCT cases. At the molecular level, localized- and diffuse-type TGCT are indistinguishable 
when evaluating CSF1 expression and the presence of the pathognomonic translocation involving 
the CSF1 gene.
Supplementary data
Supplementary data are available in the online version of this article, doi: 10.1111/his.13744
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Supplementary figure 1  Low power magnification overview of TGCT case from a 61-year-old male patient 
(L3496), the same patient as figure 1 A, figure 2, figure 3A, figure 4.  a. Hematoxyllin-eosin staining. b. CSF1 
mRNA ISH (red) of the same case depicting identical regions, nuclei are stained with DAPI (blue). White 
arrowheads indicate blood vessels with erythrocytes, giving a strong red fluorescing signal. A heterogeneous 
distribution of CSF1 expressing cells with remarkable variation in their distribution in the tissue is clearly visible. 
White squared inset, indicates regions in high power magnification shown in details in figure 2. Scale bars are 
in the right top corner (500 µm).
Supplementary figure 2 (right page)   Overview of TGCT localized case without 
recurrence from a 55-year-old female patient (L4385), presented in figure 1A. a 
& b. Hematoxillin-eosin staining low and high power overview. b & d. CSF1 mRNA 
ISH (red) of the same case depicting identical regions, nuclei are stained with DAPI 
(blue). In panel B a white squared inset indicate the region shown in high power 
magnification in panel D. e. Using correlative microscope areas with more neoplastic 
cells (mRNA ISH positive cells) were identified and scored for CSF1 locus specific 
split-apart probe set using BAC probes. Yellow signal represent co-localization 
of the signal meaning no rearrangement. White arrowheads indicate cells with 
split-apart signal, indicating rearrangement of the CSF1 gene. Scale bars are at the 
bottom left corners and 500 and 20 µm for low and high power images, respectively. 
a b








Supplementary figure 3  Correlative microscope image comparing sections after hematoxillin-eosin staining 
(a) and CSF1 mRNA ISH (b) of a diffuse, non-recurrent TGCT case from a 50-year-old male patient (L3697). 
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Current development of novel systemic agents requires identification and monitoring of extensive 
Tenosynovial Giant Cell Tumours (TGCT). This study defines TGCT extension on MR imaging to 
classify severity.
Methods
In part one, six MR parameters were defined by field-experts to assess disease extension on MR 
images: type of TGCT, articular involvement, cartilage-covered bone invasion, and involvement of 
muscular/tendinous tissue, ligaments or neurovascular structures. Inter- and intra-rater agreement 
were calculated using 118 TGCT MR scans. In part two, the previously defined MR parameters were 
evaluated in 174 consecutive, not previously used, MR-scans. TGCT severity classification was 
established based on highest to lowest Hazard Ratios (HR) on first recurrence.
Results
In part one, all MR parameters showed good inter- and intra-rater agreement (Kappa≥0.66). In 
part two, cartilage-covered bone invasion and neurovascular involvement were rarely appreciated 
(<13%) and therefore excluded for additional analyses. Univariate analyses for recurrent disease 
yielded positive associations for type of TGCT HR12.84(95%CI4.60-35.81), articular involvement 
HR6.00(95%CI2.14-16.80), muscular/tendinous tissue involvement HR3.50(95%CI1.75-7.01) and 
ligament-involvement HR4.59(95%CI2.23-9.46). With these, a TGCT severity classification was 
constructed with four distinct severity-stages. Recurrence free survival at 4 years (log rank p<0.0001) 
was 94% in mild localized (n56, 1 recurrence), 88% in severe localized (n31, 3 recurrences), 59% in 
moderate diffuse (n32, 12 recurrences) and 36% in severe diffuse (n55, 33 recurrences).
Conclusion
The proposed TGCT severity classification informs physicians and patients on disease extent and 
risk for recurrence after surgical treatment. Definition of the most severe subgroup attributes to a 




Tenosynovial Giant Cell Tumour (TGCT) affecting large joints is an orphan, mono-articular, 
potentially locally aggressive disease with high recurrence rates. According to the 2013 WHO 
classification of tumours of soft tissue and bone, at the base of growth pattern, a radiological 
distinction is made between single nodule (localized-TGCT) and multiple lesions (diffuse-TGCT). 
These types differ in their clinical presentation, response to treatment and prognosis, but 
histologically, they seem identical1-4.
Localized-type TGCT is classified as a circumscribed benign small (between 0.5 and 4 cm) mass1, 
5. Standard treatment of choice is excision. Subsequently, overall reported recurrence rates are 
relatively low: 0-6%6. On the contrary, diffuse-type TGCT, previously named Pigmented VilloNodular 
Synovitis (PVNS), extensively involves the synovial membrane and infiltrates adjacent structures6, 
7. Reported recurrence rates of diffuse-TGCT following open synovectomy are 14% up till 67% and 
after arthroscopic synovectomy 40% up till 92%6. Recurrent or residual disease, frequently requiring 
multiple, sometimes mutilating operations, may result in total joint arthroplasties, morbidity and 
loss of quality of life8-12. With this large variety in disease presentation and recurrence rates, a 
more comprehensive and outcome-based classification is asked for. The emerging era of systemic 
targeted and multimodality therapies (available in trial settings) increases the need for a method 
to select eligible patients in order to create comparable patient cohorts13-15. 
In diagnosing and treating TGCT, magnetic resonance (MR) imaging is the most distinctive imaging 
technique4, 16-19. MR imaging reveals conspicuous nodular (localized-type) or villous proliferation of 
synovium (diffuse-type). However, current literature lacks specific MR discriminating features to 
describe or quantify tumour extent in relation to clinical outcome. Uniform MR descriptions are 
of utmost importance for clinical and research purposes. Therefore this study aims to sub-classify 
tumour severity especially in diffuse-type TGCT. First, a group of radiologists and orthopaedic 
surgeons identified and defined potentially distinguishing parameters. Second, these MR 
parameters were applied on a different study-population to establish TGCT severity subgroups.




Part I: Identification and evaluation of TGCT specific MR parameters
Using case discussions in expert meetings with two dedicated musculoskeletal radiologists and 
three oncological orthopaedic surgeons, six MR parameters were selected in relation to anatomical 
or surgical landmarks. These parameters were 1 type of TGCT (based on 2013 WHO classification1, 2), 
2 articular involvement, 3 cartilage-covered bone invasion, 4 involvement of muscular/tendinous 
tissue, 5 involvement of ligaments and 6 involvement of neurovascular structures (figure 1) 
(Appendix).
To evaluate usability and reproducibility, 118 MR scans of TGCT patients, treated at the Leiden 
University Medical Centre (LUMC), were randomly retrieved (MM). The six MR parameters were 
evaluated in a heterogeneous group of TGCT cases as scans included cases of various large 
joints (knee (79; 67%), ankle (13; 11%), foot (10; 9%)), severity subtypes and treatment phases. 
MR scans were conducted using a 1.5 or 3.0 Tesla unit Philips (Best, The Netherlands) Ingenia MR 
with dedicated coils. Standard musculoskeletal scan-protocol included: T1- and T2-weighted fast 
spin echo, T1-weighted fat-suppressed post Gd-chelate contrast and optionally T2* gradient-
echo sequences in two planes (transversal and either sagittal or coronal). To assess inter- and 
intra-rater agreement, all MR scans were evaluated by one dedicated musculoskeletal radiologist 
(DH) and by two dedicated orthopaedic surgeons (RW, MS). MR evaluation was blinded to patient 
characteristics.
Inter-rater agreement and accompanying 95% confidence interval (95% CI) between three 
physicians was calculated for all 118 cases by Fleiss-Kappa (dichotomous outcomes in all parameters, 
except for articular involvement with three outcomes). To evaluate intra-rater agreement with the 
accompanying 95% CI (linear weighted kappa), 36 randomly chosen MR scans (31%) were again 
evaluated three months after initial evaluation by the senior orthopaedic surgeon (MS).
Part II: Application of TGCT MR parameter
None of the MR scans in part I were used in part II. The combined TGCT-database of two sarcoma 
centres in The Netherlands (LUMC and Radboud University Medical Centre (RUMC)) was used to 
include consecutive MR scans conducted between 2005 and 2015 (n=283). MR scan inclusion 
criteria were: pre-treatment MR scan of histologically proven TGCT of large joints, conducted in 
two planes (transversal and either sagittal or coronal), and open resection as primary treatment 
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Figure 1  Definition of six TGCT specific MR parameters
TGCT-type 
a. Localized-type on a sagittal PD-weighted FSE MR image of a 49 year old female patient. Localized-TGCT 
is defined according to WHO as a well circumscribed nodular lesion at synovial lining of bursa, joint or 
tendon sheath.
b. Diffuse-type on a sagittal PD-weighted FSE MR image of a 24 year old male patient. Diffuse-TGCT is 
defined as a multinodular lesion involving a larger part or multiple compartments of the synovial lining.
Articular involvement
c. Intra-articular well circumscribed lesion on posterior cruciate ligament on a PD-weighted FSE MR 
image of a 18 year old female patient. Intra-articular involvement is defined as TGCT involvement inside 
synovial lining of joint.
d. Extra-articular involvement, along gastrocnemius muscle insertion, on a sagittal T1-weighted FSE MR 
image of a 33 year old male patient. Extra-articular involvement is defined as TGCT involvement outside 
synovial lining of the joint.
e. Both intra- and extra-articular involvement on a sagittal T1-weighted fat-suppressed MR image after 
intravenous administration of gadolinium of a 63 year old female patient with TGCT. Extensive tumour 
growth anterior and posterior.
Cartilage-covered bone invasion
f. Cartilage covered bone invasion on a sagittal T1-weighted FSE MR image of a 59 year old male patient. 
Square presents cartilage covered bone, defined as clear invasion of bone through cartilage; not only 
touch cartilage. Circle presents not-cartilage covered bone invasion.
Muscular/tendinous tissue involvement
g. Muscular/tendinous tissue involvement, anterior vastus medialis muscle and posterior hamstrings 
tendon, on a sagittal T1-weighted fat-suppressed MR image after intravenous administration of 
gadolinium of a 63 year old female patient with TGCT. Muscular/tendinous tissue is defined as 
involvement of muscular/tendinous tissue or >180 degrees encagement of tendon/muscle.
Ligament involvement
h. Cruciate ligament enhancement on a sagittal T1-weighted fat-suppressed MR image after intravenous 
administration of gadolinium of a 64 year old male patient. Ligament involvement is defined as 
involvement of ligament or >180 degrees encagement of ligament.
Neurovascular structures involvement
i. Popliteal artery encagement on an axial PD-weighted FSE MR image of a 62 year old female patient, 
referred to a tertiary sarcoma centre with extensive TGCT. Neurovascular involvement is defined as > 
180 degrees encagement of the artery or nerve.
FSE, Fast Spin Echo; PD, Proton Density
Figure e & g is the same female patient.








in one of the two participating centres. Large joints were defined as all joints proximal to and 
excluding metatarsophalangeal and metacarpophalangeal joints. When TGCT affected the knee, 
one diagnostic arthroscopy prior to open resection was allowed, since tumour extent would not 
be affected. Open synovectomy was defined as gross total resection of disease, either one- or two-
staged, without adjuvant therapy. 174/283 Patients met the inclusion criteria (figure 2). Median 
follow-up was 36 (IQR 21-60) months, maximum follow-up 12 years after primary surgery. 
The senior author (MS) evaluated the six defined MR parameters (part I) on these pre-treatment 
scans (77 LUMC, 97 RUMC). MR evaluation was blinded to patient characteristics and clinical 
outcome. Patient and tumour characteristics were gathered: gender, localization (affected joint), 
age at time of the MR scan, date of open synovectomy, first local recurrence and date of first 
recurrence (on MR imaging), and date of last follow-up. Median follow-up was calculated from date 
of primary surgery to date of last clinical follow-up, including interquartile range (IQR). Recurrence 
free survival was calculated from date of surgery to recurrent disease or last contact.
As outcome, first recurrence was defined as new disease presence after synovectomy or growing 
residual disease (diagnosed on follow-up MR scan). Proposed risk factors were gender, localization 
(knee versus other joints) and age at the time of the MR scan (below or above 40 years). Hazard 
ratios (HRs) and their corresponding 95% CI were estimated for risk factors and MR parameters 
Figure 2  Inclusion flowchart part II TGCT severity classification.
283 consecutive TGCT MR scans
Excluded
60 not therapy naïve
39 not primarily treated with open synovectomy
10 no pre-treatment MR scan available
174 included MR scans
Severity classification of tenosynovial giant cell tumours
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(part I) by univariate and multivariate Cox regression analyses to estimate the relation on recurrent 
disease. Since estimating HR is unreliable for rarely present MR parameters, only parameters with 
an adequate number of presence (minimum of 20%) were used for additional analyses. Recurrence 
free survival close to median time of follow-up was calculated by Kaplan Meier analyses and log 
rank test. Time zero was defined as date of primary open synovectomy. 
At the base of HRs with positive associations of risk factors and MR parameters on first recurrences, 
the TGCT severity classification was established. The TGCT subgroup flow chart started with the 
MR parameter with highest HR, followed by descending HRs. Statistical Package for Social Statistics 
(SPSS) version 23 was used for analyses.
Ethical statement
This study was approved by the institutional review board from our institution (registration 
number P13.029). No funding was received.
results
Part I: Evaluation of TGCT specific MR parameters
Inter-rater agreements for type of TGCT, articular involvement, cartilage-covered bone invasion, 
and involvement of muscular/tendinous tissue, ligaments or neurovascular structures were 0.71; 
0.68; 0.66; 0.67; 0.75 and 0.73, respectively. Intra-rater agreements for these parameters were 
between 0.72 and 1.00 (table 1). Since inter- and intra-rater agreements were good20 for these six 
MR features, all parameters were considered viable to use for TGCT subgroup analyses.
Part II: Application of TGCT MR parameters
Out of 174 MR scans, the knee was affected most (122; 70%), followed by the ankle (20; 12%) 
(table 2). In univariate analyses, none of the proposed risk factors were associated with recurrent 
disease (p>0.37) (table 3) and consequently not used for further analyses. Both MR parameters 
cartilage-covered bone invasion and involvement of neurovascular structures were rarely seen on 
MR images (< 13%) and in accordance with our exclusion criteria not used for additional analyses. 
In univariate analyses, the remaining four MR parameters were associated with recurrent disease 
(p<0.002) (table 3); strongest association was seen in diffuse-type compared with localized-type 
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Table 1  Inter- and intra-rater agreem
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(HR 12.84 (95%CI 4.60-35.81)), subsequently intra- and extra-articular involvement compared 
with extra-articular (HR 6.00 (95%CI 2.14-16.80)) and involvement of muscular/tendinous tissue or 
ligaments compared with no involvement (HR 3.50 (95%CI 1.75-7.01), HR 4.59 (95%CI 2.23-9.46), 
respectively). 
Multivariate analyses for MR parameters did not show individual positive association, except for 
parameter type of TGCT (supplementary material I).
Four TGCT severity subtypes were established using a flowchart that begins with the parameters 
with highest HR (parameter type of TGCT), followed by parameters with descending HRs. These 
four subtypes showed a clinically relevant or significant prognostic value for recurrent disease 
and were classified as: mild localized (n56, 1 recurrence), severe localized (n31, 3 recurrences), 
moderate diffuse (n32, 12 recurrences) and severe diffuse (n55, 33 recurrences).
1. Mild localized contained localized-type, either intra- or extra-articular involvement 
without involvement of muscular/tendinous tissue/ligaments. 
2. Severe localized included localized-type, either intra- or extra-articular lesions and 
either or both involvement of muscular/tendinous tissue/ligaments. 
3. Moderate diffuse comprised diffuse-type with intra- and/or extra-articular disease 
without involvement of muscular/tendinous tissue/ligaments. 
4. Severe diffuse was diffuse-type including intra- and extra-articular involvement 
and involvement of at least one of the three structures (muscular/tendinous tissue/
ligaments) (figure 3).
Recurrence free survival at 4 years (close to median follow-up diffuse-type) for the four patient 
groups according to the new MR subtypes descended from 94% in mild localized, to 88% in severe 
localized, to 59% in moderate diffuse and to 36% in the least favorable subtype, severe diffuse. 
Median time to local recurrence in moderate diffuse and severe diffuse subtypes was 29.5 (IQR 
14.5-48.0) and 22.0 (IQR 11.8-33.5) months, respectively. Majority of recurrent disease cases were 
already treated with a re-operation (32/49, 65%). One patient, classified as severe diffuse, died of 
another disease, after four months and was censored at that time. Novel MR based TGCT severity 
and associated Kaplan Meier survival curves presented significant difference between the four 
patient groups (log rank p<0.0001) and additional differentiation compared with solely sub-
classifying in localized- and diffuse-TGCT (figure 4 and supplementary material II). 
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Table 2  TGCT MR scan demographics
Cases (%) Cases localizedTGCT (%)
Cases diffuse
TGCT (%)
Total number of MR scans 174 87 87
Gender
     Female 105 (60) 33 (38) 36 (41)
     Male 69 (40) 54 (62) 51 (59)
Median age at MR scan (IQR) 37 (26-48) years 37 (24-47) years 36 (26-49) years
Localization
     Knee 122 (70) 63 (72) 59 (68)
     Hip 8 (5) 0 (0) 8 (9)
     Ankle 20 (12) 10 (11) 10 (11)
     Foot 9 (5) 5 (6) 4 (5)
     Elbow 6 (3) 4 (5) 2 (2)
     Other 9 (5) 5 (6) 4 (5)
Median follow-up (IQR) 36 (21-60) months 32 (17-56) months 41 (24-63) months
Total number of recurrences
     Recurrent disease 49 (28) 4 (5) 45 (52)
     No recurrent disease 125 (72) 83 (95) 42 (48)
IQR, interquartile range
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Table 3  Risk of recurrence on MR imaging; 
univariate analyses in proposed risk factors and four MR parameters.
n (%) Hazard ratio (95% CI) P
Gender
    Male 69 (40) 1.29 (0.74-2.27) 0.37
    Female 105 (60) 1
Age
    <40 years 91 (52) 1.15 (0.66-2.02) 0.63
     >40 years 83 (48) 1
Localization
     Knee 122 (70) 1.15 (0.63-2.12) 0.65
     Other joint 52 (30) 1
TGCT-type
     Diffuse 87 (50) 12.84 (4.60-35.81) <0.000
     Localized 87 (50) 1
Articular involvement
     Intra-articular 59 (34) 1.11 (0.31-3.95) 0.87
     Intra- and extra-articular 75 (43) 6.00 (2.14-16.80) 0.001
     Extra-articular 40 (23) 1
Muscular/tendinous tissue involvement
     Yes 90 (52) 3.50 (1.75-7.01) <0.000
     No 84 (48) 1
Ligament involvement
     Yes 86 (49) 4.59 (2.23-9.46) <0.000
     No 88 (51) 1
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Figure 3  TGCT severity classification, containing four severity subtypes: mild localized, severe localized, 
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RFS 4y, Recurrence Free Survival at 4 years
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Figure 4  TGCT recurrence free survival curve for four TGCT severity subtypes, affecting large joints, estimated 
with Kaplan Meier method. Time zero was date of primary open synovectomy. One patient, classified as severe 






























This is the first study to define severity subtypes in Tenosynovial Giant Cell Tumours (TGCT) based 
on a combination of four MR imaging parameters. These subtypes correlate with a spectrum of 
disease severity ranging from low to high risk of local recurrence after surgical intervention.
Within this present era of systemic targeted and multimodality therapies (available in trial settings) 
in TGCT, standalone surgical resection cannot be regarded the gold standard anymore for more 
severe cases21. Because of the lack of clear-cut boundaries in diffuse-TGCT, complete resection is 
difficult and at times technically impossible or undesirable with joint function preservation and 
quality of life in mind. In patients with locally advanced TGCT or (multiple) recurrence(s), systemic 
therapies targeting the CSF1/CSF1R axis have been investigated; less potent drugs as nilotinib and 
imatinib22, 23, and more specific inhibitors as emactuzumab (RG7155), pexidartinib (PLX3397) and 
cabiralizumab (FPA008). Emactuzumab (N=29) had an overall response rate of 86% (two patients 
with a complete response) and a rate of disease control of 96%, including a significant functional 
and symptomatic improvement (median follow up 12 months)24. In a randomized, placebo-
controlled phase 3 study, pexidartinib showed an improved overall response rate by RECIST: 
39% in the pexidartinib-group (N=61) and 0% of placebo-group (N=59), after median six months 
follow-up25. The preliminary results with cabiralizumab (N=22) are consistent, with radiographic 
response and improvement in pain and function in five out of 11 patients 2815. However, long term 
efficacy data have not yet been reported with these newer agents. 
Patient inclusion for these trials is very heterogeneous. A strict patient selection is desirable, to 
accurately evaluate effect of these treatments. At present, patient selection for trial inclusion 
is established by preference of treating physician and might differ per centre. Defining more 
aggressive TGCT subtypes and including these uniformly defined patients into trials would more 
adequately investigate the effect and toxicities of treatment26. In this study, we propose to include 
patients defined with ‘severe diffuse’ TGCT subtype. Monitoring the effect of systemic therapy also 
benefits from clear agreements on parameters.
Uniform MR descriptions are of utmost importance for clinical and research purposes. Thus far, 
no well-defined tumour parameters exist. Definition of unambiguous MR criteria is challenging, 
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because of the rarity of the tumour and small number of heterogeneous cases, variety of joints 
involved, different disease severity as well as several treatment modalities2, 27. So far, MR imaging 
has shown to be the best discriminating method to evaluate TGCT4, 28. In our study, six objective 
clinically relevant MR parameters were defined in relation to anatomical or surgical landmarks. 
According to our exclusion criteria for the development of the severity classification, parameters 
cartilage covered bone invasion and neurovascular involvement showed inadequate number of 
presence and were therefore not used. However, in larger case series these two parameters might 
correlate with more aggressive disease and hence a higher recurrence rate.
To date, no radiology-based TGCT severity classification exists. Subdividing between localized- 
and diffuse-TGCT seems an oversimplification that fails to estimate differences in recurrent rates 
for individual patients. Murphey et al. presented an extensive review of different TGCT features 
on several imaging techniques, without relating these features to disease severity, treatment or 
recurrences4. Van der Heijden et al. further sub-classified diffuse-TGCT affecting the knee in 30 
patients into mild or severe, without linking to recurrent disease. Mild diffuse-TGCT was defined as 
involvement of either anterior or posterior compartment of the knee, with the cruciate ligaments 
as boundary. Severe diffuse-TGCT was defined as involvement of both compartments, with or 
without extra-articular extension9. In contrast to most literature, we selected a homogeneously 
treated patient population to develop four severity subtypes, by only including patients initially 
treated with an open synovectomy.
In line with most papers, especially papers on trial medication, and based on clinical practice, 
we included all large joints to sub-classify disease severity for TGCT. Prior research did not 
show a (significant) difference in recurrence rates for both localized and diffuse disease when 
comparing the knee with other joints6, 27, 29, 30. A recent TGCT incidence calculation study showed 
a predominance of the knee in 46% in localized- and 64% in diffuse-type (excluding digits)5, in 
line with our overrepresentation of the knee of 70%. In the future, a TGCT severity classification 
focused on the knee would contain more detailed knee-specific MR parameters and equal 
treatment approaches.
Limitations to this study: primary, the resulting HRs had wide confidence intervals, indicating low 
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precision in the estimates. This is likely related to the relatively small sample size, given that the 
patients were divided into several groups based on the MR parameters. Secondly, because of the 
relatively small number of recurrences in severity subtypes mild localized (n 1) and severe localized 
(n 3), Hazard Ratios may be unreliable. Therefore, it was not feasible to estimate a cox model and to 
generate a true prediction model. Additionally, localized-TGCT is known to have few recurrences 
and often remains without clinical complaints after resection. In both sarcoma centres, patients 
are therefore discharged from follow-up after the first follow-up post-surgery and requested to 
return again when clinical complaints present. In our analyses, 31 localized-type patients were 
censored at date of last clinical follow-up within the first two years in survival curve (figure 4). Less 
often, patients with diffuse-type have also lacked follow-up (13 censored first two years). It could 
be assumed that these patients did not have complaints and recurrent disease. Furthermore, in 
study part two (establishing TGCT subtypes), newest included MR scans originated from 2015. 
These cases had a maximum follow-up of two years. Since it is known that local recurrence might 
develop years after initial surgery2, 11, 29, in our study a median of 29.5 in moderate diffuse and 
22.0 months in severe diffuse-TGCT subtypes, underestimation of recurrence free survival could be 
present. Finally, even though quite a large number of MR scans (174) were used in development of 
the severity classification, in larger case-series including long follow-up time, it might be possible 
to differentiate further in disease severity and assess additional subtypes.
To conclude, in reporting TGCT affecting large joints on MR imaging, six parameters are helpful 
in discriminating disease extent. Patients can be accurately monitored by using these MR 
parameters. With respect to recurrence, a combination of four MR parameters classifies patients 
into one of four severity subtypes, presented with distinct recurrence free survival rates. In the era 
of personalized medicine, treatment is individualized for each patient depending on the extent of 
disease. Because histopathological prognostic factors are lacking, sub-classification of TGCT on MR 
imaging is a potential tool to stratify future patient prognosis and identify candidates for targeted 
therapies, thereby aiding with the decision in daily practice.
Supplementary data





TGCT MR parameters, affecting large joints, in therapy naïve primary TGCT patients
Agreement: 
	 Involvement of a structure: when signal intensity is changed to TGCT signal intensity, 
this structure is considered to be involved with TGCT and to be scored.
	 When involvement of a structure is unclear: choose ‘structure involved’ (when in 
doubt; over-scoring, not under-scoring).
MI parameters
1. TGCT-type
	 Localized-type†: well circumscribed nodular lesion at synovial lining of bursa, 
joint or tendon sheath
	 Diffuse-type††: multinodular lesion involving a larger part or all of the synovial 
lining
2. Articular involvement
	 Intra-articular$: inside synovial lining of joint
	 Extra-articular$$: outside synovial lining of joint
	 Both intra- and extra-articular
3. Cartilage-covered bone invasion
	 Yes: clear invasion of bone invading cartilage; not only touch cartilage 
	 No: no bone invasion or solely bone-usuration or bone invasion not cartilage-
covered
4. Muscular/tendinous tissue involvement*
	 Yes: involvement of muscular/tendinous tissue or >180 degrees encasement 
of tendon/muscle
	 No: no involvement or encasement of tendon/muscle
5. Ligament involvement**
	 Yes: involvement of ligament or >180 degrees encasement of ligament
	 No: no involvement or encasement of ligament
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6. Neurovascular structure involvement#
	 Yes: encasement >180 degrees of important nerves and/or vessels
	 No: no encasement of nerves or vessels
† Localized-type: be careful to always classify one nodular lesion as localized-type. Also when one 
nodular lesion is reeved by another structure (it might seem like additional nodules).
†† Diffuse-type: be careful to always classify diffuse-type when two or more tendon sheaths or 
muscles are involved. Do not classify these cases as one large nodule.
$ Intra-articular: concerning the knee: cruciate ligaments are counted as intra-articular structures 
as the synovial lining of the ligaments should be considered intra-articular.
$$ Extra-articular: concerning the knee: Hoffa
* Muscular/tendinous tissue involvement: concerning the knee: also account parameter when 
solely popliteus muscle involvement is present.
** Ligament involvement: TGCT involvement of ligament, in hand or foot: account parameter 
when intra-tarsal/digital ligaments, ankle syndesmose and plantar fascia are involved. TGCT 
concerning the knee with ligament involvement: anterior and/or posterior cruciate ligament, 
and/or medial/lateral collateral ligament.
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Tenosynovial Giant Cell Tumours (TGCT), both localized- and diffuse-type, are rare, mono-articular 
neoplasms, with a slight female predominance. The clinical behaviour between patients differs 
greatly. This study aims to evaluate the increase in TGCT-related symptoms during pregnancy and 
the influence of female sex hormones thereon. 
Methods
In a prospective-cohort-study, TGCT-related symptoms before and during pregnancy were 
evaluated in two Dutch centres and by use of the largest online TGCT patient-support group. 
Second, as a proxy for disease activity the combined TGCT-database of two sarcoma-centres 
in the Netherlands (N=455) was used to compare recurrence free survival rates between the 
sexes (during and after fertile-age). Finally, female hormonal receptor status was evaluated with 
immunohistochemistry on TGCT-specimens from eight women (18-50 years). 
Results
Forty percent (8/20) of women with diffuse-TGCT of lower extremity reported an increase in 
TGCT-related symptoms during pregnancy, predominantly an increase in swelling (62%). Mean 
VAS-score on symptoms increased between 5.9 (SD 2.1) before pregnancy to 6.6 (SD 1.7) during 
pregnancy. Similar results were reported in the patient-support group.
No differences were found in recurrence free survival rates, between both sexes, (localized- 
(p=0.206 ≤50 years, p=0.935 >50 years); diffuse-type (p=0.664 ≤50 years, p=0.140 >50 years)), 
neither in pre- versus post-menopausal women (localized- (p=0.106); diffuse-type(p=0.666)). In 
all examined localized- and diffuse-TGCT tissue-samples, oestrogen or progesterone hormone-
receptor staining was negative. 
Conclusion
An increase in TGCT-related symptoms during pregnancy was reported. This could not directly be 
linked to female sex hormones as hormone receptors were missing histopathologically. Recurrence 




Tenosynovial Giant Cell Tumour (TGCT), previously known as Pigmented Villonodular Synovitis 
(PVNS), is a rare, benign neoplasm arising from synovial joints, tendon sheaths and bursae. It 
affects a relatively young population aged 30-50 years and has a slight female predominance 
(male:female 1:1.5)1-3. Two subtypes are distinguished. The localized-type is defined as a single 
nodule, affecting only a distinct area of the synovium with an incidence rate of 10.2 per million 
person-years (excluding digits). The diffuse-type is known to be more aggressive and involves a 
larger part or the entire synovial lining. It has an incidence rate of 4.1 per million person-years4, 5. 
TGCT is a mono-articular disease predominantly affecting weight-bearing joints; knee (46% and 
64%), hip (1% and 9%), and ankle (5% and 10%) for localized- and diffuse-type, respectively3, 4. 
Pain, swelling, limited range of motion and stiffness of the affected joint are the most common 
symptoms6-9. Rapid diagnosis is difficult due to these unspecific symptoms and since most 
physicians are unfamiliar with the disease5, 10-12. Arthroscopic or open synovectomy is the standard 
of care1, 2, 5, 8. After surgical treatment, localized-type in the knee generally follows a favourable 
course with an average recurrence rate of 4 to 6% after resection (with variable follow-up). In 
contrast, diffuse-type in the knee presents with multiple recurrences, on average 14% to 40% after 
surgical treatment5.
In TGCT, answers on everyday questions are lacking: e.g. do hormone-based anticonceptiva 
influence my disease? Does pregnancy influence the clinical behaviour of TGCT? In the outpatient 
clinic and on online TGCT patient fora, an increase in TGCT-related symptoms during pregnancy 
is observed. In healthy pregnant women, joint pain in the knee and hip are frequently reported13, 
14. This pain is not only attributed to the additional weight. Elevated female sex hormones 
(oestrogen, progesterone and the oestrogen-dependent relaxin) are known to weaken soft 
tissue structures, resulting in increased joint laxity during pregnancy, joint instability and lower 
extremity dysfunction13, 15, 16. To our knowledge, only two case-reports of two pregnant women 
with both localized-TGCT exist (supplementary material). The first case report described a patient 
diagnosed with TGCT six months after pregnancy completion, as the patient was misdiagnosed 
with chondromalacia patellae17. The second patient presented with an acute onset of knee pain 
during first semester of pregnancy. It was hypothesized that pregnancy-related changes triggered 
torsion or bleeding of the tumour, leading to this acute presentation18. Elevated levels of oestrogen 
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and progesterone receptors have been identified in giant cell tumour of bone, dermatofibroma 
protuberans and malignancies of breast, endometrium, ovary, prostate, colon. Hormone receptor 
positive tumours show a better prognosis19-24. The presence of female sex hormone receptors in 
TGCT is unknown.
This study aims to evaluate patient reported TGCT-related symptoms before and during pregnancy 
in two different patient populations. Influences of sex specific hormones and female fertile life 
phase specific hormones are determined by comparing recurrence free survival rates between 
the sexes and pre- versus post-menopausal women. Finally, presence of female sex hormonal 
receptor-status in available tumour tissue is assessed.
methods
Questionnaires in two sarcoma centres and a patient-support group
Patients with diffuse-TGCT were included, since diffuse-TGCT is a more widespread and extensive 
disease, including more clinical complaints and higher recurrence rates, compared with localized-TGCT.
Two sarcoma centres
One-hundred sixty-two female patients with histopathologically proven diffuse-TGCT were 
extracted from the combined Dutch TGCT-database (Leiden University Medical Centre (LUMC) 
N=92 and Radboud University Medical Centre (RUMC) N=70) (figure 1)25. Excluded were seventy-
four patients <18 years or >50 years, non-weight bearing upper-extremity TGCT (elbow, wrist) or 
temporomandibular localization. The remaining 88 patients were invited to complete the TGCT-
questionnaire. Incomplete questionnaires were unsuitable for analysis (N=26). Finally, sixty-two 
questionnaires of patients with diffuse-TGCT of lower extremities were included.
The comprehensive TGCT-hormone questionnaire contained questions on patient- and tumour-
characteristics, initial TGCT-symptoms (prior to primary treatment), current TGCT-symptoms 
(symptoms at time of questionnaire completion) and TGCT-symptoms before and during 
pregnancy. To quantify TGCT-related symptoms, Visual Analogue Scale (VAS) questions were 
included, ranging from 0 (no symptoms) to 10 (worst symptoms) (supplementary material). The 
pregnancy questions were completed for the first pregnancy (>6 months) after TGCT-diagnosis 
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and questions were answered regarding the TGCT affected joint.
Patient-support group
Previously, an international crowdsourcing study was conducted in 337 patients to evaluate 
impact of TGCT on daily living26. An e-survey was distributed in the largest, online support group 
for TGCT-patients: the closed Facebook group ‘PVNS is pants!!’. This study contained 129 women 
with diffuse-TGCT of lower extremity, aged between 18 and 50 years (figure 2). Besides patient- 
and tumour characteristics, the e-survey contained validated questionnaires on physical function 
and quality of life. Furthermore, questions on TGCT-related symptoms and intensity of symptoms, 
pregnant at time of TGCT
N=20
not pregnant 















•	 incomplete questionnaire 
or duplicate entries, N=26
completed questionnaires
N=62
Figure 1  Inclusion flowchart of diffuse-TGCT women, treated in one of two sarcoma centres.
RUMC, Radboud University Medical Centre; LUMC, Leiden University Medical Centre.
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before and during pregnancy were included for women only. These questions were not previously 
published (supplementary material). In more than one pregnancy, questions were answered for the 
pregnancy that most affected the TGCT-related symptoms.
NetQuestionnair (NetQ), an online, professional survey software supported by the LUMC, was 
used to distribute and complete the questionnaires for the two sarcoma centers (eight months 
available) and the patient-support support group (six months available). Both questionnaires were 
approved by the institutional review board from the LUMC (comprehensive TGCT-questionnaire 
study registration number P13.029 and patient support group e-survey study P16.232). NetQ 


















pregnant at time of TGCT
N=35




automatically captured questionnaire-answers into an SPSS 23 file (Statistical Package for Social 
Sciences statistics (SPSS®) Version 23 (Chicago, IL, USA)), only accessible to TGCT researchers. 
Unique site visitors were determined by IP addresses. When duplicate entries were detected, 
the most recent one was included. Statistical analyses were mainly descriptive. To verify that 
diffuse-type women with increased TGCT-symptoms during pregnancy were comparable with 
diffuse-type women not pregnant during TGCT in the patient support group, chi-square tests 
were used for TGCT localization (knee versus hip, ankle and foot), initial surgery (arthroscopy 
versus open synovectomy), recurrence (yes versus no) and total number of surgeries (1 surgery 
versus ≥2 surgeries). Independent t-tests were used to compare continuous scores of validated 
questionnaires on physical function and quality of life.
Comparison of recurrence free survival rates
Recurrence was defined as new disease presence after synovectomy or growing residual disease 
(diagnosed on follow-up MR scan). To determine influences of sex specific hormones and female 
fertile life phase specific hormones, recurrence free survival rates between the sexes and pre- 
versus post-menopausal in women were assessed as a proxy. The combined database of two 
sarcoma centres (LUMC and RUMC) in The Netherlands (N=455, 262 diffuse-TGCT) was used25. 
This dataset contained all consecutive patients surgically treated for histopathologically proven 
TGCT between 1990 to 2017. Fertile life phase was defined between 16 and ≤50 years at primary 
diagnosis, since median age at natural menopause ranges between 49 and 52 years27.
Using SPSS®, recurrence free survival rate after index operation was calculated through Kaplan-
Meier survival method and log rank test in male and female patients ≤50 years and >50 years for 
localized- and diffuse-type separately. Similarly, recurrence free survival rates in pre- versus post-
menopausal women were compared.
Female hormone-receptors in TGCT
Immunohistochemistry was performed on paraffin-embedded pathological specimens of 
histopathologically proven TGCT tissue, obtained from eight randomly selected women between 
18 and 50 years to determine female hormone receptor status. All samples were of primary 
resected localized- (N=4) or diffuse-TGCT (N=4), located in the lower extremity (hip, knee, ankle). 
Monoclonal Rabbit Anti-Human Oestrogen receptor α and monoclonal mouse anti-human 
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progesterone receptor were used (supplementary material). Hormone receptor status was assessed 
in the LUMC by a dedicated pathologist, specialized in bone and soft tissue tumours. Slides were 
verified with positive controls of women with oestrogen or progesterone receptor positive breast 
cancer.
results
Questionnaires in two sarcoma centres and a patient-support group
Two sarcoma centres
Sixty-two women with diffuse-TGCT of the lower extremities ((knee 50 (81%), hip 6 (9%) and ankle/
foot 6 (9%)) with a median age at diagnosis of 30 (IQR 25-38) years completed the comprehensive 
Dutch questionnaire (Table 1). Twenty (32%) patients were pregnant after being diagnosed with 
TGCT. Eight (40%) of these patients self-reported an increase, two (10%) a decrease of symptoms and 
10 (50%) continued at the same level (Table 2). TGCT-related symptoms included pain, swelling and 
limited range of motion of the affected joint, swelling was predominantly increased (62%) (Table 3). In 
patients with increasing symptoms, mostly during second or third trimester (5/8 (63%)) of pregnancy, 
mean VAS score increased from 5.9 (SD 2.1) before pregnancy to 6.6 (SD 1.7) during pregnancy.
                    
Patient-support group
In 129 women, median age at time of diagnosis was 30 (IQR 24-39) years and TGCT was mostly 
located in the knee (93 (72%)) (Table 1). Thirty-five (27%) women had TGCT during pregnancy. 
Twenty-three (66%) pregnant women stated an increase, 3/35 (9%) a decrease and 9/35 (26%) did 
not experience a difference in symptoms during pregnancy. Of all reported symptoms, swelling 
(57%) of the associated joint increased the most. Additional symptoms included pain, limited 
range of motion and stiffness (Table 3). Self-reported intensity of TGCT-related symptoms after 
pregnancy was compared with reported intensity of symptoms before pregnancy; in 10/26 (38%) 
intensity increased, 6/26 (23%) intensity decreased and in 10/26 (38%) intensity continued at a 
comparable level. No differences were detected in patient- and tumour-characteristics in women 
with increased TGCT-symptoms during pregnancy compared with women not pregnant during 
TGCT (Supplementary material; Table 1).
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Table 1 Tumour- and patient-characteristics of female diffuse-TGCT patients, from two sarcoma 


















Limited range of motion
Stiffness


































Median (IQR) Median (IQR)
Age at time of diagnosis (years)





Initial symptoms, symptoms of the affected joint prior to primary treatment; Current symptoms, symptoms at 
time of questionnaire completion. *Leiden University Medical Centre (LUMC) and Radboud University Medical 
Centre (RUMC). **Largest, online patient support group for TGCT-patients: the closed Facebook group ‘PVNS 
is pants!!’ 
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Limited ROM Residual disease




+ nilotinib + 
RT 56 Gy
Swelling EPR NED
3 Knee 30 24$$ AS Swelling AS NED








6 Knee 34 84 AS Swelling 2012 OS Residual disease
7 Ankle 37 2 Pain OS during pregnancy
Residual 
disease
8 Knee 38 6 Swelling OS NED
TGCT, tenosynovial giant cell tumour; AS, arthroscopic synovectomy; OS, open synovectomy; PLX, PLX3397/
pexidartinib; EPR, endoprosthetic reconstruction; Limited ROM, limited range of motion; NED, no evidence 
of disease. $Pregnancies were uncomplicated, unless otherwise specified. +Pregnancy was prematurely 
terminated because of major pain complaints of hip. ++Last follow-up >2 years since last treatment, unless 
otherwise specified. $$B12 deficiency, right after pregnancy locking of affected knee. $$$Had to stop TNF-α-
inhibitor (indicated for oligoarthritis and Crohn’s disease). *Complication: abscess and sepsis.
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Pain 1 (13) 5 (22)
Swelling 5 (62) 13 (57)
Limited range of motion 2 (25) 3 (13)
Stiffness 0 2 (8)
Total increased symptoms 8 (100) 23 (100)
All patients were requested to indicate which TGCT-symptom increased most during pregnancy. This table presents 
self-reported increased symptoms in 8/20 (40%) and 23/35 (66%) women with diffuse-TGCT from two Dutch sarcoma 
centres and the patient-support group, respectively. In both populations swelling was the most prominent symptom.
Figure 3  Recurrence free survival curve in 155 diffuse-TGCT patients ≤50 years* (p=0.664). 
*Age at primary diagnosis
Years after index operation
male 71 49 32 20 12 8 6
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Figure 3 (continued)  Recurrence free survival curve in 107 diffuse-TGCT patients >50 years* (p=0.140). 
*Age at primary diagnosis
Years after index operation
male 42 30 17 13 10 10 9


















Comparison of recurrence free survival rates
Female recurrence free survival rates were comparable to male rates for localized-type (log rank 
p=0.206 ≤50 years, p=0.935 >50 years) and diffuse-type (log rank p=0.664 ≤50 years, p=0.140 >50 
years) (figure 3). Similarly, in women during and after fertile age, recurrence free survival rates were 
comparable for localized-type (log rank p=0.106) and diffuse-type (log rank p=0.666).
Female hormone-receptors in TGCT
All eight localized- and diffuse-TGCT tissue samples were oestrogen or progesterone hormone 
receptor negative. Further evaluation of additional patient samples was therefore deemed 
unnecessary.
discussion
This is the first study to evaluate hormonal influences on the clinical presentation of Tenosynovial 
Giant Cell Tumour (TGCT). An increase in TGCT-related symptoms during pregnancy was reported, 
in particular swelling of the affected joint. Recurrence free survival rates were comparable for both 
sexes as well as for pre- versus postmenopausal women. Oestrogen and progesterone-receptors 
were not present with immunohistochemistry in TGCT tissue. 
In the current study, 56% (31/55) of pregnant patients reported an increase in TGCT-related 
symptoms and a minority reported a decrease in these symptoms (9%; 5/55). Swelling of the 
affected joint was self-reported as the most prominent symptom during pregnancy. Since TGCT 
is a mono-articular disease, this swelling is not comparable with the clinical (bilateral) oedema 
accompanying a majority of (healthy) pregnancies14. The increase in symptoms was mainly present 
during second and third trimester of pregnancy. Similar, healthy pregnancy is associated with an 
increase in lower extremity symptoms during these trimesters14. A valid question would be why 
an increase in mono-articular TGCT swelling during pregnancy would present in these later stages 
of pregnancy. Since growth hormone is already present five weeks after conception, the question 
is whether growth hormone influences TGCT-related joint swelling. The experienced increase in 
disease burden might be caused by progressive disease, but is more likely based on increased 
effusion. Although pregnancy seems to provoke an increase in TGCT-related symptoms, this might 
be coincidental according to subjective complaints, recall bias and focus on the affected joint.
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In general, a multifactorial aetiology is responsible for lower-extremity symptoms during healthy 
pregnancy28. First; biomechanical changes, including the anterior shift of the center of gravity13, 
the extra bodyweight29 and a different gait-pattern due to an increased pressure on the lateral 
side of the foot30, are responsible for lower limb and functional knee pain in pregnant women. As 
a consequence, a decrease in physical functioning is reported during progression of pregnancy, 
also in healthy women15. Second; relaxation of joints is a physiologic process associated with 
pregnancy. This increased joint-laxity and weakened soft tissue structures is mainly based on the 
pregnancy initiated elevated levels of the hormone relaxin31. Third; discontinuation of medication 
considered unsafe for the unborn child, for instance non-steroidal anti-inflammatory drugs 
(NSAID’s) or tumour necrosis factor-blockers (TNF-α-inhibitors), might affect the experience of 
TGCT-symptoms. Additional factors of possible influence on TGCT-related symptoms are nausea/
fatigue, stress, emotional/personal problems and anxiousness for additional tasks after pregnancy. 
The increased TGCT-related symptoms during pregnancy might also be attributed to this 
multifactorial aetiology for lower extremity symptoms during healthy pregnancy. One (1/8(13%)) 
patient with increased symptoms interrupted her TNF-α-inhibitor (indicated for oligoarthritis and 
Crohn’s disease) (Table 2; patient 5).
To test the hypothesis that female sex hormones influence TGCT, we compared recurrence rates 
for both sexes. Since oestrogen and progesterone in women decline after fertile age, recurrence 
free survival rate analyses were performed for both sexes ≤50 and >50 years, without revealing 
a difference. In accordance with literature no differences in recurrence rates between male and 
female TGCT-patients were found32. To our knowledge, pre- versus post-menopausal analyses had 
not been performed before and yielded also no difference.
In all eight primary resected TGCT-tissues, oestrogen or progesterone receptors were completely 
absent. This is a small sample size, although it is unlikely that positive female sex hormone status 
will be detected by evaluating additional specimens. Hormone-based anticonceptica or female 
hormone based treatments do not seem to influence the clinical behaviour of TGCT. Future 
research is recommended to find the cause of increased symptoms in TGCT during pregnancy 
and to contribute to possible new treatment modalities, e.g. growth-factor, ED-A fibronectin 
(expressed during embryogenesis) or changes in the auto-immune system.
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Evaluation of hormonal influences in TGCT is challenging because of the rarity of the tumour 
and the heterogeneous patient population. Main limitation in our two questionnaire studies 
was participant recall bias. Information provided on a recall basis diminishes the accuracy of 
results. Preferably, an observational study would be performed, including a control group and 
radiographic evaluation of tumour severity before and after pregnancy. Furthermore, answers from 
the e-survey in the patient support group could be influenced by multicultural differences. Finally, 
while previous surgeries provoke deteriorated clinical outcome, treatments before pregnancy and 
treatment phase during pregnancy were not taken into consideration.
conclusion
In conclusion, an increase in TGCT-related symptoms during pregnancy was reported in two 
different patient cohorts. This could not directly be linked to female sex hormones as hormone 
receptors were missing histopathologically. Recurrence free survival rates between both sexes and 
between pre- versus post-menopausal women were also comparable, making a causal relation 
with female sex hormones even more unlikely.
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Tenosynovial Giant Cell Tumour (TGCT) is a rare, benign, monoarticular entity. Many case-series 
in adults are described, whereas TGCT is only incidentally reported in children. Therefore, its 
incidence rate and natural history in children are unknown.
Questions/purposes
(1) How many cases have been reported of this condition, and what were their characteristics? 
(2) What is the standardized paediatric incidence rate for TGCT? 
(3) Is there a clinical difference in TGCT between children and adults? 
(4) What is the risk of recurrence after open resection in children compared with adults?
Methods
Data were derived from three sources: (1) a systematic review on TGCT in children, seeking 
sources published between 1990 and 2016, included 17 heterogeneous, small case-series; (2) the 
nationwide TGCT incidence study: the Dutch paediatric incidence rate was extracted from this 
nationwide study by including patients younger than 18 years of age. This registry-based study, 
in which eligible patients with TGCT were clinically verified, calculated Dutch incidence rates for 
localized and diffuse-type TGCT in a 5-year timeframe. Standardized paediatric incidence rates 
were obtained by using the direct method; (3) from our nationwide bone and soft tissue tumour 
data registry, a clinical data set was derived. Fifty-seven children with histologically proven TGCT of 
large joints, diagnosed and treated between 1995 and 2015, in all four tertiary sarcoma centres in 
The Netherlands, were included. These clinically collected data were compared with a retrospective 
database of 423 adults with TGCT. Chi square test and independent t-test were used to compare 
children and adults for TGCT type, sex, localization, symptoms before diagnosis, first treatment, 
recurrent disease, followup status, duration of symptoms, and time to followup. The Kaplan-Meier 




TGCT is seldom reported because only 76 paediatric patients (39 female), 29 localized, 38 diffuse, 
and nine unknown type, were identified from our systematic review. The standardized paediatric 
TGCT incidence rate of large joints was 2.42 and 1.09 per million person-years in localized and 
diffuse types, respectively. From our clinical data set, symptoms both in children and adults were 
swelling, pain, and limited ROM with a median time before diagnosis of 12 months (range, 1-72 
months). With the numbers available, we did not observe differences in presentation between 
children and adults in terms of sex, symptoms before diagnosis, first treatment, recurrent disease, 
followup status, or median time to followup. The 2.5-year recurrence-free TGCT survival rate after 
open resection was not different with the numbers available between children and adults: 85% 
(95% confidence interval [CI], 67%-100%) versus 89% (95% CI, 83%-96%) in localized, respectively 
(p = 0.527) and 53% (95% CI, 35%-79%) versus 56% (95% CI, 49%-64%) in diffuse type, respectively 
(p = 0.691). 
Conclusions 
Although the incidence of paediatric TGCT is low, it should be considered in the differential 
diagnosis in children with chronic monoarticular joint effusions. Recurrent disease after surgical 
treatment of this orphan disease seems comparable between children and adults. With targeted 
therapies being developed, future research should define the most effective treatment strategies 
for this heterogeneous disease.




Tenosynovial Giant Cell Tumour (TGCT) is a benign, monoarticular entity. Two histologically 
identical but clinically different types are distinguished: localized and diffuse lesions1. This 
distinction can be made either on MRI or at the time of surgery. The localized type is defined by 
the World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone of 20132 as 
a well-circumscribed benign small lesion (figure 1). By contrast, the diffuse type, previously named 
pigmented villonodular synovitis (PVNS), shows unclear boundaries with extensive involvement of 
the entire synovial membrane and infiltrative growth through adjacent structures1 (figure 2). The 
knee is the most common large joint affected by TGCT with 46% of localized and 64% of diffuse-
type TGCTs affecting that joint; the hand and wrist are the next most common joints affected by 
the localized form, and the ankle and hip are the next most common joints affected by diffuse 
TGCT3. Delayed diagnosis is not uncommon as a result of different nonspecific clinical signs and 
symptoms4, 5, and the definitive diagnosis must be made histologically. The standard treatment 
remains surgical resection, but recurrence occurs in 4% to 6% patients with localized and 14% to 
40% of diffuse TGCT affecting the knee5. Histologic or radiologic risk factors for recurrent disease 
are unknown.
All described case-series on TGCT concern adults, whereas TGCT is only incidentally reported 
in children. Owing to the rarity of the disease, the available evidence base on TGCT contains 
predominantly retrospective, relatively small cohort studies, including heterogeneous data6. 
Sufficient data on paediatric patients with TGCT are lacking.
We therefore combined a systematic review with analysis from a nationwide paediatric TGCT 
incidence study in The Netherlands3 and clinical data on TGCT in children and adults from four 
tertiary sarcoma centres in The Netherlands to answer the following questions: (1) How many 
cases have been reported of this condition, and what were their characteristics? (2) What is the 
standardized paediatric incidence rate for TGCT? (3) Is there a clinical difference in TGCT between 





Children were defined as patients younger than 18 years at presentation. Large joints were defined 
as all joints proximal to the metatarsophalangeal and metacarpophalangeal joints. Data were 
derived from three sources: a systematic review, the nationwide TGCT incidence study, and from 
our bone and soft tissue tumour data registry. 
A systematic review on TGCT in children was performed, seeking sources published between 
1990 and 2016. Search terms and MeSh headings were “tenosynovial giant cell”, “diffuse type 
giant cell”, “giant cell tumors”, “PVNS”, “pigmented villonodular synovitis”, and “synovitis, pigmented 
villonodular” combined with “infant”, “child”, “neonat”, “pediatric”, “paediatric”, “toddler”, “teen”, 
“teenager”, “juvenile”, “adolescent”, “girl”, and “boy”. A total of 619 articles were identified in PubMed, 
Figure 1  Localized type TGCT: MRI of a 6-year-old boy with TGCT in his left knee. a. Sagittal T1-weighted 
image showing a well-circumscribed nodular lesion at the synovial lining of the anterior knee compartment. 
b. Sagittal T1-weighted spectral presaturation with inversion recovery (SPIR) image after IV gadolinium 
administration shows heterogeneous enhancement.
a b
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Figure 2  Diffuse type TGCT: MRI of a 16-year-old boy with TGCT in his left knee. a. Sagittal T1-weighted turbo 
spin echo (TSE) image shows extensive intra- and extra-articular villous proliferation of synovium. Posterior is a 
large Baker’s cyst. b. Transversal T2-weighted TSE image with heterogeneous low to intermediate signal of the 
TGCT anterior and posterior (white arrows). Baker’s cyst is shown posteriorly (bigger grey arrow). 
a b
EMBASE, and Cochrane library. All titles and abstracts were screened by two independent reviewers 
(MJLM, DU) including case-series with at least two TGCT paediatric patients and published in 
English. Case-series without detailed data on children were excluded, resulting in a data set of 17 
heterogeneous, mostly small case-series of two to six patients (Table 1). The largest study included 
11 patients with localized TGCT of large joints7. 
The Dutch paediatric incidence rate was extracted from the nationwide TGCT incidence study 
by including patients < 18 years of age3. Standardized incidence rates were obtained by using 
the direct method, applying age-specific incidence rates in each 1-year age group to the WHO 
standard population (http://seer.cancer.gov). This study by Mastboom et al.3 was a registry-based 
study and eligible patients with TGCT were clinically verified. Patients without histologically 
proven TGCT were not included.
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From our national bone and soft tissue tumour data registry (PALGA), a clinical data set was derived, 
including 57 patients < 18 years with (histologically proven) TGCT in large joints, treated between 
1995 and 2015, in one of the four tertiary sarcoma centres in The Netherlands. Clinical, biologic, 
and imaging data on TGCT type, sex, localization, age at diagnosis, symptoms before diagnosis, 
treatment(s), recurrence(s), and followup were collected. 
A combined retrospective database of two tertiary oncology centres (Leiden University Medical 
Centre and Radboud University Medical Centre) in The Netherlands has recorded all patients with 
TGCT since 1990 (455 patients). TGCT data on children were compared with TGCT data on 423 
adults (32 children within this database were excluded from the adult group). 
Statistical analyses, for our clinical data set, were predominantly descriptive. Chi square test  was 
used to compare children and adults on TGCT type, sex (male versus female), localization (knee 
versus other large joints), symptoms before diagnosis (pain, swelling, and loss of function: yes 
versus no), first treatment (arthroscopic resection versus open resection), recurrent disease (no 
recurrence versus recurrence), and followup status. Independent t-test was used to compare 
median duration of symptoms and median time to followup. All reported p values were two-
tailed. Statistical significance level was defined at p < 0.05. The recurrence-free survival curve was 
assessed with Kaplan-Meier methods. 
This study was approved by the institutional review board from the Leiden University Medical 
Centre (medical ethical approved protocol P13.029). Data capturing and analyses were performed 
at Leiden University Medical Centre. SPSS Version 23 (Chicago, IL, USA) was used for analyses.
results
Our systematic review identified 17 case-series involving 76 children (39 female) with TGCT, 29 
localized, 38 diffuse, and nine unknown type (Table 1). The paediatric group ranged from 3 to 18 
years of age. The knee was most frequently affected (44 [58%]). Swelling, pain, and limited ROM were 
described symptoms before diagnosis (mean duration, 15 months). The majority of patients were 
primarily treated with synovectomy, either arthroscopic or open. Recurrent disease was described 
in 10 patients (13%). Only five paediatric studies described function or quality of life after treatment. 
Patients with (multiple) recurrences experienced impaired function and quality of life, according to 
van der Heijden et al.22. Five children with diffuse TGCT, described by de Visser et al.13, had fair to 
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excellent results on the Musculoskeletal Tumour Society (MSTS) score after surgical treatment (MSTS 
by Enneking). Gholve et al.7 described 11 children with surgically treated localized TGCT without 
disabling joint function according to a telephone questionnaire survey. Seven surgically treated 
children, described by Baroni et al.4, recovered full ROM and two patients showed impaired joint 
movement with occasional mild to moderate pain in four children with localized and five children 
with diffuse type. Nakahara et al.21 showed three children with diffuse disease of the knee with almost 
maximum Knee Society Scores and improved postoperative ROM of at least 0° to 145°.
The standardized paediatric TGCT incidence rate of large joints was 2.42 and 1.09 per million person-
years in localized and diffuse types, respectively3. Between 2009 and 2013, 53 children with localized 
TGCT (excluding digits) and 24 children with diffuse TGCT were diagnosed in The Netherlands. This 
resulted in a Dutch incidence rate of 2.86 per million person-years for localized TGCT (excluding digits) 
and 1.30 per million person-years for diffuse TGCT; this was converted to standardized incidence 
rates (Supplemental Table 1 [Supplemental materials are available with the online version of CORR®.]). In 
both localized and diffuse types, the knee was most commonly affected (Figure 3). 
Clinical data of TGCT in children from the four Dutch tertiary sarcoma centres seemed similar to those 
observed in the combined two Dutch retrospective adult databases (Table 2). Fifty-seven children 
(median age at diagnosis, 16 years; range, 4-18 years) with TGCT of large joints were identified (Table 
2). Symptoms before diagnosis were swelling, pain, and limited ROM with a median duration of 12 
months (range, 1-72 months). These symptoms and the diagnostic delay seemed similar to those 
observed in adults (Table 2). Children showed a localized diffuse ratio of one to one; the knee was 
predominantly affected (13 of 28 [46%] localized, 19 of 29 [66%] diffuse) and there was a predilection 
for females (15 of 28 [54%] localized, 18 of 29 [62%] diffuse). In 423 adults, the localized:diffuse ratio 
was 1:1.6; the knee was predominantly affected (121 of 172 [70%] localized, 189 of 251 [75%] diffuse) 
with a predilection for females (107 of 172 [62%] localized, 142 of 251 [57%] diffuse).
Recurrence-free survival curves were not different with the numbers available between children 
and adults at the four involved tumour centres (Figure 4). The 2.5-year recurrence-free survival, 
after surgical treatment, in paediatric patients compared with adults was 85% (95% confidence 
interval [CI], 67%-100%) versus 89% (95% CI, 83%-96%; p = 0.527) in localized and 53% (95% 
126
Chapter six
 Table 1  Literature overview on TGCT affecting all joints in children, including at least two 
TGCT cases (1990-2016, English language)* 












Givon8 1991 2 1 M, 1 F 7 (7-7) S, W, LROM 60 (both patients) 1 L, 1 D 2 knee 1 AS, 1 US 0 24 (12-36)
Rosenberg† 9 2001 2 2 M 12 (10-14) S NA 1 L, 1 D 2 knee 1 OS, 1 US NA NA
Neubauer|| 10 2007 5 3 M, 2 F 12 (8-15) S,P 10 (2-24) 5 unknown 4 knee, 1 ankle 5 AS 1 36 (12-84)
Gholve et al.|| 7 2007 11 6 M, 5 F 12 (7-16) S, P 10 (1-24) 11 L 2 knee, 3 ankle, 4 foot, 1 hand, 1 wrist 11 OS 0 54 (15-130)
Pannier† 11 2008 6 2 M, 4 F 12‡ NA NA 2 L, 4 D 5 knee, 1 ankle 5 US, 1 MT 2 58‡
Baroni et al. 4 2010 9 4 M, 5 F 11 (7-15)¶ S, P, LROM 18 (2-48) 4 L, 5 D 9 knee 4 AS, 5 OS 0 82 (46-143)
Current 2017 57 24 M, 33 F 14 (4-18) S, P, LROM 16 (1-72) 28 L, 29 D 32 knee, 11 ankle, 5 foot, 4 hip, 2 hand, 2 other, 1 wrist 9 AS, 47 OS, 1 WS 23 55 (0-260)
Also adult cases included
Abdul-Karim 12 1992 2 2 M 10 (10-10) S, P NA 2 D 1 foot, 1 ankle 1 US, 1 AP 0 132 (108-156)
de Visser et al. 13 1999 5 4 M, 1 F 16 (12-18) NA NA 5 D 4 knee, 1 ankle 4 US, 1 RS 5 residual disease 30 (21-75)
Perka 14 2000 2 2 F 12 (8-16) S, P, LROM 12‡ 2 L 2 knee 2 US 0 NA
Somerhausen 15 2000 4 3 M, 1 F 14 (3-18) S 7 (6-8) 4 D 1 knee, 1 foot, 1 buttock, 1 thigh 4 US 0/1 NA 44.5 (0-114)
Gibbons 16 2002 3 1 M, 2 F 11 (8-15) S 28 (6-96)§ 3 L 3 foot 3 US 0 NA
Bisbinas 17 2004 5 5 F 14 (12-15) S 2‡ 5 L 5 ankle 5 OS 0 46 (12-150)
Brien 18 2004 3 1 M, 2 F 13 (12-15) S, P 7 (1-24)§ 3 D 2 foot, 1 ankle 3 US 2 NA
Sharma 19 2006 4 2 M, 2 F 14 (8-17) S, P 2‡ 4 unknown 4 ankle 4 US 0 37.5 (19-65)
Sharma 20 2007 3 2 M, 1 F 17 (16-18) S, P 5 (2-9) 3 D 3 knee 3 OS 1 96 (54-138)
Nakahara et al. 21 2012 3 2 M, 1 F 11 (8-13) NA NA 3 D 3 knee 3 OS 0 29 (20-36)
van der Heijden 22 2014 7 2 M, 5 F 14 (6-18) NA NA 7 D 7 knee 4 AS, 3 OS 4 95 (24-212)
Total 133 57 L, 67 D, 9 unknown
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 Table 1  Literature overview on TGCT affecting all joints in children, including at least two 
TGCT cases (1990-2016, English language)* 
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Neubauer|| 10 2007 5 3 M, 2 F 12 (8-15) S,P 10 (2-24) 5 unknown 4 knee, 1 ankle 5 AS 1 36 (12-84)
Gholve et al.|| 7 2007 11 6 M, 5 F 12 (7-16) S, P 10 (1-24) 11 L 2 knee, 3 ankle, 4 foot, 1 hand, 1 wrist 11 OS 0 54 (15-130)
Pannier† 11 2008 6 2 M, 4 F 12‡ NA NA 2 L, 4 D 5 knee, 1 ankle 5 US, 1 MT 2 58‡
Baroni et al. 4 2010 9 4 M, 5 F 11 (7-15)¶ S, P, LROM 18 (2-48) 4 L, 5 D 9 knee 4 AS, 5 OS 0 82 (46-143)
Current 2017 57 24 M, 33 F 14 (4-18) S, P, LROM 16 (1-72) 28 L, 29 D 32 knee, 11 ankle, 5 foot, 4 hip, 2 hand, 2 other, 1 wrist 9 AS, 47 OS, 1 WS 23 55 (0-260)
Also adult cases included
Abdul-Karim 12 1992 2 2 M 10 (10-10) S, P NA 2 D 1 foot, 1 ankle 1 US, 1 AP 0 132 (108-156)
de Visser et al. 13 1999 5 4 M, 1 F 16 (12-18) NA NA 5 D 4 knee, 1 ankle 4 US, 1 RS 5 residual disease 30 (21-75)
Perka 14 2000 2 2 F 12 (8-16) S, P, LROM 12‡ 2 L 2 knee 2 US 0 NA
Somerhausen 15 2000 4 3 M, 1 F 14 (3-18) S 7 (6-8) 4 D 1 knee, 1 foot, 1 buttock, 1 thigh 4 US 0/1 NA 44.5 (0-114)
Gibbons 16 2002 3 1 M, 2 F 11 (8-15) S 28 (6-96)§ 3 L 3 foot 3 US 0 NA
Bisbinas 17 2004 5 5 F 14 (12-15) S 2‡ 5 L 5 ankle 5 OS 0 46 (12-150)
Brien 18 2004 3 1 M, 2 F 13 (12-15) S, P 7 (1-24)§ 3 D 2 foot, 1 ankle 3 US 2 NA
Sharma 19 2006 4 2 M, 2 F 14 (8-17) S, P 2‡ 4 unknown 4 ankle 4 US 0 37.5 (19-65)
Sharma 20 2007 3 2 M, 1 F 17 (16-18) S, P 5 (2-9) 3 D 3 knee 3 OS 1 96 (54-138)
Nakahara et al. 21 2012 3 2 M, 1 F 11 (8-13) NA NA 3 D 3 knee 3 OS 0 29 (20-36)
van der Heijden 22 2014 7 2 M, 5 F 14 (6-18) NA NA 7 D 7 knee 4 AS, 3 OS 4 95 (24-212)
Total 133 57 L, 67 D, 9 unknown
*Large joints were defined as all joints proximal to and excluding metatarsophalangeal and metacarpophalangeal 
joints; large case-series not describing children in detail were not included; †language of article was French; included 
information is based on an English abstract; ‡range unavailable; §including adult cases; ||TGCT cases in digits were 
excluded; ¶case number 6, a 2-year-old girl, was excluded according to a delayed time to diagnosis of 38 months; 
TGCT = tenosynovial giant cell tumour; M = male; F = female; NA = information not available; S = swelling; 
W = warmth; LROM = limited ROM; P = pain; L = localized TGCT; D = diffuse TGCT; AS = arthroscopic synovectomy; 
OS = open synovectomy; US = unspecified 
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CI, 35%-79%) versus 56% (95% CI, 49%-64%; p = 0.691) in diffuse type, respectively. In the four 
involved sarcoma centres, most children and adults alike were primarily surgically treated by open 
resection: localized TGCT in 25 of 28 children (89%) were thus treated compared with 142 of 172 
adults (85%; p = 0.486); for diffuse TGCT in children, the proportion was 22 of 29 (76%) compared 
with 188 of 251 in adults (75%; p = 0.289).  Recurrence risk in children and adults was likewise not 
different with the numbers available: two of 28 (7%) compared with 22 of 172 (13%; p = 0.365) 
in localized type and 11 of 29 (38%) compared with 119 of 251 (47%; p = 0.921) in diffuse type, 
respectively.  
Figure 3  Skeleton showing TGCT 
localization in children extracted 
from a Dutch incidence study, 
excluding digits3. In diffuse 
TGCT, one patient was classified 
as “other”; he was treated for 
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Figure 4  Local recurrence-free survival curve of localized and diffuse TGCT (Kaplan-Meier), excluding 
digits. Time zero is the time of the primary surgery. All patients were surgically treated; patients treated 
with wait-and-see treatment are excluded. In the adult graph, two patients died and were censored at 
the time of death if a recurrence had not occurred.






























Table 2  Details of patients with TGCT of large joints in children versus adults, 
including sex, localization, age, symptoms, first treatment, recurrent disease, and followup†
Children Adults Children versus adults
Patient variables Localized TGCT Diffuse TGCT Localized TGCT Diffuse TGCT p value  localized TGCT
p value 
diffuse TGCT
Total number of patients 28 29 172 251
Sex 0.285 0.434
     Male:female ratio 13:15 (1:1.2) 11:18 (1:1.6) 65:107 (1:1.6) 109:142 (1:1.3)
Localization 0.019 0.207
     Knee 13 (46%) 19 (66%) 121 (70%) 189 (75%)
     Other joints 15 (54%) 10 (34%) 51 (30%) 62 (25%)
Age
     Median age at diagnosis (years; range) 16 (4-18) 16 (11-18) 42 (19-82) 38 (19-72)
Symptoms before diagnosis
     Swelling 24 (86%) 21 (72%) 106 (62%) 163 (65%) 0.010 0.510
     Pain 12 (43%) 17 (59%) 103 (60%) 157 (63%) 0.129 0.558
     Limited ROM 3 (11%) 4 (14%) 13 (8%) 49 (20%) 0.608 0.486
     Median duration of symptoms (months; range) 9 (1-48) 18 (1-72) 12 (1-240) 24 (1-300) 0.176 0.153
First treatment 0.486+ 0.289+
     Arthroscopic resection 3 (11%) 6 (21%) 7 (4%) 37 (15%)
     Open resection 25 (89%) 22 (76%) 147 (85%) 188 (75%)
     Wait and see 0 1 (3%) 18 (11%) 26 (10%)
Recurrent disease† N = 28 N = 28 N = 154 N = 225 0.280 0.407
     No recurrence 26 (93%) 17 (61%) 132 (86%) 106 (47%)
     ≥ 1 recurrence 2 (7%) 11 (39%) 22 (14%) 119 (53%)
Followup status 0.840 0.768
     Disease-free 19 (68%) 16 (55%) 110 (64%) 121 (48%)
     Alive with disease‡ 4 (14%) 9 (31%) 19 (11%) 94 (37%)
     Death of other disease 0 0 0 2 (1%)
     Lost to followup‡ 5 (18%) 4 (14%) 43 (25%) 34 (14%)
Median time to followup (months; range)* 25 (7-100) 77 (7-144) 36 (6-301) 54 (6-350) 0.127 0.780
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Table 2  Details of patients with TGCT of large joints in children versus adults, 
including sex, localization, age, symptoms, first treatment, recurrent disease, and followup†
Children Adults Children versus adults
Patient variables Localized TGCT Diffuse TGCT Localized TGCT Diffuse TGCT p value  localized TGCT
p value 
diffuse TGCT
Total number of patients 28 29 172 251
Sex 0.285 0.434
     Male:female ratio 13:15 (1:1.2) 11:18 (1:1.6) 65:107 (1:1.6) 109:142 (1:1.3)
Localization 0.019 0.207
     Knee 13 (46%) 19 (66%) 121 (70%) 189 (75%)
     Other joints 15 (54%) 10 (34%) 51 (30%) 62 (25%)
Age
     Median age at diagnosis (years; range) 16 (4-18) 16 (11-18) 42 (19-82) 38 (19-72)
Symptoms before diagnosis
     Swelling 24 (86%) 21 (72%) 106 (62%) 163 (65%) 0.010 0.510
     Pain 12 (43%) 17 (59%) 103 (60%) 157 (63%) 0.129 0.558
     Limited ROM 3 (11%) 4 (14%) 13 (8%) 49 (20%) 0.608 0.486
     Median duration of symptoms (months; range) 9 (1-48) 18 (1-72) 12 (1-240) 24 (1-300) 0.176 0.153
First treatment 0.486+ 0.289+
     Arthroscopic resection 3 (11%) 6 (21%) 7 (4%) 37 (15%)
     Open resection 25 (89%) 22 (76%) 147 (85%) 188 (75%)
     Wait and see 0 1 (3%) 18 (11%) 26 (10%)
Recurrent disease† N = 28 N = 28 N = 154 N = 225 0.280 0.407
     No recurrence 26 (93%) 17 (61%) 132 (86%) 106 (47%)
     ≥ 1 recurrence 2 (7%) 11 (39%) 22 (14%) 119 (53%)
Followup status 0.840 0.768
     Disease-free 19 (68%) 16 (55%) 110 (64%) 121 (48%)
     Alive with disease‡ 4 (14%) 9 (31%) 19 (11%) 94 (37%)
     Death of other disease 0 0 0 2 (1%)
     Lost to followup‡ 5 (18%) 4 (14%) 43 (25%) 34 (14%)
Median time to followup (months; range)* 25 (7-100) 77 (7-144) 36 (6-301) 54 (6-350) 0.127 0.780
*Patients lost to followup are excluded for median time to followup; lost to followup is defined as < 6 months 
followup; †+wait and see treatment was not included in calculation of independent t-test; children were included 
between 1995 and 2015 adults between 1990 and 2015; ‡patients alive with disease either have wait and see 




TGCT is most commonly seen in adults in the third and fourth decades of life, but this study confirms 
that it also affects paediatric patients. The paediatric incidence rate for both localized and diffuse 
type suggests that it is rare, but we believe it is still common enough to include in the differential 
diagnosis of both children and adults with nonspecific symptoms like swelling, pain, and limited 
ROM. We found no differences with the numbers available between children and adults in terms 
of presenting symptoms, treatments used in the few available case-series, and recurrence-free 
survival rates. In the era of personalized medicine, future research should define the most effective 
treatment for TGCT, with its various clinical scenarios, both in children and adults.
There are some limitations to this study. In our systematic review, many case-series included data from 
children with TGCT in embedded studies that also contained adults’ data. When data on children was 
not separately described, these children were not included in the overview (Table 1). The determined 
incidence rate is a conservative estimate, because our search was based on the nationwide network 
and registry of histo- and cytopathology in The Netherlands23. Patients with TGCT without a biopsy 
or treatment were not represented in this pathology-based cohort. By standardizing incidence rates, 
they could be extrapolated to other populations. However, generalizability of the standardized 
incidence rate depends on the age-specific population structure of the country compared with the 
WHO population. Included patients had histologically proven TGCT by a dedicated musculoskeletal 
pathologist (UF, HB, AS, JB). However, patients were not centrally reviewed for this study. Neither 
functional outcome nor quality of life was evaluated. For TGCT treatment, only surgical treatment 
was evaluated. Future, comparative studies on treatments should determine what should be done for 
patients (children and adults) with TGCT. Although surgery is the mainstay, other treatments are used, 
and future research needs to define what the best approaches are for the various clinical scenarios in 
which this disease presents. In our patients, children with the localized type frequently lacked longer 
term followup, mainly as a result of absence of clinical symptoms (17 censored in the first 2.5 years; 
Figure 4). Smaller patient numbers with the diffuse type sometimes lacked longer followup (nine 
censored in the first 2.5 years).
TGCT does not seem to be an adults-only disease and should be considered in the differential 
diagnosis in children with (chronic) monoarticular joint effusion. Our systematic review identified 
mainly small, heterogeneous TGCT case-series in children. Future studies might consider including 
children with TGCT to allow for optimalization of the treatment protocol in both children and adults.
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The standardized paediatric TGCT incidence rate of large joints was 2.42 and 1.09 per million 
person-years compared with an overall incidence rate of 10.2 and 4.1 per million person-years 
in localized and diffuse types, respectively3. To date, the incidence rate for chronic monoarthritis 
in children and adolescents is unknown. Savolainen et al. calculated an incidence rate of 64 
per 100,000 for all types of arthritis in children (< 16 years) in a defined population in Finland24. 
Although TGCT in children probably accounts for only a small percentage of all types of arthritis, it 
should still be considered in the differential diagnosis.
Symptoms in children seemed similar to those in adults (Table 1). Nonspecific symptoms 
accompanied by pain and diffuse joint swelling with thickening of the synovial capsule and/or 
joint effusion resulted in limited movement in approximately half of the patients. Studies in adults 
add mechanical symptoms, instability, and stiffness5, 25.
A systematic review (without age limitations) in 20135 reported average recurrence rates for 
localized TGCT in the knee after open resection (4%) and after arthroscopic resection (6%) in 
contrast to diffuse type after open resection (14%) and after arthroscopic resection (40%) at a 
mean followup of 108 months. Patel et al.25 presented 214 patients with knee TGCT of all ages with 
a recurrence rate of 9% in 100 localized patients and 48% in 114 patients with diffuse TGCT after a 
mean followup of 25 months (range, 1-168 months). Palmerini et al.26 reported 294 patients with 
TGCT of all ages in all joints with a local failure rate of 14% in localized and 36% in diffuse type after 
a median followup of 4.4 years (range, 1-20 years). The sole primary disease or patients with a first 
relapse were included. The current paediatric case-series showed comparable recurrence rates of 
7% in localized and 39% in diffuse type after a mean followup of 55 months (range, 7-350 months). 
TGCT is a rare condition in adults and it is even less common in children. Nonspecific symptoms 
often contribute to a delay in establishing a diagnosis. TGCT should be considered in chronic 
monoarthritis both in adults and in children. Recurrent disease after surgical treatment of this 
orphan disease seems comparable between children and adults. With targeted therapies now 
being developed27, future research should define the most effective treatment strategies for this 
heterogeneous disease.
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Localized-type Tenosynovial Giant Cell Tumour (TGCT) is a rare, neoplastic disease with only limited 
data supporting treatment protocols. A multicentre-pooled collection of individual patient data 
resulted in the largest global retrospective cohort of localized-TGCT patients to date. We describe 
treatment protocols and evaluate their oncological outcome, complications and functional results. 
A secondary study aim was to identify risk factors for local recurrence after surgical treatment. 
Methods
Patients with histologically proven localized-TGCT of large joints were included if treated between 
1990-2017 in one of 31 tertiary sarcoma centres. In 941 patients with localized-TGCT, 62% were female, 
median age at initial treatment was 39 years with a median follow-up of 37 months. 67% affected the 
knee and the primary treatment at a tertiary centre was one-staged open resection in 73%. Proposed 
risk factors were tested in a univariate analysis and significant factors subsequently included for 
multivariate analysis, with an endpoint of first local recurrence after treatment in a tertiary centre.
Results
Recurrent disease developed in 12% of all cases, with local recurrence free survival rates at 3, 5 
and 10 years of 88%, 83% and 79%, respectively. The strongest risk factor for recurrent disease was 
prior recurrence (p<0.001). Complications were noted in 4% after surgical treatment of localized-
TGCT. Initial symptoms of pain and swelling improved after surgical treatment(s) in 71% and 
85%, respectively. For therapy naïve cases, univariate and multivariate analyses yielded positive 
associations with local recurrence for tumour size ≥5 cm vs <5 cm (HR 2.50; 95%CI 1.32-4.74; p=0.005) 
and initial treatment with arthroscopy vs open resection (HR 2.18; 95%CI0.98-4.84; p=0.056). 
Conclusions
Risk factors for recurrent disease after resection of localized-type TGCT were larger tumour size 
and initial treatment with arthroscopy. Relatively low complication rates and good functional 
outcome warrant an open approach with complete resection when possible, to reduce recurrence 




In 2013 the WHO defined Tenosynovial Giant Cell Tumours (TGCT), after unification of Giant 
Cell Tumour of the Tendon Sheath and Pigmented Villonodular Synovitis (PVNS), as a benign 
mono-articular disease, arising from the synovial lining of joints, bursae or tendon sheaths in 
predominantly young adults1, 2. 
Clinically and radiographically, TGCT is subdivided into a lobulated often well-bordered lesion 
(localized-type) that does not involve the surrounding (teno-)synovial lining and a more 
aggressive lesion, involving a large part or all of the synovial lining (diffuse-type)1-3. Despite 
sharing the same histopathology and genetics, the natural course of disease in localized- and 
diffuse-TGCT is incomparable and necessitate a separate assessment of treatment protocol and 
surgical outcome. Based on anatomical site of the localized-type tumour, differentiation is made 
between disease affecting digits and disease occurring in and about larger joints4-6. The present 
study focuses on localized-TGCT of large joints (figure 1), most commonly affecting the knee or 
other weight bearing joints1, 2, 6, 7.
The macroscopic appearance of localized-TGCT is typically a well-circumscribed lobulated lesion, 
with white to grey, yellow and brown mottled areas. According to the WHO, localized-TGCT is a 
small lesion, with a size range of 0.5 to 4 cm1, 2. However, according to the authors’ experience, the 
largest size can frequently exceed 4 cm, especially when compressed in relatively tight joints (e.g. 
foot and ankle) or situated in the anterior or posterior aspect of the knee.
The main patients complaints related to localized-TGCT include pain, joint effusion, stiffness, 
locking and limited range of motion8, 9. The predominant standard of care for localized-TGCT is 
surgical resection of the tumour, in order to: (1) reduce debilitating symptoms and prevent joint 
destruction caused by local compression of cartilage; (2) improve limb function; and (3) minimize 
the risk of local recurrence. Clinical and oncological outcomes following surgery depend on 
multiple factors including the localization and extent of disease and possibly the technical 
experience of the surgeons3, 7, 10-12. 
The current literature mainly consists of relatively small, or larger but heterogeneous case-series, 
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as localized-TGCT of large joints is an orphan disease, with an incidence of 10.2 per million person-
years6. A systematic review, including predominantly small case-series up to ten patients, showed 
comparable recurrence rates after arthroscopic and open resection of the knee (6% versus 4%, 
respectively)13. However, studies included in this review had different follow-up times ranging 
from not available to 18, up till 112 months. Complications and functional outcomes after surgical 
treatment are only sparsely reported and surgical treatment by arthroscopic or open resection for 
localized-TGCT at present remains a matter of debate7-9, 14-16. 
Evaluation of a large number of individual patients is preferred to evaluate the best treatment 
strategy and possibly identify risk-factors for recurrent disease. Individual participant data meta-
analysis offers advantages, above a meta-analyses, as missing data can be accounted for at the 
individual level, subgroup analyses can be performed (e.g. per affected joint) and follow-up 
information can be updated17. Therefore, we aimed to collaborate with tertiary sarcoma centres all 
over the world to include individual participant data of TGCT affecting large joints.
The primary aim of this international multicentre cohort study is to provide comprehensive and 
up to date insights on TGCT surgical treatment as well as oncologic and functional outcomes 
and complications in this largest global retrospective cohort of patients with localized-TGCT. 
Secondarily, risk factors for local recurrence after surgical treatment are identified.
 methods
Recruitment and inclusion criteria
Patients with histologically proven TGCT of large joints were included if treated between 1990 and 
2017 in one of 31 sarcoma centres globally (supplementary material). Large joints were defined as 
all joints proximal to the metatarsophalangeal and metacarpophalangeal joints. Identification and 
collection of TGCT cases was performed in the centres of origin and data were collected based on 
the initial treatment at tertiary centres. Data were encrypted and transferred to the international 
multicentre database at the Leiden University Medical Centre (LUMC). Patient accrual occurred 
between May 2016 until May 2018.
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Figure 1  Intra-articular localized-TGCT in the posterior part of the left knee in a 19 year old female. a. Sagittal 
T1-weighted Magnetic Resonance (MR) imaging after intravenous contrast injection with fat suppression. TGCT 
shows marked enhancement after contrast injection. b. TGCT shows an intermediate to low signal intensity on 
a sagittal T2-weighted MR scan. c. On a sagittal proton-density weighted MR imaging, localized-TGCT presents 
with low signal intensity. d. Macroscopic aspect of a well-circumscribed localized-TGCT after complete open 
resection. Arrow shows brownish areas, representing hemosiderin depositions. On the ruler, 1 block equals 1 cm.
a b
c d




Collected patient-, tumour- and treatment characteristics with corresponding definitions are 
shown in appendix table 1. Complete data on core criteria was necessary for reliable analyses. The 
following characteristics were defined as core criteria: TGCT-type, admission status, date and type 
of initial treatment at tertiary centre and first local recurrence.
Patient-, tumour- and treatment characteristics
Thirty-one specialized sarcoma centres spread throughout Europe, North America, Canada and Asia 
collaborated to provide a total of 2169 TGCT cases. The present study focuses on localized-TGCT (table 
1), therefore patients with diffuse-TGCT (N=1192) or unknown type TGCT (N=36) were excluded.
Statistical analyses
The endpoint for statistical analysis was local recurrence free survival after initial treatment in a tertiary 
centre. Recurrent disease was defined as new disease presence after resection performed in a tertiary centre 
or progressive residual disease (as diagnosed on repeated follow-up Magnetic Resonance (MR) imaging).
To investigate the effect of risk factors on outcome, univariate analyses were performed and 
significant factors (p<0.05) were subsequently included in a multivariate analysis. Proposed 
risk factors were admission status (therapy-naïve versus recurrent disease), sex (male versus 
female), age (≤35 years versus >35 years), localization (knee versus hip versus foot and ankle 
versus upper extremity), bone-involvement (present versus absent), surgical technique (open 
versus arthroscopic) and size (<5 cm versus ≥5 cm). Patients with treatment ‘wait and see’ or 
‘endoprosthetic reconstruction’ were excluded from statistical analyses (N=85).
Observed recurrence free survival probabilities at 3, 5, and 10 years were computed for all cases 
and subgroups based on admission status and localization.
All data were selected for completeness on core criteria (appendix table 1 and figure 1). Statistical 
analyses were carried out using R version 3.4.1. Exact survival information and statistical methods 
are shown in supplementary material.
Purposefully, an estimate of the median time to recurrence was not provided. Calculating such 
a median, based on patients for whom a recurrence was recorded, would assume that all other 
patients could not experience a recurrence in the future. The extent of this so-called immortal time 




^Therapy-naïve or primary admission at tertiary centre are considered similar. ^^≥1 Surgery elsewhere 
or recurrent admission are considered similar. *Digits are excluded. #Symptoms were defined as either 
pain, swelling, stiffness or limited range of motion (table 8-9). $Wait and see or conservative treatment are 
considered similar. +Endoprosthetic reconstruction or wait and see as initial treatment are excluded for 
risk and survival analyses. &Resection not specified is considered either arthroscopic- or open resection.
Table 1  Patient-, tumour- and treatment characteristics
Characteristics Overall (%)
Total number 941 (100)
Admission status (N=941)
     Therapy naïve^




     Male
     Female
360 (38)
581 (62)
Median age at initial treatment years (N=882)
     IQR
     ≤35 years





Localization (N=941) (figure 2)
     Knee
     Hip
     Ankle
     Foot*
     Shoulder
     Elbow
     Wrist
     Hand*











     Present
     Absent
57 (8) 
632 (92)
Median duration of symptoms# months (N=571)
     IQR
9
4-24
Type of (surgical) treatment at tertiary centre (N=930)
     Arthroscopic resection
     One-staged open resection
     Endoprosthetic reconstruction+
     Wait and see$,+






Median tumour size initial treatment in cm (N=637)
     IQR
     <5 cm





Adjuvant therapy initial treatment (N=787)
     External beam radiotherapy
     90Yttrium
     Systemic targeted therapy
     Other










This study is conducted according to the Declaration of Helsinki (October 2013) and approved by 
the institutional review board (CME) from the Leiden University Medical Centre (LUMC) (May 4th, 
2016; G16.015).
Source of Funding
The department of orthopaedics of the Leiden University Medical Centre (LUMC) receives research 









Figure 2  Skeleton showing localization of TGCT in 941 localized-





In 823 patients with localized-TGCT of large joints and complete survival data, 100 (12%) had a 
recurrence during the follow-up period. Recurrence free survival (RFS) continued to decrease with 
longer follow-up times (table 2-3, figure 3-5).
Univariate- and multivariate analyses for local recurrence
The risk factor admission status was highly associated with significant differences in recurrence risk 
(p <0.001) in univariate analysis of 823 patients with localized-TGCT and complete core data: RFS at 
5 years in patients entering the tertiary hospital with recurrent disease (surgery elsewhere) was 34% 
(95% CI 17-51), compared with 86% (95% CI 82-89) in therapy naïve patients (figure 3). After excluding 
patients initially treated elsewhere, the risk factors tumour size and surgical technique were found to 
Table 2  Oncologic outcome after surgical treatment of localized-TGCT affecting large joints
Localized-TGCT
First local recurrence after initial treatment at a tertiary centre (N=823)
     Present
     Absent
100 (12%) 
723 (88%)
Total number of recurrences (N=100)
     1
     2




Mean total number of surgeries (N=657)
Mean total number of surgeries in recurrent disease (N=100)
1.2 (range 1-5)
2.1 (range 1-5)
Median follow-up months (N=823) 37 (95%CI 33-40)
Status last follow-up (N=743)
     No evidence of disease
     Alive with disease - wait and see
     Alive with disease - awaiting treatment
     Death of other disease






*Lost to follow-up was defined as follow-up less than 6 months or stratified during follow-up as lost to follow-up
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7be positively associated with first local recurrence (table 4-5, figure 3-5). Younger patients ≤35 years 
also had fewer recurrences than older patients (82% vs 88%, p=0.04). Similar results were calculated 
in a subgroup analysis in therapy naïve patients with localized-TGCT affecting the knee.
Observed recurrence free survival according to admission status and localization
As arthroscopic resection is less common in the hip, foot/ankle and upper extremity, arthroscopic 
and open resection were compared for TGCT affecting the knee (figure 5). The highest recurrence 
rates occurred in therapy naïve patients with tumours located within the knee joint who were 
initially treated with an arthroscopic resection (18%) (figure 6). 
When comparing therapy naïve patients with patients initially treated elsewhere, a declining RFS 
was observed at 3, 5 and 10 years in subgroup analyses of patients with tumours located in the 
knee, foot/ankle and upper extremity (table 6). 
Complications
A total of 34 (4%) complications after surgical treatment of localized-TGCT were reported (table 
7). The majority of these complications presented after open resection (30/34; 88%). Following 
arthroscopic resection, two complications were reported (6%).
Functional outcome
Prior to surgical treatment, the majority of patients had symptoms of pain (73%) and swelling (66%) 
(table 8). After surgical treatment, at final follow-up, symptoms of pain, swelling, joint stiffness and 
limited range of motion were absent in the majority of cases.
Table 3  Localized-TGCT recurrence free survival (RFS) of all patients and therapy naïve patients 
treated at a tertiary centre
Year N all % RFS all (95%CI) N therapy naïve % RFS therapy naïve (95%CI)
3 388 88 (85-91) 372 90 (88-93)
5 231 83 (80-87) 223 86 (82-89)
10 66 79 (75-84) 63 82 (78-87)
N is number of patients at risk at 3, 5, and 10 years
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Figure 3  Local recurrence free survival curve in localized-TGCT stratified for admission status (p<0.001)
Time zero was date of initial resection at tertiary centre. Primary: patient with therapy-naïve disease initially 










primary 791 490 298 172 99 53
recurrent 32 14 10 8 5 1
years 0 2 4 6 8 10
number at risk
strata: primary recurrent
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Table 4  Univariate analyses in 791 patients with therapy naïve localized-TGCT
Variable N % RFS at 5 years 95%CI P value
Age
≤35 years 343 82 77-88 0.04
>35 years 447 88 84-92
Sex
male 292 88 82-93 0.56
female 499 85 80-89
Localization
knee 529 85 81-89 0.71
foot/ankle 156 84 76-93
upper extremity 82 90 81-98
Size
<5 cm 454 89 85-94 0.009
≥5 cm 124 76 66-87
Bone involvement
absent 543 85 81-89 0.70
present 50 74 57-91
Surgical technique
open 629 87 83-91 0.04
arthroscopic 132 80 72-88
RFS: Recurrence free survival, 95%CI: 95% Confidence interval
Table 5  Multivariate analyses in 554 patients with therapy naïve localized-TGCT
Variable Hazard ratio 95% CI P value
Age per year 0.99 0.97-1.01 0.425
Size <5 cm 1
≥5 cm 2.50 1.32-4.74 0.005
Surgical technique open 1
arthroscopic 2.18 0.98-4.84 0.056




<5 cm 454 267 149 91 58 36
≥5 cm 125 75 36 21 13 6
years 0 2 4 6 8 10
number at risk









Figure 4  Local recurrence free survival curve in therapy naïve patients with localized-TGCT stratified for size 
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Figure 5  Local recurrence free survival curve in patients with therapy naïve localized-TGCT affecting the knee 
stratified for surgical technique (p=0.02). Time zero was date of initial resection at tertiary centre. Open: open 
resection, arthroscopic: arthroscopic resection
Years since surgery
open 400 256 154 77 40 21
arthroscopic 114 70 52 35 22 9
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For a mean of 501 (53%) patients with localized-TGCT, complete data were available both prior to 
treatment and at last follow-up (table 9). The majority of patients experienced pain and swelling 
prior to initial treatment, of which 71% and 85% were resolved after surgery at final follow-up.   
Swelling or stiffness might coincide with recurrent disease as 34% (21/61) and 40% (8/20) of 
patients with swelling and joint stiffness respectively at final follow-up had recurrent disease. In 
contrast to pain, limited range of motion or chronic use of analgesics, as 20% (25/124), 30% (8/27) 
and 29% (7/24), respectively, had recurrent disease. 
Chronic analgesic treatment versus complications
Two of 26 patients (8%) with a complication used chronic analgesic treatment compared to five of 
429 (3%) patients without a complication.
Figure 6   Flowchart localized-TGCT. Primary: patient was first seen at tertiary centre with therapy-naïve 
disease, recurrent: patient initially treated elsewhere, AR: Arthroscopic resection, OR: Open resection, SR: 
Surgical resection (either arthroscopic or open resection). Treatments other than surgical resections were not 
included in this flowchart (e.g. endoprosthetic reconstruction, wait and see treatment or adjuvant therapy). 
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Table 6  Recurrence free survival (RFS) probabilities for localized-TGCT
Admission
status Localization N
+ %RFS at 
3 years 95% CI
%RFS at 
5 years 95% CI
%RFS at 
10 years 95% CI
primary knee 529 89 87-93 85 81-89 81 76-87
primary foot/ankle 156 90 84-96 84 76-93 81 71-91
primary upper extremity* 82 93 86-100 90 81-98 86 74-97
recurrent knee 16 44 19-68 44 19-68 **
recurrent foot/ankle 11 30 3-57 18 0-41 18 0-41
recurrent upper extremity* 3 67 13-100 67 13-100 67 13-100
Since the hip was affected sporadically (primary N=24; recurrent N=2) without recurrent disease during follow-up, 
reliable analyses were not possible. +N: number at baseline (time point = 0), *Upper extremity including other localization, 
**Survival estimates of recurrent knee patients at 10 years could not be estimated (due to lack of follow-up information). 
Primary: patient was first seen at tertiary centre with therapy-naïve disease, recurrent: patient initially treated elsewhere, 
95%CI: 95% Confidence interval. 
Table 7  Complications after surgical treatment at tertiary centre (N=763)
Complications after surgical treatment N (%)
Superficial wound infection 11 (1)
Deep wound infection 1 (0.1)
Joint stiffness$ 5 (0.7)
Haemorrhage 1 (0.1)
Neurovascular damage 3 (0.4)
Thrombosis 3 (0.4)
Other+ 10 (1) 
As osteoarthritis is either caused by extensive disease or by (multiple) treatments, this was not taken into account for 
complications. $Joint stiffness requiring manipulation under anaesthesia. +Other surgical complications after initial 
treatment included: joint subluxation (hip), compartment syndrome, ligament incision during surgery, complex 
regional pain syndrome, tourniquet blistering, tendinitis. 
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Table 8  Symptoms prior to treatment and at final follow-up
Symptom Pre-treatment Final follow-up
Pain (PT 767, FF 522) 560 (73%) 128 (25%)
Swelling (PT 675, FF 525) 448 (66%) 64 (12%)
Joint stiffness (PT 663, FF 525) 65 (10%) 21 (4%)
Limited range of motion (PT 667, FF 523) 110 (16%) 27 (5%)
Chronic analgesic treatment* (FF 568) 25 (4%)
Presented numbers indicate presence of symptom. *Chronic analgesic treatment data were only collected at 
final follow-up, PT: total number pre-treatment, FF: total number final follow-up
Table 9  Comparing symptoms localized-TGCT prior to treatment to last follow-up
No pain last fu Pain last fu Total
No pain initially 122 (24%) 18 (4%) 140
Pain initially 260 (52%) 104 (21%) 364
No swelling last fu Swelling last fu
No swelling initially 160 (32%) 11 (2%) 171
Swelling initially 284 (56%) 50 (10%) 334
No stiffness last  fu Stiffness last fu
No stiffness initially 427 (86%) 16 (3%) 443
Stiffness initially 50 (10%) 4 (1%) 54
No limited range of motion 
last fu
Limited range of motion 
last fu
No limited range of motion 
initially 385 (77%) 16 (3%) 401
Limited range of motion 
initially 88 (18%) 9 (2%) 97
fu: follow-up.




The results of this international multicentre study offer reliable insight into the outcome of the 
treatment of patients with the orphan and heterogeneous disease localized-type Tenosynovial 
Giant Cell Tumour (TGCT). We evaluated oncologic results, complications and functional results 
after surgical treatment. The greatest strength of this dataset is that it represents the largest 
collection of localized-TGCTs of large joints in the scientific literature, including a subgroup of 
patients with long follow-up (>10 years).
Oncologic outcome
Surgical resection of TGCT has been the treatment of choice by either an arthroscopic or open 
technique, based on the preference of the patient and treating physician, and might also differ by 
centre. Physicians in favour of arthroscopic resection claim faster recovery, a lower complication 
rate and less joint morbidity23-30. However, opponents of arthroscopic resection point out the risk 
of inadequate excision, higher recurrence rates and a theoretical risk of joint seeding and portal 
contamination13, 16.
In the current study, we identified higher recurrence rates after arthroscopic (18%) compares to 
open resection (9%) of therapy naïve localized-TGCT affecting the knee joint. This is also presented 
in the systematic review of van der Heijden et al. (6% after arthroscopic and 4% after open 
resection)13. These higher recurrence rates may be explained by the longer follow-up times on 
average and the larger sample size of localized-TGCT cases (table 4-5, figure 3-5). The single most 
important and significant risk factor for local recurrence is recurrent disease at presentation. In a 
subgroup analysis of patients with primary disease treated in a tertiary centre, the greatest risk for 
first local recurrence was associated with tumour size ≥5 cm and arthroscopic resection at initial 
treatment. This could be attributed to the fact that arthroscopic en bloc and complete resection 
is likely only possible in a small percentage of cases with small/pedunculated and accessible 
lesions, whereas in most cases intralesional removal would be performed arthroscopically thereby 
potentially leaving residual disease in the joint. Several other studies reported higher rates of 




All surgical treatments are associated with complications and data following resection of TGCT are 
currently lacking in recent literature. The present study reported a complication rate of 4% after 
surgical treatment for localized-TGCT. The most common complication in localized-TGCT was a 
superficial wound infection after open resection.
Functional outcome
TGCT related symptoms are mainly joint pain, swelling, stiffness and limited range of motion, but 
these occur with great variability in extent and severity. Gelhorn et al. concluded that not all patients 
experience all symptoms to the same extent (e.g. swelling but no pain, or pain and swelling but no 
stiffness or limited range of motion)9. Symptoms prior to initial treatment at a tertiary centre were 
compared with symptoms at last follow-up. Initial symptoms of pain and swelling improved after 
surgical treatment(s) in 71-85% of patients. This is comparable with a crowdsourcing study in 337 
TGCT patients originating from 30 countries8. Stiffness and limited range of motion seemed not 
to be debilitating symptoms in the majority of patients, either initially or at last follow-up. There 
was no relationship between symptoms at last follow-up and recurrent disease. Symptoms are 
subjective for each patient and not all patients were included with complete data. Nevertheless, 
the main initial TGCT-related complaints are pain and swelling and these could potentially improve 
after surgical treatment(s).
Joint specific analyses
In daily practise, TGCT patients present as a heterogeneous group. To provide reliable results, 
homogeneous subgroup analyses are essential. This was possible with our individual participant 
data meta-analysis. Even though quite a large number of TGCT cases were collected, complete risk 
factor subgroup analyses were only feasible for TGCT affecting the knee (67%). 
Limitations
As a result of increased awareness about TGCT, more patients are now being referred to (tertiary) 
orthopaedic oncological referral centres as new targeted therapies are being examined in on-
going RCTs33-35. However, data on patients treated at non-specialized centres are lacking in both 
the literature and within the present study. Therewith, selection (referral) bias is induced. The 
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degree of selection bias according to affected joints is negligible, as similar percentages of affected 
localizations (figure 2) were reported in a recent incidence calculation study with nationwide 
coverage6. Non-specialized centres that resect smaller tumours without local recurrence were not 
present, possibly introducing an overestimation of LR for localized-TGCT in general.
As data were collected by local investigators or physicians according to the multicentre study 
design, data quality depended on data registry on site. Only data available in the source data file 
of the patients could be retrieved. In addition, interpretation of individual parameters could differ. 
No central histopathological review was performed, as it was assumed that each centre provided 
the correct diagnosis as set by their histopathology department.
Recurrence rates could either be over-estimated or under-estimated. Over-estimation since 
date of a second operation or follow-up status ‘alive with disease’ was classified as recurrence 
(if recurrence data was missing). On the contrary, under-estimation could be present if patients 
with recurrent disease did not return at all or did not return to their original centre. It should 
be noted that patients with recurrent disease had a longer follow-up compared with patients 
without recurrent disease. This could be explained by the fact that patients without symptoms 
and (assumed) without recurrent disease were dismissed from follow-up and therefore presented 
with shorter follow-up times. Plausibly, patients without symptoms are not experiencing recurrent 
disease. In addition, if treatments were recently performed, patients also had shorter follow-up 
times and are still at risk of recurrence. 
conclusion
We present the largest international study that evaluated the clinical profile, management and 
outcome for patients with TGCT. Localized-TGCT remains a heterogeneous and orphan disease, 
with an overall recurrence free survival of 83% at 5 years. Risk factors for recurrent disease were 
larger tumours, primary treatment with arthroscopy and initial surgical treatment outside of a 
tertiary centre. Relatively low complication rates and good functional outcomes warrant complete 
resection, most commonly accomplished by an open surgical approach, to reduce recurrence 
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Table 1  Collected patient and tumour characteristics with corresponding definitions.
Characteristic Definition
TGCT-type Localized-/diffuse-TGCT as defined by the 2013 WHO1, 2
Admission status Previously treated*
Sex Male/female
Age at initial treatment Age at initial treatment
Side Left/right
Localization TGCT affected joint
Bone involvement Discontinuation of cortex by tumour ingrowth*
Date first diagnosis Date first diagnosis
Duration of symptoms Duration of symptoms in months
Pain, swelling, stiffness and 
limited range of motion 
prior to initial treatment 
and at last follow-up
(Clinically relevant) Pain, swelling, stiffness+ and limited range of motion 
prior to initial treatment* and at last follow-up
Total number surgeries All surgeries related to TGCT, including re-operations for complications
Date initial treatment** Date initial treatment at tertiary centre and date(s) of consecutive treat-ment(s)
Initial treatment**
Type of initial treatment and consecutive treatment(s): arthroscopic re-
section, one-staged open resection, two-staged open resection, (tumour)
prosthesis, amputation, wait and see++, synovectomy not specified
Tumour size Largest size in any dimension (cm), according to the 2013 WHO classifica-tion1, 2, <5 and ≥5 cm were compared
Adjuvant therapy Nothing, radiotherapy, 90Yttrium, targeted therapy, cryosurgery, other
Date complication Date complication related to surgical treatment
Complication 
Type of complication related to surgical treatment: no complication, super-
ficial wound infection, deep wound infection, joint stiffness+, haemorrhage, 
neurovascular damage, thrombosis, other, unknown
Total number recurrences Total number local recurrences
Date final follow-up Date final follow-up
Status last follow-up
No evidence of disease, alive with disease wait and see, alive with disease 
planned surgery of adjuvant therapy, death of disease, death of other dis-
ease, lost (<6 months follow-up)
Chronic analgesic treat-
ment at last follow-up Chronic analgesic treatment at last follow-up
Characteristics in bold were core criteria. *These parameters were answered by present or absent. **(Date) 
initial treatment, initial treatment in tertiary centre is not necessarily first treatment of the patient. +Stiffness 
requiring manipulation under anaesthesia. ++Wait and see and conservative treatment are considered similar. 
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Figure 1  Proportion of data missing per variable in localized-TGCT (N=941). 
Symptoms prior to initial treatment at tertiary centre include pain, swelling, stiffness and limited range of 
motion. Symptoms at last follow-up include pain, swelling, stiffness, limited range of motion and chronic 
analgesic treatment at last follow-up. 
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Supplementary material participating international sarcoma reference centres
1. Leiden University Medical Center, Leiden, The Netherlands
2. Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
3. IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
4. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
5. Istituto Ortopedico Gaetano Pini, Milano, Italy
6. Mount Sinai School of Medicine, New York, USA
7. Medical University Graz, Graz, Austria
8. Halen İstanbul Üniversitesi, Istanbul, Turkey 
9. AOU Città della Salute e della Scienza, Torino, Italy
10. Orthopedic Hospital Gersthof, Vienna, Austria
11. Careggi University-Hospital, Firenze, Italy
12. University Medical Center Groningen, Groningen, The Netherlands
13. Academic Medical Center, Amsterdam, The Netherlands
14. Mount Sinai Hospital, Toronto, Canada
15. Beijing Jishuitan Hospital, Beijing, 100035, China
16. Institut Roi Albert II, Brussels, Belgium
17. Royal National Orthopedic Hospital, London, the United Kingdom
18. Hospital de Navarra, Pamplona, Spain
19. Centre hospitalier universitaire de Nantes, Nantes, France
20. Ludwig-Maximilians-University Munich, Munich, Germany
21. Medical University of Innsbruck, Innsbruck, Austria
22. Massachusetts General Hospital Harvard, Boston, United States of America
23. Chiba Cancer Center, Chiba, Japan
24. National Cancer Center, Tokyo, Japan
25. Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
26. Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine
27. Universitätsklinikum Jena, Jena, Germany
28. University of the Phil-Phil General Hospital, Manila, Philippines
29. Catholic University of Korea, Seoul, Korea
30. Cairo University, Cairo, Egypt
31. Wilhelmsburger Krankenhaus Groß Sand, Hamburg, Germany
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Supplementary material exact survival information and statistical methods
For some cases exact survival information was not available (appendix figure 1). In 7 out of 61 cases, 
we could recover the missing recurrence indicator: in 2 cases patients had a second treatment and 
in 5 cases patients had follow-up status ‘alive with disease’ and were classified as recurrent disease. 
If the exact time of recurrence was not recorded, an approximation was sometimes possible. If 
the date of surgery to treat a local recurrence was known, this was used instead (N=33). If this 
information was missing as well, then the date of last recurrence was used as an upper bound 
(N=5). Otherwise the date of last recorded follow-up was used as an upper bound (N=69). If data 
on recurrence status or date of recurrence was missing and could not be recovered as described, 
patients were excluded for risk- and survival analyses (N=64).
Some centres did not record follow-up time in patients without recurrent disease. To prevent 
exclusion of these patients, we imputed their follow-up time (N=97). Multiple imputation 
technique was applied and 5 complete data sets were imputed using the R-package Amelia II18. 
Statistical analyses were conducted on all data sets and the results were then pooled following 
Rubin’s rule19.
As a consequence of the approximation of the time of recurrence by upper bounds in some cases, 
common survival methods (Kaplan-Meier estimate, log rank test) were substituted by methods 
that allow interval censoring. Observed survival curves and probabilities were computed using 
non-parametric maximum likelihood estimates for interval censored data with the R-package 
interval20. P-values for the univariate analyses were calculated with the score test of Sun (1996)21.
Covariates that were found to have a significant association with local recurrence free survival in 
the univariate analysis were included in a multivariate Cox regression analysis using the icenReg 
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Diffuse-type Tenosynovial Giant Cell Tumour (TGCT) is a rare, locally aggressive and difficult to treat 
disease. An international multicentre-pooled retrospective study of individual patient data was developed 
to describe global treatment protocols, evaluate oncological outcome, complications and functional 
results. A secondary study aim was to identify risk factors for local recurrence after surgical treatment.
Methods
Patients treated in 31 sarcoma reference centres between 1990 and 2017, with histologically proven diffuse-
TGCT of large joints were included. Of 1192 cases of diffuse-TGCT, 58% were female with a median age 
35 years. 64% affected the knee and in 54% primary treatment was one-staged open synovectomy. Risk 
factors were tested in a univariate analysis and significant factors subsequently included for multivariate 
analysis, with first local recurrence after surgical treatment in a tertiary centre as the primary outcome.
Results
At a median follow-up of 54 (95%CI 50-58) months, recurrent disease developed in 44% of all 
surgically treated cases, with local recurrence free survival (RFS) at 3, 5, 10 years of 62%, 55% 
and 40%, respectively. The strongest risk factor for recurrent disease was prior recurrence (HR 
3.5 95%CI 2.8-4.4, p<0.001) with a 5-year RFS of 64% in surgery naïve patients compared with 
25% in patients operated for recurrent disease. Complications were noted in 12% of patients. Pain 
and swelling improved after surgical treatment(s) in 59% and 72% of patients respectively. In a 
subgroup analysis including only naïve cases affecting the knee, neither sex (male;female), age 
(≤35years;>35years), bone-involvement (present;absent), surgical technique (open;arthroscopic) 
nor tumour size (<5cm;≥5cm) yielded an association with the first local recurrence. 
Conclusion
This largest international individual data study of patients with diffuse-TGCT, provides a comprehensive 
and up to date disease overview, evaluating the clinical profile and management of the disease. Since 
complete resection of diffuse-TGCT could be regarded as nearly impossible and recurrence rates are 
unacceptably high after both arthroscopy and open synovectomy in the knee, even in specialized 




In the most recent WHO classification (2013), giant cell tumour of the tendon sheath and 
pigmented villonodular synovitis (PVNS) were unified by one overarching term: tenosynovial 
giant cell tumours (TGCT). This rare, mono-articular disease arises from the synovial lining of 
joints, bursae or tendon sheaths in predominantly young adults1, 2. Excluding digits, TGCT is most 
commonly diagnosed around the knee and can be found in other weight bearing joints as well1-4.
Two clinically and radiographically distinct subtypes of TGCT are defined with different natural 
courses of disease. The localized-type is defined as a well-circumscribed nodule. On the contrary, 
the diffuse-type is known as an ill-circumscribed, locally aggressive and invasive tumour (figure 1, 
chapter 1, page 13)1, 2, 5. Even though histopathology and genetics seem identical, the biological 
behaviour of both subtypes is incomparable and therefore necessitates separate evaluations, 
analyses and treatments. The current study focuses on diffuse-TGCT of large joints.
Macroscopically, diffuse-type TGCT involves a large part or even the complete synovial lining of 
a joint with either a typical villous pattern (intra-articular) or a multi-nodular appearance (extra-
articular), including a diverse colour pattern, varying from white-yellow to brown-red areas. This 
subtype shows an infiltrative growth pattern. Definite diagnosis is established on microscopy by 
an admixture of mononuclear cells (histiocyte-like and larger cells) and multinucleated giant cells, 
lipid-laden foamy macrophages (also known as xanthoma cells), siderophages (macrophages 
including hemosiderin-depositions), stroma with lymphocytic infiltrate and some degree of 
collagenisation. Molecular analysis is generally not required to confirm the diagnosis.
Pain, (haemorrhagic) joint effusion, stiffness and limited range of motion are the main 
clinical complaints6. These non-specific symptoms frequently cause a delay in diagnosis7. The 
predominant standard of care is surgical resection of diffuse-TGCT, either arthroscopically or 
with an open resection or a combination of both, in order to: (1) reduce debilitating symptoms 
and joint destruction caused by the disease process; (2) improve limb function; and (3) minimize 
the risk of local recurrence. Clinical and oncological outcomes following surgery largely depend 
on multiple factors including preoperative diagnostic evaluation, the localization and extent of 
disease and possibly the choice of treatment modalities by orthopaedic surgeons3, 5, 8-10. Diffuse-
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TGCT frequently causes significant morbidity due to the invasiveness of the surgical resection 
and the high rate of local recurrence (14-40% depending on surgical procedure and follow-up 
time), with deteriorated health-related quality of life6, 8, 9, 11-14. Therefore, treatment of diffuse-TGCT 
may include adjuvant or multimodality treatment such as external beam radiation therapy10, 15, 16, 
radiation synovectomy with 90Yttrium17 or CSF1 inhibitors, such as nilotinib, imatinib, pexidartinib, 
emactuzumab, cabrilazimab and MSC11018-22. Of note, so far none of these agents have been 
formally approved for use in the disease, and long-term efficacy is unknown.
The incidence of diffuse-TGCT of large joints is 4.1 per million person-years4. Therefore, the current 
literature mainly consists of relatively small, or larger but heterogeneous case-series. Risk-factors for 
recurrent disease in individual patients need to be identified by evaluating outcomes of different 
treatment strategies. Since (larger) randomized controlled trials on the role of surgery in TGCT are 
lacking, individual participant data meta-analysis is currently the highest achievable evidence. It 
offers advantages above a meta-analyses, including: (1) missing data can be accounted for at an 
individual patient level, (2) subgroup analyses can be performed (e.g. per affected joint) and (3) 
follow-up information can be updated23. Therefore, we aimed to collaborate with tertiary sarcoma 
centres across the globe to include individual patient data in this investigation.
The main aim of this international multicentre cohort study is to provide comprehensive and 
up to date insights on the surgical treatment and outcome for patients with diffuse-type TGCT. 
Oncologic results, complications and functional results are described. In addition, risk factors for 




Recruitment and patient inclusion criteria
Patients of any age treated between January 1990 and December 2017 in one of 31 international 
sarcoma centres (supplementary material: participating international sarcoma reference centres, 
page 160) with histologically proven TGCT of large joints were retrospectively included. Large 
joints were defined as all joints proximal to the metatarsophalangeal and metacarpophalangeal 
joints. Identification and collection of the patients was performed in the centres of origin and data 
were analysed from initial treatment at these tertiary centres. Data were encrypted and transferred 
to the international multicentre database at the Leiden University Medical Centre (LUMC), with 
patient collection ending as of May 2018.
Study parameters
Collected patient-, tumour- and treatment characteristics with corresponding definitions are 
shown in appendix table 1 (chapter 7, page 158). The following characteristics were defined as 
core criteria: TGCT-type (localized-; diffuse-; unknown-type), admission status (therapy-naïve; 1st 
recurrence; 2nd recurrence; 3rd recurrence; etc.) date and type of initial treatment at a tertiary centre 
(arthroscopic synovectomy; one-staged synovectomy; two-staged synovectomy; synovectomy 
not specified; (tumour)prosthesis; amputation; wait and see); and first local recurrence after 
treatment (yes; no) in a tertiary centre. Complete data on these core criteria were necessary for 
reliable analyses.
Patient-, tumour- and treatment characteristics
Thirty-one specialized sarcoma centres spread throughout Europe, North America, Canada and 
Asia collaborated to provide a total of 1192 diffuse-TGCT cases (table 1). As per entry criteria, 
patients with localized-TGCT (N=941) and unknown type TGCT (N=36) were excluded.
Statistical analyses
The primary endpoint was local recurrence free survival (RFS) after initial treatment in a tertiary 
centre. Recurrent disease was defined as the presence of new disease after resection (and 
synovectomy) performed in a tertiary centre or progressive residual disease (as diagnosed by local 
investigators on repeated follow-up Magnetic Resonance (MR) imaging).
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Table 1 Patient-, tumour- and treatment characteristics
Characteristics Overall (%)
Total number 1192 (100)
Admission status (N=1192)
     Therapy naïve^




     Male
     Female
499 (42)
693 (58)
Median age at initial treatment years (N=1122)




     Knee
     Hip
     Ankle
     Foot*
     Shoulder
     Elbow
     Wrist
     Hand*











     Present
     Absent
259 (30) 
588 (70)
Median duration of symptoms# months (N=744)
     IQR
18
6-36
Type of surgical treatment at tertiary centre (N=1163)
     Arthroscopic synovectomy
     One-staged open synovectomy
     Two -staged open synovectomy##
     (Tumour)prosthesis+,¥
     Amputation¥
     Wait and see$,¥








Median tumour size initial treatment in cm (N=701)
     IQR
     <5 cm





Adjuvant therapy initial treatment (N=1033)
     External beam radiotherapy
     90Yttrium
     Systemic/molecular targeted treatment
     Other






IQR, Interquartile Range; ^Therapy-naïve or primary admission status at tertiary centre are considered similar; ^^≥1 Surgery 
elsewhere or recurrent admission status are considered similar; *Digits are excluded; #Symptoms were defined as either pain, 
swelling, stiffness or limited range of motion (table 7-8); ##A two-stage synovectomy is defined as two synovectomies within 
six months; +An arthrodesis is classified as (tumour)prosthesis; $Wait and see and conservative treatment are considered 
similar; ¥(Tumour)prosthesis, amputation or wait and see as initial treatment are excluded for risk and survival analyses.
172
Chapter eight
To investigate the effect of risk factors on the outcome, univariate analyses were performed and 
significant factors (p<0.05) were subsequently included into a multivariate analysis. Proposed risk 
factors were admission status (therapy-naïve versus recurrent disease), sex (male versus female), age 
(≤35 years versus >35 years), localization (knee versus hip versus foot/ankle versus upper extremity), 
bone-involvement (present versus absent), surgical technique (open versus arthroscopic) and 
tumour size (<5 cm versus ≥5cm). Patients with a wait and see policy or as initial treatment (tumour)
prosthesis surgery or an amputation were excluded from statistical analysis (N=142).
Observed RFS probabilities at 3, 5, and 10 years were computed for all cases and subgroups based 
on admission status and localization.
Figure 2 Skeleton showing localization of TGCT 
in 1192 diffuse-TGCT cases. 15 diffuse-TGCT cases 









Diffuse-type tenosynovial giant cell tumours
173
8
For some patients exact survival information was not available (appendix: proportion of data 
missing per variable). In 34 out of 107 cases, we could recover the missing recurrence indicator: 
9 patients had a second treatment and 25 patients had follow-up status ‘alive with disease’ and 
were classified as having recurrent disease. When the exact time of recurrence was not recorded, 
an approximation was applied where possible. When the date of surgery to treat a recurrence was 
known, this was used as the date of local recurrence instead (N=177). When this information was 
missing as well, the date of last recurrence was used as an upper bound (N=58). Otherwise the 
date of last recorded follow-up was used as an upper bound (N=69). When data on recurrence 
status or date of recurrence was missing and could not be recovered as described, patients were 
excluded for risk- and survival analyses (N=84).
Some centres did not record follow-up time for patients without recurrent disease. To prevent 
exclusion of these patients, we imputed their follow-up time (N=79). Multiple imputation technique 
was applied and 5 complete data sets were imputed using the R-package Amelia II24. Statistical 
analyses were conducted on all data sets and the results were then pooled following Rubin’s rule25.
As a consequence of the approximation of the time of recurrent disease by upper bounds in some 
cases, common survival methods (Kaplan-Meier estimate, logrank test) were substituted by methods 
that allow for interval censoring. Observed survival curves and probabilities were computed using 
non-parametric maximum likelihood estimates for interval censored data with the R-package 
interval26. P-values for the univariate analyses were calculated with the score test of Sun (1996)27.
Covariates that were found to have a significant association with local recurrence free survival in 
the univariate analysis were included in a multivariate Cox regression analysis using the icenReg 
R-package, which allows for interval censored data28.
All data were selected for completeness on core criteria (appendix, chapter 7, page 158). Statistical 
analyses were carried out using R version 3.4.1.
On purpose, an estimate of the median time to recurrence was not provided. Calculating such a 
median based on patients for whom a recurrence was recorded, would assume that all other patients 
could not experience a recurrence in the future. The extent of this so-called immortal time bias is 




This study is conducted according to the Declaration of Helsinki (October 2013) and approved by the 
institutional review board (CME) from the Leiden University Medical Center (LUMC) (May 4th, 2016; G16.015).
results
Oncologic outcome
In 966 patients with surgically treated diffuse-TGCT and complete survival data, 425 (44%) had a 
tumour recurrence following treatment. The recurrence free survival (RFS) continued to decrease 
with longer follow-up times (table 2-3, figure 3).
Univariate- and multivariate analyses for local recurrence
In univariate analysis of 966 patients with surgically treated diffuse-TGCT and complete core data, 
the risk factor admission status was found to be significantly associated with recurrence: 5-year 
RFS was 64% for therapy naïve patients (95% CI 60-68) compared to 25% for patients entering the 
tertiary hospital with recurrent disease (95% CI 19-31; p <0.001). This difference was confirmed by 
multivariate analysis (HR 3.5 95% CI 2.8-4.4, p<0.001).
After excluding patients admitted with recurrent disease, surgical technique was also positively 
associated with first local recurrence (table 4). This result was confirmed by cox regression analysis 
(HR 1.407; 95% CI 1.02-1.95, p=0.04). In a subgroup analysis of therapy naïve patients with diffuse-
TGCT affecting the knee, surgical technique was not found to be associated with first local 
recurrence (p=0.113).
Observed recurrence free survival according to admission status and localization
Highest recurrence rates are report in TGCT affecting the knee; 43% after arthroscopic synovectomy 
and 37% after open synovectomy (figure 4). A progressively declining RFS was seen at 3, 5 and 10 
years in a subgroup analysis of the knee, hip, foot/ankle and upper extremity locations in patients 
either admitted with therapy naïve TGCT or patients admitted with recurrent TGCT (table 5). After 
10 years follow-up, patients with therapy naïve disease affecting the knee were found to have 
the lowest RFS rates of all sites (46%, 95% CI 39-54). All patients entering a tertiary hospital with 
recurrent disease exhibited very low RFS at 10 years (figure 3a). 
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Table 2  Oncologic outcome after surgical treatment of diffuse-TGCT of large joints of all patients 
primary treated at a tertiary centre
Characteristics Overall (%)
First local recurrence after initial treatment at tertiary centre (N=966)
     Present
     Absent
425 (44)
541 (56)
Total number of recurrences (N=425)
     1
     2




Mean total number of surgeries (N=707)
Mean total number of surgeries in recurrent disease (N=425)
2.0 (range 1-10)
2.7 (1-10)
Median follow-up months (N=966)
     95% CI
54 
50-58
Status last follow-up (N=891)
     No evidence of disease
     Alive with disease - wait and see
     Alive with disease - awaiting treatment
     Death of other disease






*Lost to follow-up was defined as follow-up less than 6 months or stratified during follow-up as lost to follow-up. 
Table 3  Diffuse-TGCT recurrence free survival (RFS) all patients versus therapy naïve patients 
treated at tertiary centre
Year N all % RFS all (95%CI) N therapy naïve % RFS therapy naïve (95%CI)
3 474 62 (59-65) 372 70 (67-74)
5 297 55 (51-58) 227 64 (60-68)
10 89 40 (35-45) 70 50 (44-56)












primary 758 506 310 170 97 63
recurrent 208 128 88 53 30 18
years 0 2 4 6 8 10
number at risk
strata: primary recurrent
Figure 3a  Local recurrence free survival curve in diffuse-TGCT stratified for admission status (p<0.001).
Time zero was date of initial resection at tertiary centre. Primary: patient with therapy-naïve disease initially 
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Figure 3b Local recurrence free survival curve in patients with therapy naïve diffuse-TGCT affecting the knee 
stratified for surgical technique (p=0.11). Time zero was date of initial resection at tertiary centre. Open: open 
resection, arthroscopic: arthroscopic resection.
Years since surgery
open 346 225 146 71 39 29
arthroscopic 99 65 40 25 13 8
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Figure 4  Flowchart of diffuse-TGCT patients with treatments and recurrences for each affected joint.
Primary: patient was first seen at tertiary centre with therapy-naïve disease, recurrent: patient initially treated 
elsewhere, AS: Arthroscopic synovectomy, OS: Open synovectomy. Treatments other than AS and OS were not 

























A total of 105 (12%) complications occurred following surgical treatment of diffuse-TGCT (table 
6). The majority of these complications developed after one- or two-staged open synovectomy 
(86/105; 82%). In comparison, 12 complications (11%) were reported following arthroscopic 
synovectomy.
Functional outcome
Prior to surgical treatment, the majority of patients had symptoms of pain (76%) and swelling 
(75%) (table 7). After surgical treatment, at final follow-up, these symptoms largely disappeared, 
although 37% and 24% of patients respectively were still symptomatic. Joint stiffness and limited 
range of motion were only present in 21% and 27% of cases, respectively, and these symptoms 
improved slightly after treatment (17% and 19% at final follow-up). 
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Table 4  Univariate analyses in 758 patients with therapy naïve diffuse-TGCT
Variable N %RFS at 5 years 95%CI P value
Age
≤35 years 391 64 59-70 0.94
>35 years 364 63 57-69
Sex
male 307 63 56-69 0.86
female 451 64 59-70
Localization
knee 471 61 56-66 0.10
hip 70 65 54-77
foot/ankle 158 72 64-81
upper extremity 59 59 44-74
Size
<5 cm 217 71 64-78 0.42
≥5 cm 295 64 58-71
Bone involvement
present 158 61 52-69 0.82
absent 425 64 58-69
Surgical technique
open 595 66 61-70 0.03
arthroscopic 120 54 44-64
A mean of 578 (48%) patients with diffuse-TGCT had complete data on symptoms both prior to 
initial treatment and at final follow-up (table 8). The majority of patients experienced pain and 
swelling prior to initial treatment, of which 59% and 72% resolved after surgical treatment(s). 




Table 6  Complications after surgical treatment at tertiary centre (N=906)
Complications after surgical treatment N (%)
Superficial wound infection 15 (2)
Deep wound infection 10 (1)
Joint stiffness 32 (4)
Haemorrhage 7 (1)
Neurovascular damage 15 (2)
Thrombosis 1 (0.1)
Other+ 25 (3)
+Other surgical complications after initial treatment included: joint luxation (hip), compartment syndrome, ligament 
incision during surgery, complex regional pain syndrome, tourniquet blistering, tendinitis. As osteoarthritis is 
either caused by extensive disease or by (multiple) treatments, it was not taken into account for complications.




+ % RFS at 
3 years 95% CI
% RFS at 
5 years 95% CI
% RFS at 
10 years 95% CI
primary knee 471 68 63-73 61 56-66 46 39-54
primary hip 70 67 56-79 65 53-77 54 38-70
primary foot/ankle 158 79 72-87 72 64-81 57 44-70
primary upper extremity* 59 69 56-82 59 44-75 55 38-71
recurrent knee 145 29 21-36 25 18-32 15 8-21
recurrent hip 8 40 6-74 40 6-74 **
recurrent foot/ankle 39 43 27-59 24 10-38 18 4-33
recurrent upper extremity* 16 25 3-47 25 3-47 15 0-33
+N: number at baseline (time point = 0), *Upper extremity including other localization, **10 years RFS and 
associated 95%CI of recurrent hip cases could not be estimated (due to lack of follow-up information). Primary: 
patient was first seen at tertiary centre with therapy-naïve disease Recurrent: patient initially treated elsewhere, 
95%CI: 95% Confidence interval.
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Table 7   Symptoms prior to treatment and at final follow-up
Symptom Pre-treatment Final follow-up
Pain (PT 969, FF 630) 738 (76%) 233 (37%)
Swelling (PT 775, FF 627) 579 (75%) 149 (24%)
Joint stiffness (PT 759, FF 617) 161 (21%) 105 (17%)
Limited range of motion (PT 760, FF 624) 209 (27%) 118 (19%)
Chronic analgesic treatment* (FF 714) 92 (13%)
*Chronic analgesic treatment data was only available at final follow-up; PT, pre-treatment; FF, final follow-up
Table 8   Comparing symptoms diffuse-TGCT prior to treatment to last follow-up
No pain last fu Pain last fu Total
No pain initially 118 (20%) 36 (6%) 154
Pain initially 255 (43%) 179 (31%) 434
No swelling last fu Swelling last fu
No swelling initially 119 (20%) 13 (2%) 132
Swelling initially 328 (56%) 125 (22%) 453
No stiffness last fu Stiffness last fu
No stiffness initially 383 (68%) 55 (10%) 438
Stiffness initially 82 (14%) 47 (8%) 129
No limited range of motion 
last fu
Limited range of motion 
last fu
No limited range of 
motion initially 337 (59%) 59 (10%) 396
Limited range of 




Local recurrence versus symptoms final follow-up
A higher percentage of patients with pain, swelling, stiffness and limited range of motion at final 
follow-up had recurrent disease (pain; 55% recurrence versus 45% no recurrence, swelling; 66% 
versus 34%, stiffness; 51% versus 49%, limited range of motion; 56% versus 44%).
More patients with recurrent disease 21% (64/300) used chronic analgesic treatment at last follow-
up compared to patients 6% (24/388) without recurrent disease.
Surgical technique versus functional outcome at last follow-up
Surgical technique did not influence functional outcome at last follow-up (pain: 41% symptoms 
after AS versus 37% after OS, swelling: 29% versus 22%, stiffness: 13% versus 18%, limited range of 
motion: 16% versus 21%, chronic analgesic treatment: 18% versus 12%).
Chronic analgesic treatment versus complications
24% (16/67) of patients using chronic analgesic treatment had a complication, compared with 
10% (50/482) of patients without a complication. 




This international multicentre study offers new insights into the outcome of patients with the 
orphan and heterogeneous disease diffuse-type Tenosynovial Giant Cell Tumour (TGCT). The 
greatest strength of this dataset is that it represents the largest collection of surgically treated 
diffuse-TGCT patients in the scientific literature, including RFS estimates for the knee, hip, foot/
ankle and upper extremity locations with long-term follow-up (>10 years). Oncologic results, 
complications and functional results after surgical treatment are evaluated.
Oncologic outcome diffuse-TGCT
The fundamental question of whether curative treatment is necessary, or should be attempted in 
non-lethal diffuse-TGCT often arises in literature. Debilitating symptoms and (progressive) joint 
destruction commonly result from untreated diffuse-TGCT but can also occur following treatment. 
At present, the choice of treatment is established by the preference of the patient, treating 
physician and might differ by treatment centre. Surgical treatment for the locally aggressive diffuse-
TGCT is challenging, as pathologic tissue can be widely spread throughout the joint and may be 
technically difficult to access and remove. In extensive disease, less than radical or only partial 
resection could be preferred to improve symptoms with joint preservation in mind. However, 
higher rates of recurrence have been described after macroscopically incomplete resections8, 29-31.
Some reports consider arthroscopic management of TGCT superior to open surgery, because of 
less morbidity and a shorter recovery period32-36. Standard arthroscopy of the knee using only 
anteromedial and anterolateral approaches however, does not allow surgical access to remove all 
areas where diseased tissue is likely to be present. Therefore Blanco et al. and Mollon et al. used 
multiple portals including posteromedial and posterolateral in arthroscopic synovectomy37-39. Chin 
et al. stated that knee arthroscopy alone is an inferior treatment for extra-articular TGCT40. Open 
synovectomy, either one- or two-staged, seems to be the preferred surgical approach to diffuse-
TGCT in most centres, because of tumour visibility and reported lower short-term recurrence 
rates11, 41, 42. The disadvantage of a one- or two-staged open resection, could be deteriorated joint 
function accompanied with decreased patient health-related quality of life13. A systematic review 
showed lower recurrence rates for open synovectomy (average 14%, maximum 67%) compared 
to arthroscopic synovectomy (average 40%, maximum 92%) in diffuse-TGCT11. Patel et al. (N=214) 
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reported a statistically significant higher risk of recurrence in diffuse-type TGCT with arthroscopic 
compared to open synovectomy (83.3% vs 44.8%, RR = 1.86 95% CI 1.32–2.62, P = 0.0004)9. 
Palmerini et al. (N=206) did not find a difference in recurrence based on surgical technique for 
localized- and diffuse-TGCT combined8. 
A combined anterior arthroscopic- and posterior open synovectomy in the knee might be a 
viable option, but is only incidentally reported. Mollon et al. described the combined approach 
of a multiportal anterior and posterior arthroscopy and a posterior open synovectomy largely for 
resection of extra-articular popliteal disease, and reported two recurrences in 15 patients38. Colman 
et al. retrospectively evaluated 11 diffuse-TGCT patients treated by the combined approach and 
also reported relatively low short-term recurrence rates (9%)43. A randomized controlled trial for 
arthroscopic synovectomy versus open synovectomy has not been performed. 
The present study calculated recurrence free survival rates for diffuse-TGTC at 3, 5 and 10 years 
of 62%, 55% and 40%, respectively. This clearly underlines that with longer follow-up, recurrence 
rates continue to increase (table 2-3, figure 3). The greatest risk factor for local recurrence is recurrent 
disease at presentation in a tertiary centre (HR 3.5 95% CI 2.8-4.4 in multivariate analyses). In 
therapy naïve patients with primary treatment in a tertiary centre, the largest risk factor for local 
recurrence was arthroscopic synovectomy. The suspicion arises that more (macroscopic) tumour 
tissue remains after arthroscopic synovectomy; however this largely depends on the extend of the 
arthroscopy performed, whether multiple and posterior portals were used to access and remove 
disease throughout the knee joint, and whether this approach is combined with an open approach 
to remove residual intra-articular disease and/or extra-articular disease extension. However, none 
of the assumed risk factors yielded significant differences when the analysis was performed in a 
subgroup of therapy naïve patients with diffuse-TGCT affecting the knee. This could be attributed 
to the near impossibility of achieving a complete macroscopic resection in widely spread, ill-
defined diffuse-TGCT patients and the impossibility of an R0 resection: macroscopically and 
microscopically complete resection, neither with an arthroscopic- nor open resection.




Within the current era of systemic targeted and multimodality therapies (some only available 
in trial settings) in TGCT, standalone surgical resection can no longer be regarded as the only 
treatment for more severe diffuse forms of the disease. Surgery has been considered the treatment 
of choice for decades, and the current study which included patients from 1990 onwards, consists 
mainly of patients treated with a surgical procedure. 
High recurrence rates, as confirmed by the present study, indicate the need for adjuvant therapies 
to improve treatment outcomes for patients with diffuse-TGCT. Nonetheless, Gortzak et al. reported 
no significant differences in residual disease, complication rates and overall physical and mental 
health scores between patients surgically treated for TGCT of the knee with (N=34) or without (N=22) 
adjuvant 90Yttrium, after a mean follow-up of 7.3 years17. Verspoor et al. evaluated 12 patients treated 
with surgical synovectomy and additional cryosurgery. They did not find better results compared 
to surgical resection alone44. Griffin et al. reported on 49 patients with diffuse-TGCT, most of whom 
had both intra- and extra-articular and recurrent disease. They reported 3 (6%) recurrences following 
synovectomy and radiation10. A meta-analysis suggested that open synovectomy (N=19 studies, 
N=448) or synovectomy combined with perioperative radiotherapy (11 studies, N=123) is associated 
with a reduced rate of recurrence16. Mollon et al. reserved the use of external beam radiation for 
patients at high risk for local recurrence, if they had the following characteristics: multiple episodes 
of recurrent intra-articular disease, extra-articular extension, or gross residual disease remaining 
following surgery38. Currently, sufficient data including adequate patient numbers is lacking to 
support the use of external beam radiation in primary cases, however the authors feel it should only 
be performed in specific instances such as extensive or recurrent diffuse-TGCT cases.
In patients with locally advanced TGCT or (multiple) recurrence(s), systemic therapies targeting 
the CSF1/CSF1R axis have been recently investigated including nilotinib, imatinib, pexidartinib 
(PLX3397), emactuzumab (RG7155) and cabiralizumab (FPA008). Some systemic treatments for 
TGCT have been proven to be effective18, 19, and novel and potentially more potent agents are 
under investigation20-22. The disadvantages of adjuvant or targeted therapies are acute and long-




Patients with aggressive disease accompanied with a high risk of recurrence following surgery 
alone should be selected for (new) systemic and (neo)adjuvant treatment modalities. Diffuse-
TGCT presents as a heterogeneous disease with different disease severities. Some patients present 
with tumours that are surgically relatively easy to access and these patients might not require 
(neo)adjuvant therapies. Mastboom et al. defined the most severe diffuse-TGCT subgroup on MR 
imaging as having diffuse-type TGCT including intra- and extra-articular disease and involvement 
of at least one of the following three tissues: muscle, tendon or ligament)5. These patients seem 
most eligible for multimodality or (neo)adjuvant strategies.
Complications
The literature on TGCT frequently lacks descriptions of complications after surgical treatment. 
This study reported a complication rate of 12% following surgical management of patients with 
diffuse-TGCT, predominantly after open resection (82%). The most common complication was joint 
stiffness after open synovectomy, which might be difficult to prevent after the surgical treatment 
of extensive disease. The true complication rate might be even higher, since it is suspected that 
not all complications are scored. 
Symptoms
TGCT related symptoms are mainly pain, swelling, stiffness and limited range of motion, but these 
are reported with a great variability in degree and severity. Gelhorn et al. concluded that not 
all patients experience all symptoms to the same extent (e.g. swelling but no pain, or pain and 
swelling but no stiffness or limited range of motion)6. Symptoms prior to initial treatment at a 
tertiary centre were compared for each patient with symptoms at last follow-up. Initial symptoms 
of pain and swelling improved following treatment(s) in 43-56% of patients. This is comparable 
with a crowdsourcing study in 337 TGCT patients originating from 31 countries14. In the majority 
of patients, stiffness and limited range of motion did not seem to be principal symptoms either 
initially, or at last follow-up. These symptoms are subjective for each patient and not all patients 
were included with complete data. Nevertheless, pain and swelling are the main TGCT-related 
complaints initially and frequently improve after surgical treatment(s).
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As expected, diffuse-TGCT patients with recurrent disease demonstrated higher rates of symptoms 
at final follow-up, including a 3.5-fold higher rate of chronic analgesic use, compared to patients 
without local recurrence at last follow-up. Also, patients using chronic analgesics had a higher rate 
of complications.
Interestingly, after arthroscopic synovectomy in diffuse-TGCT, patients exhibited more pain, 
swelling and a higher use of chronic analgesics, compared with open synovectomy. On the 
contrary, open synovectomy was associated with higher rates of stiffness and limited range of 
motion, which can be attributed to the larger surgical procedure resulting in additional scar tissue.
Joint specific analyses
Within this individual participant data meta-analysis, a homogeneous subgroup analysis for 
diffuse-TGCT affecting the knee of therapy naïve patients was performed (figure 3b). Despite the 
large number of patients in this study with diffuse-TGCT cases, the numbers in other joint locations 
were too small to allow analysis of those specific groups.
Limitations
The main limitation of this study is selection (referral) bias, since data on patients treated at non-
specialized centres was lacking. Selection bias of affected joints seems absent when comparing 
percentages of affected joints (table 1, figure 2) with a recent incidence calculation study including 
nationwide coverage (in both studies 64% of diffuse-TGCT affects the knee)4.
Even though TGCT is a benign disease, particularly diffuse-TGCT can become a chronic illness 
with substantial morbidity to the joint leading to functional and patient health-related quality 
of life impairment, caused by the course of the disease itself and multiple treatments13. As data 
were collected by local investigators or physicians according to the multicentre study design, data 
quality depended on data registry on site. Only data available in the source data file of the patients 
could be retrieved. In addition, interpretation of individual parameters could differ. No central 
histopathological review was performed, as it was assumed that each centre provided the correct 
diagnosis as set by their histopathology department. Within our study we did not collect which 
patient had multiportal arthroscopy or standard anterior portal arthroscopy. 
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Recurrence rates could either be over-estimated or under-estimated. Over-estimation could occur 
because the follow-up status ‘alive with disease’ was classified as recurrence (if recurrence data 
were missing). On the contrary, under-estimation could be present if patients with recurrent 
disease, did not return at all or did not return to their original centre. It should be noted that 
patients with recurrent disease had a longer follow-up compared to patients without recurrent 
disease. The explanation could be that patients without symptoms and (assumed) without 
recurrent disease were dismissed from follow-up and therefore had shorter follow-up times. In 
addition, if treatments were recently performed, patients also had shorter follow-up times and are 
still at risk of recurrence. 
conclusion
This is the largest global individual data study on patients with diffuse-type TGCT and provides a 
comprehensive and up to date disease overview, evaluating the clinical profile and management 
of TGCT. Our study demonstrated that surgery is by far the most frequently performed treatment in 
tertiary referral hospitals. However, even in specialised centres, local control of this heterogeneous 
orphan disease, remains a major issue, with overall recurrence free survival of 55% at 5 years. 
Since complete resection of diffuse-TGCT is often impossible and recurrence rates are high after 
both arthroscopy and open synovectomy of the knee, the optimal surgical approach should be 
left to the discretion of an experienced surgical and multidisciplinary team. However, in the era 
of multimodality therapy, standalone surgical resection can no longer be regarded as the only 
effective treatment for patients with diffuse-TGCT and alternative or combined approaches should 
be considered.
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Tenosynovial Giant Cell Tumours (TGCT), are rare colony stimulating factor-1(CSF-1)-driven 
proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due 
to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks CSF-1 receptor. 
This study investigated the long term effects of IM in TGCT.
Methods
We conducted an international multi-institutional retrospective study to assess the activity of 
IM: data was collected anonymously from individual patients with locally advanced, recurrent or 
metastatic TGCT.
Results
Sixty-two patients from 12 institutions across Europe, Australia and the United States were 
identified. Thirty-nine patients were female (63%), median age at treatment start was 45 (range 
20-80) years, with a median time from diagnose to treatment of 3.5 (range 0-38,2) years. Median 
follow-up after treatment start was 52 (IQR 18-83) months. Four patients with metastatic TGCT 
progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable 
patients achieved CR or PR.  One- and five-year progression-free survival rates were 71% and 48%, 
respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1-80) months. 
Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), 
mostly grade 1-2 (89%). Five patients experienced grade 3-4 toxicities.
Conclusion
This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we 
confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high 




Tenosynovial giant-cell tumour (TGCT), historically known as pigmented villonodular synovitis 
(PVNS), is a rare, at times locally aggressive neoplasm affecting the joints or tendon sheaths in 
young adults. It is most common around large joints such as the knees, ankles and hips1, 2. Known 
subtypes are localized and diffuse TGCT. The localized subtype comprises a single nodule and has 
a favourable course while the diffuse subtype involves the synovial lining as well as surrounding 
structures and is associated with a significant risk of recurrence (>50% depending on follow up 
times), despite being a benign neoplasm2-4. Metastatic forms have been described, but seem to 
occur very rarely5, 6.
Surgical resection is the primary treatment for both subtypes. However, diffuse TGCT is difficult to 
remove completely and often requires a total synovectomy, or at time a joint replacement, or rarely 
even amputation1, 2, 7. In patients with extensive and/or recurrent TGCT, other available treatment 
modalities include radiation synovectomy8, external beam radiation therapy9, and cryosurgery10. 
Their therapeutic value has only been assessed in retrospective, in most cases single centre series 
and their long term side effects and complications are poorly described11.
Recurrent TGCT is rarely lethal, but frequently becomes a debilitating chronic illness with 
substantial morbidity to the joints and quality of life impairment, caused by the disease itself and 
the multiple treatments2, 12.
In TGCT, a neoplastic clone constitutes a subpopulation (2-16%)13 of cells that overexpress colony-
stimulating factor-1 (CSF-1). A t(1;2) translocation that links the CSF1 gene on chromosome 1p13 
to the COL6A3 gene on chromosome 2q35 has been described and is believed to be responsible 
for the overproduction of CSF1 by neoplastic cells13, 14. Inhibition of CSF1/CSF-1 receptor (CSF-1R) 
signaling has shown efficacy in the treatment of locally advanced and recurrent diffuse TGCT15-17.
Imatinib mesylate (IM) inhibits the CSF-1R kinase among other kinases17. We have previously 
reported on the efficacy of IM in TGCT. In the present study we provide long term follow-up on 
these initial patients and data on 33 additional consecutive patients.




This retrospective study was conducted at 12 referral centres across Europe (9 institutions), the 
United States of America (2 institutions), and Australia (1 institution). The file of all patients with 
locally advanced, recurrent or metastatic TGCT, treated with IM were reviewed. Patients information 
were extracted from individual patients’ files at each institution by the local investigators and was 
provided in an anonymous form for final analyses. Histopathologic examination was performed 
at centre of origin by pathologists with extensive experience in mesenchymal tumours. Response 
was measured using version 1.0 of Response Evaluation Criteria in Solid Tumours (RECIST). Data 
were described using percentages for qualitative variables and medians with ranges for continuous 
variables. Patients were not treated on a research protocol. They provided informed consent to 
treatment with a ‘off-label’ medical treatment, and treatment decision was left to the treating 
physician.  This retrospective analysis was approved by the Ethics Committee in Lyon (Committee 
for the Protection of Individuals, Sud-Est IV, Lyon, France – L10-153 dated 9 December 2010).
Survival was plotted using the Kaplan-Meier method. Progression-free survival (PFS) was 
calculated from the date IM was started to the date of disease progression or death. The time to 
treatment failure (TTF) was calculated from the date IM was started to the date it was stopped 
because of toxicity, disease progression, or death, whichever occurred first. For patients with a 
surgical resection or other additional therapy after treatment with IM, PFS and TTF were censored 
at the time of surgery. Disease specific survival was calculated from the date IM was started to the 
date of death due to TGCT. Symptomatic response was defined as improvement of pain and/or 
joint function in patients who had symptoms at baseline. All statistical analyses were performed 
using R version 3.4.0 (R Foundation, Vienna, Austria).
results
Patients
A total of 62 patients with histopathologically proven TGCT treated with imatinib were identified, 
their main characteristics are described in Table 1. Briefly, median age at diagnosis was 39 (IQR 
31-53) years and 45 (IQR 36-56) years at start of treatment with IM, the majority of patients were 
female (N=39, 63%), and the knee (N=35, 56%) was the most commonly affected joint (Table 1). At 
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start of IM treatment, three (5%) patients had biopsy proven metastatic disease, 15 (24%) locally 
advanced disease and 44 (71%) locally recurrent disease. Among patients with prior operations 
for TGCT (n=47), the median number of prior operations was 2 (range 1-9), and the time since the 
last operation was 23 (range 1-192) months. Median follow up of all patients was 52 (IQR 18-83) 
months.
Treatment efficacy
Sixty-one patients received 400 mg and one patient received 600 mg IM daily. The 3 patients with 
metastatic disease at treatment start progressed rapidly on IM and were excluded from further 
analysis. One other patient with metastatic disease after multiple surgical treatments and IM, was 
excluded for further analyses too, leaving 58 patients for the rest of the analysis.
Median duration of IM treatment was 9 (IQR 5-27) months. At last follow-up, the majority of patients 
(n=38; 66%) had discontinued treatment. Seventy-seven percent (95% CI 67-89), 41% (95% CI 29-
57) and 36% (95% CI 25-52) of patients were still on IM after 6-, 12- and 24-months, respectively 
(figure 1). The treatment failure-rate was 82% (95% CI 71-95) after 12 months.
Response could not be assessed in 3 patients, two of which were lost to follow-up and one who 
discontinued early due to febrile neutropenia, leaving 55 patients with locally advanced or locally 
recurrent TGCT assessable for response. Seventeen patients (31%; 95% CI 19-43) had a RECIST-
defined response, including 2 (4%) patients with a complete response. The median time to best 
response was 6 (range 1-23) months.
Forty of 51 patients (78%) reported symptom improvement (table 2), including 14 of 15 patients 
with radiological response (CR or PR). Among patients with radiological SD, 22 of 30 patients (73%), 
for whom data was available, had symptom improvement.
The 1-, 2- and 5-years overall PFS, metastatic patients (N=4) excluded, was 71% (95% CI 60-85), 60% 
(95% CI 48-75) and 48% (95% CI 36-65) respectively, (figure 2).
 
 
















































































































Imatinib in tenosynovial giant cell tumours
201
9
Table 1  Descriptive of diffuse-type TGCT patients receiving imatinib mesylate treatment
Patients N (%)
Total 62 (100)
Median age at diagnosis (IQR), yrs 39 (31-53)











Head and Neck 2 (3)
Wrist 2 (3)





Median N of surgeries (range) 2 (1-9)
Median time since last surgery (range), mo 23 (1-192)
Disease status
Locally advanced 20 (32)
Recurrence after surgery 39 (63)*
Metastatic disease 3 (5)
Abbreviations: TGCT= Tenosynovial Giant Cell tumour, IM= imatinib mesylate, N= Number of patients, 




Overall 38/58 patients (66%), metastatic patients (N=4) excluded, eventually discontinued IM after 
a median of 7.0 (range 1-80 months). the most common reason for treatment discontinuation 
was patient decision to stop (n=14, which possibly reflect low grade chronic toxicity), followed 
by planned surgery (n=10), toxicity (n=7), physician’s decision (n=5) and progression (n=1). One 
patient discontinued IM because of the diagnosis of another tumour requiring therapy. Among 
the 27 patients who discontinued treatment for reasons other than surgery or progression, 
progression (either radiological progression or requirement for another line of therapy – i.e. 
surgery, other medical therapy or radiotherapy) eventually occurred 17 patients after a median of 
12 (range 4-84) months, while 10 patients never progressed (nor required additional therapy) after 
a median follow-up to 78 (range 1-109) months, suggesting that IM was able to provide prolonged 
symptomatic relief at least in a proportion of patients.
Table 2 Summary of imatinib mesylate efficacy in patients with locally advanced or recurrent 
diffuse-type TGCT 
Parameter Patients N (%)
RECIST best response*
Complete remission 2 (4)
Partial response 15 (27)
Stable disease 36 (65)
Progressive disease 2 (4)
Overall response rate 17 (31)
Rate of disease control 53 (96)
Symptomatic response 40 (78)**
Median IM treatment duration (IQR), mo 9.3 (5-26)
Median PFS (IQR), mo 18 (8-55)
Abbreviations: TGCT= Tenosynovial Giant Cell tumour, IM= imatinib mesylate, N= Number of patients, 
mo=months, yrs= years, IQR= inter quartile range. Overall response rate includes complete remission and 
partial response; Rate of disease control includes complete remission, partial response and stable disease; 
Symptomatic response was indicated as present or not (40/51=78%). Metastatic patients (n=4) were excluded.
*N=3 RECIST best response not available; **N=9  symptomatic response not available.




Forty-five of 58 patients (78%), metastatic patients (N=4) excluded, reported at least one adverse 
event with IM. The most common adverse events were edema (N=28, 48%), fatigue (N=29, 50%), 
nausea (N=21, 34%) and skin rash/dermatitis (N=7, 12%), mostly grade 1-2 (89%). Additional grade 
1-2 complaints were diarrhea, reflux, auditory hallucinations, conjunctivitis, sexual impairment, 
asthenia, alopecia, cramps and dyspnea. Five (11%) patients had grade 3-4 toxicities, including 
neutropenia, acute hepatitis, facial edema, skin toxicity and fatigue (table 3).
Table 3 Main toxicities associated with imatinib mesylate and reasons for discontinuation, 
metastatic patients excluded
Patients N (%)
Variable All grades Grade 3-4
Edema/ fluid retention 28 (48) 1 (2)
Fatigue 29 (50) 1 (2)
Nausea 20 (34)
Skin rash/ dermatitis 7 (12) 2 (3)
Other* 15 (26) 3 (5)
Treatment status
Continued on IM 20 (34)





Patient choice 14 (24)
Physician decision 5 (9)
Other tumour 1 (2)
IM= imatinib mesylate, N= Number of patients. Forty-five (78%) patients reported at least one adverse event 
with IM. *Other grade 1-2 complaints were diarrhea, reflux, auditory hallucinations, conjunctivitis, sexual 
impairment, asthenia, alopecia, cramps and dyspnea. Five (11%) patients had grade 3-4 toxicities, including 




To our knowledge, this retrospective study provides the largest case series, with long follow-
up, of patients with locally advanced, recurrent or metastatic diffuse-type TGCT treated with IM. 
We confirmed that IM has activity in TGCT with an overall response rate of 31% in patients with 
locally advanced/recurrent TGCT. Interestingly all patients with metastatic TGCT progressed on IM, 
suggesting that metastatic TGCT is either a different disease or loses its dependency on the CSF1/
CSF1R axis during malignant transformation. The main issue, is the drop-off rate, with more than 
half of the patients discontinuing therapy within a year of therapy (59%; 95% CI 29-57), in most 
cases for unclear reasons (patients decision, physician’s decision) suggesting an unfavourable 
efficacy/toxicity balance. Eleven percent of patients reported grade 3-4 toxicities, which is 
consistent with the rates reported with IM for adjuvant gastrointestinal stromal tumours (GIST) or 
chronic myeloid leukaemia (CML)18-21.
To date, surgical resection remains the treatment of choice for diffuse-type TGCT, but is associated 
with high recurrence rates and multiple additional surgeries11. It is challenging to balance between 
increased morbidity of multiples or invasive surgeries12, 22, alternative therapeutic options, and daily 
symptoms of the tumour. A more aggressive resection or other multimodality treatments, such as 
external beam radiation therapy, radiosynovectomy and cryosurgery, may adversely affect joint 
function, quality of life and development of osteoarthrosis, which, given the young age group, are 
relevant factors2, 23. This would justify a less invasive approach, using systemic therapy, provided 
those are associated with tumour shrinkage and, most importantly, symptomatic improvements24.
In the present study, age, localization and gender distribution were consistent with the literature10, 
23, 25. The extent of disease in our patient group is emphasized by an disease specific survival of 90% 
including four metastatic patients and 49% of patients had three or more surgeries before start 
IM. Similar to previous case-series, we calculated a 1- and 5-years PFS of 71% and 48%, metastatic 
patients excluded, respectively10, 23, 25. Because of heterogeneity of patients and a variety of 
treatments, it is debatable to compare these numbers.
The overall response rate appears higher compared to nilotinib (6% (95% CI unknown), a different 
tyrosine kinase inhibitor, with similar potency against CSF1R26. Our overall response rate (31% 
(95% CI 19-43, metastatic patients (N=4) excluded) was consistent with our previous report on the 
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short term results of IM (19% (95% CI 4-34) with similar disease control rate (96% versus 93%)17. 
In the present study, 38 (66%) patients discontinued IM; 14 (37%) without subsequent treatment, 
of which ten patients had stable disease at final follow up. Thirteen (62%) patients eventually 
progressed, after discontinuing IM for toxicity or non-specific medical reason (N=21, 55%). Both 
stable and progressive patients can be a result of discontinuing IM treatment or the natural course 
of disease.
Newer, more specific inhibitors of CSF1R, currently only available in trial-setting such as 
emactuzumab (RG7155)27, pexidartinib (PLX3397)15, and cabiralizumab28 (FPA008, Five-Prime), 
have shown promising clinical activity on similar groups of diffuse TGCT patients in prospective 
clinical studies with more formal criteria and timelines for response assessment than this 
retrospective series. Emactuzumab (N=29)16 had an overall response rate of 86% (two patients 
with a complete response) and a rate of disease control of 96%, including a significant functional 
and symptomatic improvement (median follow up 12 months). Pexidartinib showed (N=23)15 an 
overall response rate of 52% (all patients had a partial response) and a rate of disease control of 
83%. Responses were associated with an improved joint function (median duration of response 
exceeded eight months). The preliminary results with cabiralizumab (N=22) are consistent, with 
radiographic response and improvement in pain and function in five out of 11 patients28. However, 
long term efficacy data have not yet been reported with these newer agents.
Virtually all patients treated with IM for either CML or GISTs, experience29 at least one mild or 
moderate adverse effect (grade 1-2). Toxicities of IM are determined by the disease stage and 
the doses used, advanced disease and higher doses result in more frequent and severe toxicities. 
Most side effects occur early in the course of treatment and tend to decrease in frequency and 
intensity in time29. We consider a 10-15% rate of grade 3-4 toxicities in a generally benign but 
locally aggressive disease, such as diffuse TGCT, too high. Only 22% of patients did not experience 
any side effects.
Although target anti-cancer therapies are described as ‘well tolerated’, the perception of tolerability 
may vary in the context of a, most often, benign condition. Understanding, monitoring and 
managing the side effects will be important to optimize systemic therapy for patients with TGCT.
206
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Discontinuation of treatment due to toxicities was seen for IM (this series), emactuzumab15 and 
pexidartinib16 in 12%, 20% and 9% patients, respectively. TGCT patients might be less willing to 
cope with adverse event-related and study-related procedures. Here, we report prolonged clinical 
benefit and symptomatic relief, even after discontinuation of treatment. A similarly persistent 
effect was observed was also observed with monoclonal antibodies and more specific CSF1R 
tyrosine kinase inhibitors this24. This suggest that intermittent treatment administration may be 
an option to improve long term tolerability.
The place of systemic treatment in a benign, locally aggressive disease, such as TGCT, and how to 
optimally deliver this treatment, remains unclear. More specifically, the role of CSF1R inhibitors 
in the peri-operative setting still needs to be explored: the number of patients who underwent 
operation after IM in our series is too low to draw any conclusions. Despite limitations related to 
its retrospective nature, this study adds to the knowledge of targeting the CSF-1/CSF-1R pathway 
in patients with TGCT. An optimal treatment strategy should be developed for the patient group 
that benefits most from systemic therapy. The combination of a short period of treatment and the 
durable effect after discontinuation, should be pursued. It is challenging to maintain compliance 
for years, especially with, even “minor”, toxicities, in the context of a non-life-threatening disease.
A limitation of all, including this, clinical TGCT studies is the lack of a control group and the 
absence of specific and validated patient-reported outcome measures to document treatment-
induced symptomatic, functional and economic (back to work) improvement16. Quality of life and 
functional forms should be implemented. These measures are critical endpoints in demonstrating 
clinical relevance and impact of treatments for benign diseases in which death is not a relevant 
outcome variable30. Clinical benefit necessitates objective measures to correlate with tumour 
reduction.




Identification of a biologic aggressive subgroup of diffuse TGCT, at risk of increased surgical 
morbidity or recurrent disease, should aid to decide which patients benefit most of systemic 
treatments. With the advent of more potent CSF-1R inhibitors, such as emactuzumab, pexidartinib 
and cabiralizumab, the role of IM in extensive TGCT might weaken, but may be balanced by the 
favourable safety profile of IM. Availability of these new compounds, both in terms of registration 
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To evaluate health-related quality of life (HRQoL) and joint function in TGCT patients before and 
after surgical treatment.
Patients and methods
This prospective cohort study run in two Dutch referral centres, assessed patient-reported outcome 
measures (SF-36, VAS and WOMAC) in 359 consecutive patients with localized- and diffuse-type 
TGCT of large joints. Patients with recurrent disease (N=121) and a wait-and-see policy (N=32) 
were excluded. Collected data were analysed at specified time intervals pre-(baseline) and/or 
postoperatively up to 5 years.
Results
In total 206, 108 localized- and 98 diffuse-type, TGCT patients were analysed. Median age at 
diagnosis of localized- and diffuse-type was 41 (IQR 29-49) and 37 (IQR 27-47) years, respectively. 
SF-36 analyses showed statistically significant and clinically relevant deteriorated preoperative- 
and direct postoperative scores compared with general population means, depending on subscale 
and TGCT subtype. After 6 months of follow up, these scores improved to general population 
means and continued to be fairly stable the following years. VAS scores, for both-subtypes, 
showed no clinically relevant differences pre- or postoperatively. Pain experience varied hugely 
between patients and also over time. WOMAC scores, for both TGCT subtypes, showed no clinically 
relevant differences pre- versus postoperatively. However, in diffuse-type patients WOMAC pain 
and physical function scores showed a trend towards improvement postoperatively.
Conclusion
Patients report a significant better HRQoL after surgery in TGCT whereas joint function showed 
a trend towards improvement. Pain scores –which vary hugely between patients and in patients 
over time- did not improve. A disease specific patient-reported outcome measure would help to 




Tenosynovial giant cell tumours (TGCT) of large joints, historically known as pigmented villonodular 
synovitis (PVNS), are rare colony stimulating factor-1 (CSF-1)-driven proliferative, mono-articular 
disorders. They affect the joints or tendon sheaths at all ages, however mostly at young adulthood. It 
most commonly affects large, weight bearing joints such as knees, ankles and hips1, 2. The incidence 
rate of localized-extremity (excluding digits) and diffuse-type TGCT is 10 and 4 per million person 
years, respectively3. Localized-type comprises a single nodule and has a favourable course after 
surgical treatment. Diffuse-type involves the synovial lining as well as surrounding structures. It 
can behave locally aggressive and is challenging to remove completely. There is a significant risk of 
recurrence after surgical treatment (>50% depending on follow up times)2, 4, 5.
Diffuse-type TGCT often requires one or multiple synovectomies, or at times a joint replacement, 
and rarely even amputation1, 2, 6. In patients with extensive and/or recurrent TGCT, other available 
treatment modalities include radiation synovectomy7, external beam radiation therapy8, and 
cryosurgery9 of which the effects are controversial10. More recently, systemic therapy has been 
introduced, targeting the CSF-1 receptor. At first treatment with the multi targeting tyrosine 
kinase inhibitor imatinib started, very recently more promising data of a CSF-1 specific targeting 
agent were presented11-13. Systemic treatment may need to be given for one to several years, but 
the optimal treatment duration has still to be determined. Despite the variety of treatments, it is 
unclear which one is the most effective with the least impact on quality of life.
A limitation of most clinical TGCT studies is the absence of disease specific and validated patient-
reported outcome measures (PROMs) to document disease and treatment related functioning and 
symptomatology. Overall survival is the primary endpoint in oncologic clinical trials, however this 
is not appropriate for TGCT, which is rarely lethal14. Alternate treatment endpoints in TGCT include 
response rates, progression free survival, and avoidance of morbid therapies. As indicated, quality 
of life (QoL) and functional scores are of utmost importance, but they are mostly not reported 
or only described for small, heterogeneous patient groups2, 15. The impact of therapies and the 
relevance of treatment outcomes to patients’ quality of life is therefore essential especially in a 
benign but locally aggressive disease16,17.
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The aim of our study is to investigate HRQoL, pain and joint function in surgically treated non-
recurrent TGCT patients, pre- and/ or postoperatively over time.
methods
This prospective cohort study was conducted at two Dutch referral centres; Radboud University 
Medical Centre (RadboudUMC) and Leiden University Medical Centre (LUMC). Between 2011 until 
2018 patients diagnosed with primary therapy-naïve or recurrent TGCT (magnetic resonance 
imaging (MRI) and histological confirmed) of large joints, were asked to participate. Large 
joints were defined as all joints except the digits. Three hundred and fifty-nine consecutive 
patients were identified; 136 (38%) with localized TGCT, 223 (62%) with diffuse TGCT. During 
regular outpatient clinic visits, patients who consented were requested to complete PROMs 
questionnaires. To further reduce heterogeneity of the group, patients with recurrent disease at 
presentation, treated conservatively (wait-and-see policy) and patients in absence of QoL and 
function scores after primary surgery, were excluded from this analysis (figure 1). Also, if patients 
developed relapse after surgical treatment, they were excluded from this time on. Hundred-and-
eight localized- and 98 diffuse-type therapy-naïve patients were used for final analyses (figure 1). 
The study protocol (RadboudUMC (file number CMO 2012/555) and LUMC (file number CMO 
P13.029)) was approved by the local institutional ethical review boards and was carried out in 
the Netherlands in accordance with the applicable rules concerning the review of research ethics 
committees and informed consent. Patients provided written informed consent when they 
completed questionnaires (SF 36, VAS and WOMAC).
The used PROMs included the Dutch translation of a generic HRQoL instrument, the 36-item 
Short Form Health Survey (SF-36)18, a Visual Analog Scale (VAS) for pain and the Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC). SF-36 is an instrument for measuring 
general health, including eight subscales: Physical functioning (PF), Social functioning (SF), 
Role limitations due to physical problems (RP), Role limitations due to emotional problems (RE), 
General mental health (MH), Vitality (VT), Bodily pain (BP) and General health (GH). SF-36 scores 
were computed by summing the item scores and transforming the scores onto a 100-point scale 
(0= “worst health” and 100= “best health”). VAS for worst pain was used to estimate patients pain 
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Figure 1  Flowchart of consecutive patients with TGCT, included for quality of life analyses.
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diffuse, N=19
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intensity of the affected joint for the past 24 hours, using a series of 0- to 10-point (0= “no pain” 
and 10= ”pain as bad as you can imagine”)19. The Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) was used to evaluate affected joint function20. The WOMAC is a 
24-item instrument assessing pain, stiffness and difficulty performing daily activities originally 
designed for osteoarthritis. All items are measured on a 5 point scale; ranging from “no” up to 
“worst imaginable”. The WOMAC data were standardized to a range of values from 0-100, for which 
lower values indicate more pain, more stiffness, or worse physical functioning. Gelhorn et al. 16 
used a modified version of WOMAC for TGCT patients.
Patient demographics and clinical, histological, radiological, treatment and follow-up data were extracted 
from individual patients’ files at each institution by the local investigator (FGMV or MJLM) and were 
provided in an anonymous form for analyses. Definitive histological diagnosis was performed at the centre 
of origin by dedicated pathologists with extensive experience in mesenchymal tumours. Recurrences 
and PROMs were analysed according to TGCT subtype. Data were described using percentages for 
qualitative variables and medians with interquartile ranges (IQR) for continuous variables.
As patient questionnaires were completed at different points in time they were categorized in the 
following time intervals: pre-surgery (=0 or baseline), post-surgery after 0-3, 3-6, 6-12, 12-24, 24-36, 
36-48, 48-60 months. At final analyses we did not have questionnaires in all time intervals for each 
individual patient, some had solely pre- or post-operative scores. In case of recurrent disease after 
primary treatment in a therapy-naïve patient, QoL and functions scores were used up to recurrence 
development, confirmed on MR imaging. Follow-up time was defined as the period between first TGCT 
confirmation (MR imaging and histologic) and most recent patient contact. Time to recurrence was 
calculated as time from first treatment until proven (MR imaging and histologic) first recurrent disease.
Differences between QoL scores (SF-36, VAS, WOMAC) were tested using t-tests. SF-36 scores were 
compared with Dutch general population scores18, and WOMAC and VAS baseline (preoperative) 
scores were compared with postoperative scores.
To estimate the clinical relevance, the mean differences were compared with the minimal clinically 
important difference (MCID). MCID is a QoL measure that represents the smallest difference or 
change beyond statistical significance in an outcome measure score that would be considered 
clinically relevant by the value patients place on change21. The MCID for SF-36 has been estimated 
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at to be 10 points by Escobar et al.22 in patients undergoing total knee replacement. For VAS pain 
a MCID of 2 was used23. The MCID for standardized WOMAC values has been estimated at around 
15-20 points22, with relative improvements of 21-41% for its subscales23-25. We used a MCID for 
WOMAC of 20 points based on consensus in the project team and the study of van der Wees et al.26
All statistical analyses were performed using R version 3.4.0 (R Foundation for Statistical Computing, 




After exclusion of patients with recurrent disease (N=121) and patients with a wait-and-see policy 
(N=32), 206 patients remained for further analyses (figure 1). Median age at diagnosis of localized- 
(N=108) and diffuse-type (N=98) TGCT was 41 (IQR 29-49) and 37(IQR 27-47) years, respectively. The 
majority of patients were female (localized N=62 (57%)), had diffuse-type TGCT N=64 (65%)), and had 
the knee as the most common affected joint in both subtypes (localized N=84 (78%)) and diffuse N=72 
(74%)). Pain (localized N=61 (57%) and diffuse N=58 (60%)) and swelling (localized N=66 (61%) and 
diffuse N=65 (67%)) were the most prevalent clinical symptoms at diagnosis for both subtypes (table 1).
Treatments
As primary treatment, three (3%) localized-type patients were treated with arthroscopic 
synovectomy, 103 (95%) with one-staged synovectomy and two (2%) with (endo-)prosthesis. Seven 
patients (6%) had a first recurrence after median 2.9 (2.1-5.6) years. Overall median follow up of 
localized therapy-naïve patients was 2.0 (IQR 0.7-4.6) years. At final follow up, 104 (96%) patients 
had no evidence of disease, 4 (4%) patients were alive with disease, without planned treatment.
Diffuse-type patients were treated with arthroscopic (N=3 (3%)), one-staged (N=75 (76%)) or two-
staged (N=18 (19%)) synovectomy. Two patients received an (endo-) prosthesis. Twenty-seven 
patients (28%) had a first recurrence after median 1.3 (1-3) years, thereafter they were excluded 
from further analyses. Overall median follow up of diffuse-type patients was 2.7 (IQR 1.4-4.9) years. 
At final follow up, 70 (71%) patients had no evidence of disease, 27 (28%) patients were alive with 
disease and one patient died of another disease.
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Table 1  Characteristics of therapy-naïve TGCT patients 
Localized N (%) Diffuse N (%)
Total 108 98
Median age at diagnosis (IQR), yrs. 41 (29-49) 37 (28-47)
Sex
Male 46 (43) 34 (35)
Female 62 (57) 64 (65)
Tumour localization
Knee 84 (78) 72 (74)
Ankle 10 (9) 10 (10)
Hip 1 (1) 7 (7)
Other 13 (12) 9 (9)
Pre-surgery symptoms
Pain 61(57) 58 (60)
Swelling 66 (61) 65 (67)
Loss of function 8 (7) 20 (21)
Stiffness 5 (5) 14 (14)
Recurrent disease
No 101 (94) 71 (72)
Yes 7 (6) 27 (28)
Median time to first recurrence (IQR) 2.9 (2.1-5.6) 1.3 (1-3)
Complications
None 106 (98) 91 (93)
Deep wound infection - 2 (2)
Superficial wound infection 1 (1) 2 (2)
Hemorrhage - 1 (1)
Joint stiffness 1 (1) 1 (1)
Neurovascular damage - 1 (1)
Median follow up time (IQR), yrs 2.0 (0.7-4.6) 2.7 (1.4-4.9)
Abbreviations: TGCT= Tenosynovial Giant Cell Tumours, N= Number of patients, mo=months, 
yrs= years, IQR= inter quartile range, other= Foot, shoulder, elbow, wrist or temporomandibular 
joint, AWD= alive with disease.
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HR Quality of life
Compared to Dutch general population means18, localized-type patients preoperatively scored 
significantly lower on PF(13.2(95%CI 6.0-20.5)), SF(18.7(95%CI 10.3-27.2)), RP(25.8(95%CI 11.9-39.8)), 
RE(20.6(95%CI 7.3-34.0)) and BP(21.2(95%CI 12.7-29.8)). These differences were also clinically relevant 
(mean difference> MCID 10). This effect lasted up to 3 months postoperatively on RP(40.1(95%CI 
16.7-63.5)) and BP(17.2(95%CI 2.2-32.1)). Thereafter, these means improved to general population 
means and continued fairly stable during the following years (figure 2a, table 2b).
Figure 2a  SF-36 scores of localized-type, therapy-naïve, TGCT patients. 
Spider plot showing SF-36 scores preoperative (baseline),  6-12 months postoperatively and of Dutch general 
population means18: physical functioning (PF), social functioning (SF), role limitations due to physical problems 
(RP), role limitations due to emotional  problems (RE), general mental health (MH), vitality (VT), bodily pain (BP) 
and general health (GH).
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Figure 2b  SF-36 scores of diffuse-type, therapy-naïve, TGCT patients. 
Spider plot showing SF-36 scores preoperative (baseline),  6-12 months postoperatively and of Dutch general 
population means18: physical functioning (PF), social functioning (SF), role limitations due to physical problems 
(RP), role limitations due to emotional  problems (RE), general mental health (MH), vitality (VT), bodily pain (BP) 
and general health (GH).
Diffuse-type patients preoperatively scored statistically significant and clinically relevant (mean 
difference> MCID 10) lower on PF(23.7 (95% CI 16.7-30.8)), SF (15.6 (95% CI 8.8-22.5)), RP (37.4 
(95% CI 25.3-49.5)), VT (10.0 (95% CI 3.5-16.4)) and BP (21.6 (95% CI 14.7-28.5)) compared to 
general population means. This difference with the general population remained significant for 
up to 3 months postoperatively on PF (21.9 (95% CI 5.0-38.8)), SF (19.9 (95% CI 3.0-36.9)), RP (40.1 
(95% CI 16.2-64.1)), VT (13.0 (95% CI 1.5-24.5)) and BP (22.4 (95% CI 5.3-39.4)) and up to 6 months 
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Table 2a  SF-36 scores of localized-type, therapy-naïve, TG
C
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postoperatively on PF (14.8 (95% CI 3.3-26.4)). Thereafter, the mean SF-36 scores of diffuse-type 
patients improved to Dutch general population means and continued fairly stable the following 
years. Compared to general population means diffuse-type patients scored statistically significant 
and clinically relevant lower on GH 3-6 months (10.6 (95% CI 9.8-23.2)), 6-12 months (10.3 (95% CI 
2.3-18.9)) and 24-36 months (10.7 (95% CI 4.5-16.9)) postoperatively (figure 2b, table 2b).
Visual analog scale for pain
No statistical significant nor clinical relevant difference in pain scores were found in localized-type 
patients preoperatively (median VAS score 4, IQR 1-6) versus 3 months postoperatively (median 
VAS score 3.5, IQR 1-5), which in fact remained the same up to five years follow up. Median VAS 
scores in diffuse-type patients showed no clinical relevant difference preoperatively (median VAS 
score 4, IQR 2-6) versus 3 months postoperatively (median VAS score 2, IQR 1-4), and also here the 
scores remained the same up to five years follow up. Pain experience in both subtypes TGCT varied 
widely between and within patients over time (range 0-7 years follow up).
Joint function
Mean WOMAC scores on pain, stiffness and physical functioning for both localized- and diffuse-
type patients showed no significant differences pre-(baseline) versus postoperatively. Patients 
of both subtypes scored significantly better at some postoperative time intervals compared to 
baseline scores, however mostly clinically irrelevant (mean difference< 20) (table 3a and b).
In diffuse-type patients (table 3b) WOMAC pain and physical function scores showed a trend 
towards improvement in scores from preoperatively (baseline) to postoperative up to 5 years 
follow-up.
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To our knowledge, this study provides the largest prospective cohort, including longest follow up 
time, to report on PROMs in therapy-naïve patients with localized- and diffuse-type TGCT of large 
joints followed up until relapse of disease or end of study. In both TGCT subtypes HRQoL (SF-36) 
was statistically significant and clinically relevant decreased before surgical treatment on the main 
physical domains (RP, PF, BP) and some mental domains (SF, RE, VT) compared to general population 
means. These low scores lasted for up to 6 months postoperatively depending on TGCT subtype and 
SF-36 subscale. Thereafter, all SF-36 subscales improved to general population means and continued 
fairly stable the following years. Pain experience (VAS) in both subtypes varied widely between and 
within patients over time. Mean function (WOMAC) scores on pain, stiffness and physical functioning 
for both subtypes TGCT showed no clinically relevant difference pre-(baseline) versus postoperatively. 
However, in diffuse-type patients WOMAC pain and physical function scores showed a trend towards 
improvement in scores from preoperatively(baseline) to postoperatively up to five years follow-up.
TGCT can behave locally aggressive causing joint destruction and provoke significant pain, swelling, 
decrease in range of motion, and stiffness11. This morbidity can lead to impairment of HRQoL and 
function because of pain, medication use, disability, the knowledge of having a tumour (despite 
its benign character), and loss of working hours16. To improve these consequences, treatments are 
performed, which –unfortunately- might contribute to further joint destruction10. The prolonged 
course of the disease and the need for multiple surgeries has been reported to result in a worse 
joint function for many patients27. In addition to the physical and financial burden for the patient, 
TGCT also involves high healthcare burden28. Finding an efficient treatment is important.
This study reported on the loss of HRQoL in patients with TGCT compared to general population 
means. The improvements in HRQoL after surgical resections were present 3-6 months after surgery. 
This could be explained by the morbidity of an operation and the associated recovery time.
We did not find statistically significant and clinically relevant differences in pain experience. This 
might be explained by a variability in symptom experience as described by Gelhorn et al.16 They 
found that not all patients experience all symptoms and there was variability in how patients 
experienced symptoms within and among days.
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The statistically significant but lack of clinically relevant improvement in joint function (WOMAC) 
could be explained by the destruction the disease already caused, or by the small number of 
questionnaires left after exclusion of many patients to optimize the homogeneity of the patient 
group. The lack of disease specific instruments to evaluate adequate PROMs for TGCT, may have 
led to underreporting disease specific issues.
SF-36 was developed to get more general insight into patients’ health and as a means of making 
comparisons across conditions29. VAS was developed as a pain assessment tool used for cancer 
patients19. The WOMAC was originally developed to evaluate the outcome of a total knee 
replacement in patients with osteoarthritis.20 SF-36, VAS and WOMAC are a good start in assessing 
the patients perspective in TGCT, since they are validated, easy to apply and globally known. These 
measures are frequently used for other diseases, allowing to compare TGCT patients with other 
patient groups, for example patients with joint replacements for osteoarthrosis30,22, 31. Gelhorn et 
al. investigated ‘patient-reported symptoms of TGCT’. They concluded that pain (VAS), swelling, 
stiffness and impaired joint function (WOMAC) are important PROMs.
Van der Heijden et al. 15 evaluated 30 patients with therapy-naïve and recurrent diffuse-type TGCT 
at a mean of 8 (range 2-32) years after diagnosis. HRQoL impairment (SF-36) was seen in all patients 
initially treated with arthroscopic synovectomy (62 range 26-94) and an open synovectomy (80 
range 63-98), compared to healthy controls15. The patient population was small and heterogeneous, 
in which outcome measures were assessed at different time points after treatment. In the study of 
Verspoor at al.2, which experienced similar limitations, HRQoL (SF-36) scores were not significantly 
different between localized- and diffuse-type TGCT. However, both patient groups had impaired 
HRQoL compared to general population means one the general health subscale. Diffuse patients 
also scored significantly lower on other subscales (PF, MH and VT). The current study, with a more 
homogenous, larger patient cohort and measurements at categorized time intervals, showed a 
similar impairment in therapy-naïve patients on PF preoperatively for both subtypes and up to 
6 months postoperatively in diffuse-type patients who generally need more extensive surgery 
compared to localized-type TGCT.
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Case series reporting on joint function before treatment often included both subtypes, various 
localizations, a mixture of therapy-naïve and recurrent TGCT including multiple treatments15, 27, 
32-34. Therefore, it is extremely challenging to perform a meta-analysis to prove treatment effect(s) 
in the rare disease TGCT. Through the emergence of systemic treatments for TGCT, attention for 
additional outcome measures besides recurrences has been raised, such as HRQoL and joint 
function. International cooperation has been initiated, resulting in large registries including QoL 
and joint function35. In the recent years targeted therapy has been added to the armamentarium. 
At ASCO 2018 results of pexidartinib (PLX3397)12, a selective inhibitor of CSF-1 receptor, KIT, 
and FLT3-ITD, were promising in a randomized, placebo controlled, phase 3 study. Pexidartinib 
compared to placebo resulted in an significantly improved overall response rate (39.3% vs 0%) and 
PROMIS physical function (4.06 vs 0.89), after a median 6 months follow up12. In this study range of 
motion, PROMIS physical function, worst stiffness and pain response were secondary endpoints12.
The joint localization of TGCT might influence physical function36, 37. Therefore, a sensitivity analysis 
was performed on our patients with TGCT affecting the knee, which showed similar results to our 
primary analysis. In a univariate analyses on TGCT locations with recurrent disease as outcome, 
Palmerini et al.38 did not find a difference between knees, hips and ankles.
Two crowdsourcing studies39, 40, using an online patient support-group, reported on physical 
function and HRQoL in TGCT patients. In patients with diffuse-type TGCT, recurrences requiring 
repeated surgery and joint replacement were reported to have a lower HRQoL and functional 
outcome39, 40. Because of selection bias, it is possible that severe cases including (additional) 
recurrences were more likely to be online to complete the e-survey. However, all studies, including 
the current one suggest an impaired effect on HRQoL and function in patients with TGCT. The 
challenge remains to find the exact quantification method.
This study has some limitations that need to be discussed. Because of the rarity of TGCT, it 
is challenging to perform a prospective study with adequate patient numbers. To reduce 
heterogeneity of the patient group, we chose to exclude recurrent patients, at the expense of 
decreasing patient numbers. Still, heterogeneity in severity and duration of illness remained.
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Selection bias should be taken into account, because this study only contains patients from two 
tertiary Dutch referral centres. Overrepresentation of extensive disease, could have resulted in an 
overestimation of the impact on HRQoL and joint function. Also, patients with complaints more 
often visit the outpatient clinic completing questionnaires. These patients might have more 
extended, metastatic, disease. By excluding patients with recurrent TGCT, this possible bias was 
reduced. On the contrary, patients who do well, like localized-type TGCT patients, were discharged 
early reducing their follow up time and number of questionnaires.
It should be noticed that HRQoL and function scores were taken at variable points after treatment 
for individual patients, which reduced  numbers at some specific time points. Not all patients 
had preoperatively and postoperative available measures, causing an  increase in the range of 
these outcome measures. Furthermore, it is preferred to adjust SF-36 measures for age, because 
of physiologically declined HRQoL and joint function decrease in ageing18, 41. In the current study 
correction for age could not be achieved by differences in ages per time interval and the age 
distribution within time intervals.
Patients with localized-type TGCT generally do not have a high burden of their disease. The 
question is whether PROMs are essential in patients with localized disease, who can generally be 
treated curatively with a radical excision and are not eligible for systemic therapy. To date, surgical 
resection remains the treatment of choice for TGCT, but is associated with high recurrence rates and 
multiple additional surgeries in diffuse-type disease.10 The balance between increased morbidity 
of multiple or invasive surgeries15, 42, alternative therapeutic options, and daily symptoms of the 
tumour is challenging. A more aggressive resection or other multimodality treatments, such as 
external beam radiation therapy, may adversely affect QoL, joint function and the development of 
osteoarthrosis, which are, given the young adult age group, factors of major importance2, 38. Use 
of a control group and of specific and validated PROMs will better document treatment-induced 
symptomatic, functional and economic (back to work) consequences of these treatments16.
When systemic treatments show tumour growth arrest and symptomatic improvements, a less 
invasive approach would be justified11. The recent studies on targeted therapy used a control 
group and as secondary outcome measure PROMIS physical function12.
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These measures are critical endpoints in demonstrating clinical relevance and impact of treatments 
for benign diseases in which death is no outcome variable.16 Clinical benefit necessitates objective 
measures to correlate with tumour reduction. When significant changes in TGCT specific 
developed outcome measures are found, one should try to specify if this is the consequence of the 
disease itself, of the ‘multiple’ treatment(s) received, or of other factors, such as comorbidities, the 
knowledge of having a tumour or issues not related to disease.
conclusion
Patients report a significant better HRQoL after surgery in TGCT whereas joint function showed 
a trend towards improvement. Pain scores –which vary hugely between patients and in patients 
over time- did not improve. A disease specific patient-reported outcome measure would help to 
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abstract
Background
Tenosynovial Giant Cell Tumour (TGCT) is a rare, benign lesion affecting the synovial lining of 
joints, bursae, and tendon sheaths. It is generally characterized as a locally aggressive and often 
recurring tumour. A distinction is made between localized- and diffuse-type. The impact of TGCT 
on daily living is currently ill-described. 
Objective
The aim of this crowdsourcing study was to evaluate the impact of TGCT on physical function, 
daily activities, societal participation (work, sports, and hobbies), and overall quality of life from 
a patient perspective. The secondary aim was to define risk factors for deteriorated outcome in 
TGCT.
Methods
Members of the largest known TGCT Facebook community, PVNS is Pants!!, were invited to an 
e-survey, partially consisting of validated questionnaires, for 6 months. To confirm disease 
presence and TGCT-type, patients were requested to share histological or radiological proof of 
TGCT. Unpaired t tests and chi-square tests were used to compare groups with and without proof 
and to define risk factors for deteriorated outcome.
Results
Three hundred thirty-seven questionnaires, originating from 30 countries, were completed. 
Median age at diagnosis was 33 (interquartile range [IQR]=25-42) years, majority was female (79.8% 
[269/337]), diffuse TGCT (70.3% [237/337]), and affected lower extremities (knee 70.9% [239/337] 
and hip 9.5% [32/337]). In 299 lower-extremity TGCT patients (32.4% [97/299]) with disease 
confirmation, recurrence rate was 36% and 69.5% in localized and diffuse type, respectively. For 
both types, pain and swelling decreased after treatment; in contrast, stiffness and range of motion 
worsened. Patients were limited in their employment (localized 13% [8/61]; diffuse 11.0% [21/191]) 
and sport-activities (localized 58% [40/69]; diffuse 63.9% [147/230]). Compared with general US 
population, all patients showed lower Patient-Reported Outcomes Measurements Information 
System-Physical Function (PROMIS-PF), Short Form-12 (SF-12), and EuroQoL 5 Dimensions 5 
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Levels (EQ5D-5L) scores, considered clinically relevant, according to estimated minimal important 
difference (MID). Diffuse versus localized type scored almost 0.5 standard deviation lower for 
PROMIS-PF (P<.001) and demonstrated a utility score of 5% lower for EQ-5D-5L (P=.03). In localized 
TGCT, recurrent disease and ≥2 surgeries negatively influenced scores of Visual Analog Scale (VAS)-
pain/stiffness, SF-12, and EQ-5D-5L (P<.05). In diffuse type, recurrence resulted in lower score for 
VAS, PROMIS-PF, SF-12, and EQ-5D-5L (P<.05). In both types, patients with treatment ≤1year had 
significantly lower SF-12.
Conclusions 
TGCT has a major impact on daily living in a relatively young and working population. Patients 
with diffuse type, recurrent disease, and ≥2 surgeries represent lowest functional and quality of 
life outcomes. Physicians should be aware that TGCT patients frequently continue to experience 
declined health-related quality of life and physical function and often remain limited in daily life, 
even after treatment(s).
introduction
Tenosynovial Giant Cell Tumour (TGCT), previously pigmented villonodular synovitis (PVNS), is a rare, 
proliferative neoplasm affecting the synovial lining of joints, bursae, and tendons sheaths. According 
to growth pattern, a radiological distinction is made between a well-circumscribed lesion (localized 
type) and a locally more aggressive lesion (diffuse type)1, 2. The incidence rate reveals its rarity: for 
localized type (excluding digits), 10.2 per million person-years and for diffuse type, 4.1 per million 
person-years. TGCT is a monoarticular disease, concerning large joints, typically about the knee: 46% 
in localized-type and 64% to 75% in diffuse-type. Male-female ratio is about 1:1.5 for both types, with 
a median age at the time of TGCT diagnosis of 30 to 50 years1-3. Most common initial symptoms are 
pain, stiffness, and swelling. Additional symptoms might be limited range of motion, instability, giving 
way, and locking complaints4. Due to these unspecific signs and the rarity of the disease, patients 
frequently experience a delay of years in diagnosis3, 5, 6. To treat these symptoms, current treatment 
of choice is surgical excision, either by arthroscopic or open synovectomy7. After surgical resection, 
high recurrence rates are known, with the localized type up to 50% and the diffuse type up to 92%6. 
239
11
Impact of tenosynovial giant cell tumours on daily living
Once TGCT is diagnosed, a high health care burden is identified with a significant increase in 
health care costs, ambulatory expenses, and physical therapy8. In describing treatment benefits 
and standard oncologic end points, patient-reported outcome instruments are increasingly used. 
Visual Analog Scale (VAS) for worst pain-stiffness and Patient-Reported Outcomes Measurement 
Information System- Physical Function (PROMIS-PF) questionnaires were identified as most valuable 
measures for TGCT symptoms in a relatively small TGCT patient cohort (n=22)4. 
The impact of TGCT symptoms following surgery(s) and recurrences on daily living, sports, and 
work activities is currently ill-described. Although TGCT is not considered lethal, this tumour is 
hypothesized to have major impact on daily living. Especially diffuse disease is notorious for its 
negative influence on both local recurrence risk and functional outcome9.
Use of an e-survey is a unique possibility to reach a large elusive TGCT population and to globally 
evaluate impact of TGCT on patients’ daily life. This crowdsourcing study evaluates effect of TGCT on 
physical function, daily activities, societal participation (work, sports, and hobbies), and overall quality of 
life from a patient perspective. Secondary aim is to define risk factors for deteriorated outcome in TGCT.
methods
Study design
This cross-sectional crowdsourcing study was performed at Leiden University Medical Centre, 
Leiden, The Netherlands, in accordance with good clinical practice [the Declaration of Helsinki 
(2000)]. This study was conducted from December 2016 until end of May 2017 (6 months), using 
the largest known online TGCT community on Facebook, PVNS is Pants!!, to gather participants for 
the Web-based questionnaire. The study was conducted conforming to the Checklist for Reporting 
Results of Internet E-Surveys (CHERRIES), the checklist focusing on Web-based surveys10 (Appendix 
1). NetQuestionnaire (NetQ) was used to complete the TGCT questionnaire. NetQ is a professional 
Web-survey software, approved for (bio)medical research and supported by the Leiden University 





Members of PVNS is Pants!! were requested to participate in our international crowdsourcing 
study “Evaluation of Tenosynovial Giant Cell Tumour on daily living” (Appendix 2). At the time of 
writing (December, 2016), this closed Facebook community contained 2179 members. A patient-
friendly TGCT-research-related message was posted in the Facebook community every 4 weeks 
to encourage TGCT patients to complete the questionnaire. Additional study updates and easily 
understandable information on TGCT were posted on the page of a newly designed TGCT study 
Facebook account11.
All members of the Facebook community had access to the questionnaire. Solely patients 
with TGCT diagnosis were requested to participate in this study. To achieve a higher level of 
evidence, confirmation of TGCT (histological or radiological) was requested after completing the 
questionnaire. Sending (anonymized) medical reports to our protected email account was highly 
desirable but left to the discretion of the participant. 
Members of Facebook community PVNS is Pants!! have been notified that (research-minded) 
doctors are members of this closed Facebook community for several years. Participation in this 
study was voluntary, and no incentives were offered. Informed consent was given by completing 
the survey. This study was approved by the Institutional Review Board (CME) from our institution 
(registration number P16.232, December 5, 2016).
Unique site visitors were determined by Internet protocol (IP) addresses. When duplicate entries 
were detected, the most recent one was included in the analyses. All password-protected 
documents were only accessible to TGCT researchers and saved on the secured departmental 
drive of our hospital. Data of participants were anonymized when medical proof was received or 
when the participant did not respond to our third request for medical confirmation. To ascertain 
TGCT diagnosis and TGCT type, all medical reports were verified by 2 TGCT researchers (MJLM, RP). 
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Questionnaire
On the very active Facebook community PVNS is Pants!!, several patient-initiated questionnaires 
and polls were performed, for instance, about treatments, coping strategies, daily limitations, and 
emotional struggles. Members expressed their desire for studies regarding these topics, since the 
majority of TGCT studies concern physical function and recurrent disease as outcome parameters. 
Therefore, a Web-based questionnaire, using mostly validated questionnaires, was composed to 
describe impact of TGCT on health-related outcome and daily living from a patient perspective. A 
prerequisite was that the questionnaire would be relevant for the heterogeneous TGCT population: 
for different large joints, different ages, males or females, localized or diffuse type, and for patients 
at different treatment stages.
To assess relevance and completeness of our questionnaire, a pilot test with the composed 
questionnaire was performed. One dedicated orthopaedic oncologic surgeon (MAJS), 2 medical 
doctors (MJLM, RP), and 5 TGCT patients in our outpatient clinic, all fluent in written and spoken English 
language, tested the e-survey. Validated questionnaires were used as published by the owners. After 
the pilot test, a few nonvalidated questions were added or rephrased (Appendix 3).
Nonvalidated questions concerned patient and tumour characteristics, medical history, TGCT symptoms, 
performed treatments, recurrences, employment status, sports, and number of visits to general 
practitioner and orthopaedic surgeon. The majority of questions had a multiple-choice character, 
including a not applicable or other answer option. The exact number of nonvalidated questions 
depended on given answers. For instance, patients with an extensive TGCT-related history were asked 
additional questions on their history, in contrast to the patients awaiting their initial treatment.
Validated questionnaires on physical function and quality of life included: VAS for worst pain and 
stiffness in the last 24 hours, PROMIS-PF items, Short Form-12 Health Survey (SF-12), and EuroQoL 
EQ-5D-5L (EQ-5D-5L Descriptive System and EQ-5D-5L VAS). A total of 32 validated questions were 
included. VAS for pain and stiffness was used to estimate patient’s pain and stiffness intensity for 
the past 24 hours: no pain/stiffness at all (0) and worst pain/stiffness imaginable (10). 
242
Chapter eleven
PROMIS-PF instruments were used to measure self-reported capability of physical activities. In 
this study, short forms of physical functioning for lower and upper extremity were used with 5 
response options: without any difficulty (5), with a little difficulty (4), with some difficulty (3), with 
much difficulty (2), and unable to do (1). Raw score was calculated by summing up the values of 
the response to each question and was converted into a T score by the Assessment Centre from 
PROMIS-PF. A mean of a standardized T score of 50 with a standard deviation of 10 reflects the 
general US population12. 
The SF-12, a generic measure of health status, functioned as a shorter alternative for the SF-36. 
Number of answer options differed per question. Physical component summary (PCS) score and 
mental component summary (MCS) score were calculated. Similar to PROMIS-PF, the general US 
population had a mean of 50 with a standard deviation of 1013.
The EQ-5D-5L is one of the most commonly used generic health status measures in the world. 
Its descriptive system comprises 5 dimensions of health: mobility, self-care, usual activities, pain 
or discomfort, and anxiety or depression, with the following 5 levels of problems per dimension: 
no problems (1), slight problems (2), moderate problems (3), severe problems (4), and extreme 
problems (5)14. For each participant, answers per dimension were combined into an EQ-5D-5L 
health state. This health state was converted into a single index value (so-called utility score) for 
quality of life, by using the Crosswalk Index Value Calculator version 1.0 from the EuroQoL Group15. 
Utility scores were measured on an ordinal scale of 0 to 1, with 0 indicating death and 1 indicating 
full health16. Crosswalk valuation set for US population was used for all participants, since majority 
of the patients originated from the United States (42.7% [144/377]). A specific analysis, called 
sensitivity analysis, was performed using the valuation set for UK population, the second largest 
patient population (20.2% [68/337]) in this study. Scores calculated with US valuation set were 
compared with scores obtained by using UK valuation set to assess representativeness of the 
scores from validated questionnaires14 (Appendix 4).
Statistical Analysis
NetQ automatically captured questionnaire answers into an SPSS 23 file. Evaluation of TGCT on 
daily living was mainly descriptive.
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Chi-square tests were used to compare patient groups with and without medical proof regarding 
gender (male vs female), TGCT localization (knee vs other large lower extremity joints [hip, ankle, 
and foot]), initial surgery (arthroscopy vs [one- or two-staged] open synovectomy), recurrence (yes 
vs no), total number of surgeries (1 surgery vs ≥2 surgeries), and time since last treatment for TGCT 
(≤1 year ago vs >1 year ago) (Appendix 5).
Independent t tests were used to compare the mean age at the time of diagnosis and continuous 
scores of validated questionnaires. All reported P values were two-tailed. Statistical significance 
level was defined at P<.05.
Effect size, as a quantitative measure of the strength of a phenomenon, was calculated for both 
PROMIS-PF and SF-12 scores in localized- and diffuse-type patients, compared with general US 
population score. Effect size, or Cohen d, is the ratio of difference between two means divided by 
the standard deviation, expressed in standard deviation units. An effect size between 0.2 and 0.5 
is considered small, 0.5 and 0.8 medium, and above 0.8 large17.
The minimal important difference (MID), a quality of life measure, represents the smallest 
difference or change beyond statistical significance in an outcome measure score that would 
be considered clinically relevant by the value patients place on change. MID for EQ-5D-5L Index 
Scores is estimated between .037 and .069, based on the simulation-based instrument-defined 
MID estimates18. MID for PROMIS-PF was determined by Yost et al. in advanced-stage cancer 
patients19. Differences in T scores between 4.0 and 6.0 were considered clinical relevant. MID for 
SF-12 PCS and MCS scores were calculated by Díaz-Arribas et al. in >450 patients with low back 
pain and were stated at >3.29 for PCS and >3.77 for MCS20.
results
The TGCT questionnaire was initiated by 445 participants within a time frame of 6 months. For the 
present analysis, only fully completed, unique questionnaires (337) were included (Figure 1). The 
majority of incomplete questionnaires were early dropouts with a great lack of information and 
therefore unsuitable for analysis.
244
Chapter eleven
Most patients were female (79.8% [269/337]) and median age at diagnosis was 33 (interquartile 
range [IQR]=25-42) years. Patients originated from 30 different countries (United States: 42.7% 
[144/337]; United Kingdom: 20.2% [68/337]; and the Netherlands: 12.8% [43/337]). TGCT was 
typically located in lower extremities: knee (70.9% [239/337]), hip (9.5% [32/337]), ankle (11.0% 
[37/337]), and foot (3.0% [10/337]). Diffuse TGCT was diagnosed in 237 of 337 (70.3%) patients 
(Table 1). According to few TGCT patients with TGCT located in the upper extremity, 12 out of 337 
patients (3.6%) were excluded for further analyses. Additionally, 26 out of 337 lower-extremity 
Figure 1  Flowchart Tenosynovial Giant Cell Tumour (TGCT) questionnaire. 
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Table 1  Patient and tumour characteristics (N=337)
Characteristics Value
Age at time of questionnaire (years), median (IQRa) 41 (32-50)
Age at time of TGCT diagnosis (years), median (IQR) 33 (25-42)




Country of residence, n (%)
United States of America 144 (42.7)
United Kingdom 68 (20.2)

















aIQR: interquartile range (25-75%)
bTGCT: tenosynovial giant cell tumour
cOther included multiple TGCT locations (all in lower extremity)
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patients (7.7%) with unknown TGCT type were also excluded (Figure 1). Questionnaires of 299 
lower-extremity patients with localized or diffuse TGCT were analysed.
Disease Confirmation
Confirmation of TGCT was sent by 32.4% (97/299) of lower-extremity participants. In 81% (78/97) 
TGCT type was in concordance with questionnaire answer, in 16/97 (16%) medical reports TGCT 
type did not match the answer and was therefore adjusted according to the report and 3/97 (3%) 
patients answered TGCT type unknown and TGCT type was added in consistence with the report.
No important differences between patients with and without medical proof were detected 
(Appendix 5), neither for localized or diffuse type separately. Therefore, patients with medical proof 
were considered representative for the entire study population and additional analyses were 
performed for the entire patient group. 
Medical History and Tenosynovial Giant Cell Tumour Symptoms
5/69 (7%) and 29/230 (12.6%) in localized- and diffuse-type patients, respectively, had an 
autoimmune disease, mostly diabetes mellitus type I, Hashimoto, psoriasis, and thyroid disease. 
In all, 22/69 (32%) of localized-type and 70/230 (30.4%) of diffuse-type patients experienced a 
Table 2  Initial and current symptoms for localized and diffuse Tenosynovial Giant Cell Tumour 
(TGCT) (n=337)
TGCTa-related symptom Localized TGCT (n=69) Diffuse TGCT (n=230)
Initial, n (%) Current, n (%) Initial, n (%) Current, n (%)
Pain 57 (83) 47 (68) 186 (80.9) 170 (73.9)
Swelling 53 (77) 29 (42) 190 (82.6) 139 (60.4)
Stiffness 38 (55) 41 (59) 128 (55.7) 148 (64.3)
Limited range of motion 38 (55) 29 (42) 140 (60.9) 149 (64.8)
aTGCT: tenosynovial giant cell tumour
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trauma at TGCT-affected joint, before diagnosis; sports injuries or fall incidents leading to a sprain 
or rupture. In all, 5/69 (7%) and 12/230 (5.2%) of patients in localized and diffuse TGCT had surgery 
of the affected joint before TGCT diagnosis, respectively, for example, meniscus or anterior cruciate 
ligament (ACL) reconstructions. In all, 6/230 (2.6%) of diffuse-type participants experienced both 
trauma and surgery before TGCT diagnosis.
Majority of patients (92.6% [277/299]) were treated for TGCT. For both types, pain and swelling 
improved compared with initial situation. After treatment, more patients reported stiffness and 






Initial surgery, n (%) 
Arthroscopic synovectomy 38 (57) 113 (53.8)
Open synovectomy (one- or two-staged) 26 (39) 90 (42.9)
Combined arthroscopic/open synovectomy 3 (4) 0 (0.0)
Total joint replacement/(tumour) prosthesis 0 (0) 5 (2.4)
Amputation 0 (0) 2 (1.0)
Adjuvant therapy, n (%) 5 (7) 53 (25.2)
Radiotherapy 4 (6) 18 (8.6)
90-Yttrium 1 (1) 14 (6.7)
Systemic 0 (0) 15 (7.1)
Otherb 0 (0) 6 (2.9)
Recurrent disease, n (%) 24 (36) 146 (69.5)
Additional surgery, n (%) 23 (34) 125 (59.5)
Arthroscopic synovectomy 7 (10) 32 (15.2)
Open synovectomy (one- or two-staged) 10 (15) 74 (35.2)
Combined arthroscopic/open synovectomy 1 (1) 4 (1.9)
Total joint replacement/(tumour) prosthesis 2 (3) 12 (5.7)
Amputation 3 (4) 3 (1.4)
aTGCT: tenosynovial giant cell tumour
bOther adjuvant therapies were cryosurgery, burning tools, steroid injections, 
or combination of multiple adjuvant therapies
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limited range of motion (Table 2). A minority of the patients (<6%) currently experienced additional 
symptoms, including instability, buckling, hyperextension and/or hypermobility, clicking or 
locking or popping of joint, numbness, electric shocks, tingling, dull ache, heat of the affected 
joint, or hematoma.
Treatment(s)
Most performed initial surgery was arthroscopic synovectomy (57% [38/67] localized, 53.8% 
[113/210] diffuse) and open synovectomy, one- or two-staged (39% [26/67] localized, 42.9% [90/210] 
diffuse). In all, 5/67 (7%) localized-type and 53/210 (25.2%) diffuse-type patients had adjuvant 
therapies after initial surgery, mainly radiotherapy and 90-Yttrium. In all, 24/67 (36%) of localized 
type had recurrent disease after 1.5 (range 1-6) years, in contrast to 146/210 (69.5%) of diffuse type 
after 2.2 (range 1-23) years (table 3). Additional surgery was performed in 23/67 (34%) of localized 
type and 125/210 (59.5%) of diffuse type, predominantly open synovectomy (one- or two-staged).
Impact of Tenosynovial Giant Cell Tumour on Daily Life
Due to TGCT, 8/61 (13%) and 21/191 (11.0%) of working population in localized and diffuse TGCT, 
respectively, was currently not able to (fully) perform their employment. Of these patients, 4/8 (50%) 
localized patients and 17/21 (81%) diffuse patients had recurrent disease. Majority of patients, 40/69 
(58%) of localized and 147/230 (63.9%) of diffuse type, were unable to perform sport activities. In 
these patients, recurrent disease presented in 15/40 (38%) of localized type and 94/147 (63.9%) 
of diffuse type. Disease burden was estimated by mean number of visits to general practitioner 
(5.6 [range 1-50] visits for localized type, 7.1 [range 1-60] visits for diffuse type), and orthopaedic 
surgeon (8.3 [range 1-97] visits for localized type, 11.9 [range 1-100] visits for diffuse type). Results 
of validated questionnaires are shown in Table 4 (localized vs diffuse type), Table 5 (localized type), 
and Table 6 (diffuse type). Results with positive association are described in the text.
Worst Pain and Stiffness in Last 24 Hours: Visual Analog Scale Score
For localized type, best VAS pain score was 2.76 and VAS stiffness score was 2.80. In diffuse type, 
best scores for pain and stiffness were 3.04 and 3.08, respectively. Patients with recurrence of TGCT 
had deteriorated VAS score for pain and stiffness (P=.01 localized type and P<.001 diffuse type). In 
localized type, patients with ≥2 surgeries had higher VAS score for pain (P=.02) and stiffness (P=.01).
249
11


























































































































































































































































































































































































































































































































































































































































and 1 full 
health, MID 
.037-.069
score Pi score Pi score Pi score Pi score Pi score Pi
Gender 
Male (n=14) 2.93 .53 3.29 .79 48.5 .04 43.3 .23 49.4 .42 .81 .18
Female (n=55) 3.47 3.51 43.5 39.8 47.0 .75
Age of diagnosis 
<35 years (n=36) 3.36 .997 3.39 .82 44.1 .63 40.1 .74 45.4 .07 .76 .95
≥35 years (n=33) 3.36 3.55 45.0 40.9 49.8 .77
TGCT localization 
Knee (n=53) 3.04 .08 3.13 .07 44.2 .57 41.0 .43 47.2 .63 .77 .41
Hip, ankle, foot, other 
(n=16) 4.44 4.56 45.5 38.8 48.6 .74
Initial surgery 
Arthroscopy (n=38) 3.45 .58 3.26 .63 44.2 .52 40.7 .96 47.2 .73 .76 .92
Open surgeryh 
(n=26) 3.04 3.62 45.6 40.8 48.0 .77
Recurrence 
Yes (n=24) 4.50 .01 4.71 .01 42.8 .20 38.3 .17 45.7 .27 .70 .01
No (n=45) 2.76 2.80 45.4 41.7 48.5 .80
Total no. of surgeries
1 surgery (n=44) 2.77 .02 2.86 .01 45.4 .20 42.2 .03 48.4 .19 .79 .02
≥2 surgeries (n=23) 4.48 4.65 42.6 36.7 45.0 .71
Last treatment for TGCT 
≤1 year ago (n=31) 3.77 .26 3.81 .38 42.4 .06 37.6 .04 46.0 .34 .74 .29
>1 year ago (n=36) 3.00 3.19 46.1 42.6 48.3 .78
aVAS: Visual Analogue Scale. bPROMIS-PF: Patient-Reported Outcomes Measurement Information System-
Physical Functioning. cMID: minimal important difference represents the smallest difference or change beyond 
statistical significance in an outcome measure score that would be considered important by the value patients 
place on change18-20 . dSF: Short-Form. ePCS: physical component summary. fMCS: mental component summary. 
gDS: descriptive system. hOne- or two staged open synovectomy. iP: P value
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Table 6




































and 1 full 
health, MID 
.037-.069
score Pi score Pi score Pi score Pi score Pi score Pi
Gender 
Male (n=51) 3.63 .70 4.13 .71 42.2 .23 39.9 .11 49.0 .04 .75 .17
Female (n=179) 3.84 3.98 41.0 37.5 45.6 .71
Age of diagnosis 
<35 years (n=119) 3.70 .58 3.74 .09 42.1 .07 39.2 .07 46.9 .38 .73 .22
≥35 years (n=109) 3.89 4.32 40.4 36.8 45.6 .71
TGCT localization 
Knee (n=170) 3.78 .93 3.92 .07 41.6 .29 38.1 .99 46.3 .98 .73 .40
Hip, ankle, foot, other
(n=60) 3.82 4.55 40.5 38.1 46.3 .71
Initial surgery 
Arthroscopy (n=113) 3.93 .82 4.19 .64 41.6 .66 38.3 .86 45.6 .64 .73 .25
Open surgeryh 
(n=190) 3.84 4.01 41.2 38.0 46.4 .70
Recurrence 
Yes (n=146) 4.23 <.001 4.55 <.001 40.5 .02 37.7 .49 45.1 .04 .70 .02
No (n=84) 3.04 3.08 42.7 38.7 48.2 .75
Total no. of surgeries
1 surgery (n=86) 3.79 .69 3.74 .09 42.0 .20 38.7 .48 46.1 .89 .73 .44
≥2 surgeries (n=124) 3.94 4.38 40.8 37.7 46.3 .71
Last treatment for TGCT 
≤1 year ago (n=72) 4.10 .37 4.35 .37 40.4 .17 35.4 .01 45.6 .59 .70 .17
>1 year ago (n=138) 3.76 4.00 41.8 39.5 46.5 .73
aVAS: Visual Analogue Scale. bPROMIS-PF: Patient-Reported Outcomes Measurement Information System-
Physical Functioning. cMID: minimal important difference represents the smallest difference or change beyond 
statistical significance in an outcome measure score that would be considered important by the value patients 
place on change18-20. dSF: Short-Form. ePCS: physical component summary. fMCS: mental component summary. 
gDS: descriptive system. hOne- or two staged open synovectomy. iP: P value
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Patient-Reported Outcomes Measurements Information System-Physical Function: T Score
All TGCT patients had clinically relevant impaired T scores (44.5 and 41.3 for localized and diffuse 
type, respectively) compared with the general US population (T score of 50). Corresponding effect 
size was medium for localized type (d=0.55) and large for diffuse type (d=0.87). When comparing 
both types, diffuse-type patients scored lower (P<.001). In localized type, female patients scored 
lower (P=.04). Diffuse-type recurrent patients had decreased scores (P=.02). 
Short Form-12 Health Survey: Physical and Mental Component Summary Score
In comparison with general US population (score of 50), both types had impaired PCS (40.5 localized 
and 38.1 diffuse type) and MSC scores (47.5 localized and 46.3 diffuse type). In all patients in all 
compared groups, PCS score was clinically relevant declined, in contrast to MCS score which did 
not transcend the MID threshold in majority of patient groups. A large effect size was calculated 
for mean PCS scores (0.95 and 1.19 for localized and diffuse type, respectively) and a medium 
effect size (0.25 and 0.38 for localized and diffuse type, respectively) for MCS scores. In localized 
type, higher number of surgeries (≥2) affected PCS score negatively (P=.03). Localized- and diffuse-
type patients who underwent treatment for TGCT ≤1 year ago, showed lower PCS score (P=.04 
localized, P=.01 diffuse). In diffuse type, female patients demonstrated a decreased MCS score 
(P=.04), as well as patients with recurrence of TGCT (P=.04).
EuroQoL 5 Dimensions 5 Levels Health Questionnaire: Index Value
All patients, in all groups (Tables 4-6), presented declined EQ5D-5L utility scores compared with 
full health (1), and all scores transcended MID threshold. Overall, utility score was lower in diffuse 
patients compared with localized patients (P=.03). In localized type, participants with recurrence 
of TGCT and ≥2 surgeries scored lower (P=.01 and P=.02, respectively). Similarly, diffuse patients 
with recurrence had decreased scores (P=.02). Median health question VAS score was 75 (IQR 65-
85) for localized and 75 (IQR 56.5-85) for diffuse type. No differences between scores calculated 
with US and UK valuation sets were detected in sensitivity analysis (Appendix 4).
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discussion
Principal Findings
The name of the largest online community of patients with TGCT, PVNS is pants!!, suggests impact 
on quality of life. One of the community members motivated the name: “Pants is British slang for 
crap or garbage.” To date, it is unknown what the effect of TGCT on daily living is. A questionnaire 
was composed in consultation with TGCT patients to determine functional, socioeconomic, and 
health burden for TGCT patients. We intended to evaluate TGCT in the real world and concluded 
that TGCTs have a large impact on daily living, with declined health-related quality of life and 
limitations in daily activities, sports, work, and hobbies: especially the diffuse type of lower 
extremities and recurrent disease including multiple surgeries. 
Limitations
The most important limitation to this study is selection bias. By using crowdsourcing to gather data, 
it is likely to have a higher number of patients with severe or recurrent diseases21. Consequently, 
when extrapolating these results to generally described populations of TGCT patients in literature, 
care should be taken not to overestimate the decreased physical function and additional 
socioeconomic limitations. TGCT usually affects young adults. Since younger patients are more 
likely to be on the World Wide Web, and our included patient population had a median age of 
33 (25-42) years at time of diagnosis, also in concordance with the WHO classification1, 2 and 
Mastboom et al.3, we considered our participants representative for the heterogeneous disease 
TGCT. Additionally, the CHERRIES was completed. This checklist provides an understanding of the 
sample (self-)selection and its possible differences from a representative sample10 (Appendix 1). 
An additional limitation to this study is that patients in different stages of different treatments 
were included. To assess comparability within study population, we compared patients who had 
treatment less than a year ago with performed treatment over a year ago. No positive associations 
were discovered, except for the SF-12 PCS score in both types. This underlines the postoperative 
limitations during the first year of follow-up after treatment. As we set out to evaluate impact of 
TGCT on daily living in the real world heterogeneous TGCT population, the inclusion of patients 
in different treatment stages matched intention of our study. Furthermore, a known disadvantage 
of quality of life questionnaires (eg, SF-12) is the generalizability of the questions. Impaired 
overall quality of life could be attributed to TGCT but also to additional physical abnormalities or 
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psychological problems. Also questionnaires may be completed by patients that have been ill-
informed on their disease. In all, 28 patients filled out unknown type of TGCT, and 16% of patients 
who confirmed TGCT with medical proof filled out localized TGCT instead of diffuse TGCT or 
vice versa. Undeniably, differentiating in localized and diffuse TGCT is challenging even for (un)
specialized physicians. The relatively high recurrence rate in this study could also be reflected by 
unawareness of disease specifics. Recurrence rates in our study were 36% and 70% for localized 
and diffuse type, compared with on average 4% to 6% (up to a maximum of 50%) and 14% to 40% 
(up to a maximum of 92%) according to van der Heijden et al.6, respectively. It is conceivable that 
residual disease or clinical symptoms were filled out as recurrent disease. 
The use of self-reported questionnaires harbours the risk of incorrectly answered questions. One 
could argue that all patients should have been analysed together, not subdividing into localized 
and diffuse type. However, differences between two types are major, and therefore separate 
analyses were necessary for a realistic view of impact of TGCT on daily living.
Crowdsourcing
The presumed definition of crowdsourcing is the practice of obtaining services, ideas, or content 
by collecting contributions from a comprehensive group from an online community rather 
than from traditional data suppliers9. However, the exact definition for crowdsourcing remains 
controversial, as 40 definitions originating from 32 unique articles, published between 2006 and 
2011, were described by Estellés-Arolas22. It is therefore challenging to well define crowdsourcing 
coherently. After analyses of the 40 (sometimes contrasting) definitions, 8 characteristics common 
to any given crowdsourcing initiative were found: the crowd, the task at hand, the recompense 
obtained, the crowdsourcer or initiator of the crowdsourcing activity, what is obtained by them 
following the crowdsourcing process, the type of process, the call to participate, and the medium. 
First, in our study, the crowd is presented by patients with TGCT (preferably confirmed by medical 
reports). Second, the task at hand is completing a questionnaire about the effect of TGCT on 
daily living. Third, participating in this study was voluntary, therefore no recompenses were 
offered. Fourth, the initiators of this study are members of the Facebook group PVNS is Pants!! 
accompanied with the executors, known as the authors of this paper. Fifth, the researchers and 
subsequently the participants and TGCT patients gain more knowledge on the impact of TGCT on 
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daily living. Sixth, the type of process is an evaluation process, aiming to evaluate effect of TGCT on 
daily living. Seventh, all patients with TGCT, fluent in English language, were invited to complete 
the questionnaire. Lastly, the medium Facebook was used to broadcast the questionnaire.
Facebook is the best applicable social network site for survey research, because it is continuously 
growing, internationally known and exceeds 2 billion users globally (June 2017). The Facebook 
community PVNS is Pants!!, created in 2009, is the largest TGCT online support group and mainly 
consists citizens of the United States. On this very active, closed Facebook community, patients are 
daily updating experiences on their disease, ask for advice from fellow TGCT patients, and comment 
on other posts to provide their knowledge or sympathy. By actively posting and commenting on 
research proposals, patients expressed their willingness to participate in research on TGCT. From 
these posts, we learned that adequate patient information on TGCT is lacking. Our crowdsourcing 
study stimulated patients’ involvement in research and was an opportunity to align research 
questions with the public’s interest23, 24. TGCT is a rare disease and time to definitive diagnosis is 
prolonged due to unspecific symptoms and unfamiliarity of the disease5. A challenge in studying 
a rare disease is the lack of big data. Crowdsourcing is an effective and low-cost alternative to 
traditional methods of participant recruitment due to the possibility to reach large groups of 
individuals in a relatively short time frame25. Van der Heijden et al.9 concluded that crowdsourcing 
is a promising way for evaluation of rare diseases. Czajka et al.21 used crowdsourcing to efficiently 
recruit a global cohort and is the largest study on patients with multiple hereditary exostoses. 
Crosier et al.26 used Facebook to recruit patients with auditory hallucinations; within 6 weeks, over 
250 patients had completed this survey. Pohlig et al.27 concluded that enrollment of patients in 
prospective studies is time-consuming and could be facilitated by use of crowdsourcing.
To obtain a higher level of scientific value, patients were requested for medical proof to 
ascertain TGCT diagnosis. To our knowledge, no other crowdsourcing studies considered disease 
confirmation. Patient data and outcome for validated questionnaires were comparable for 
patients with and without medical proof. Patients were not uniformly diagnosed and treated as 
they originated from 30 different countries globally. Neither was distinguished between treatment 
in peripheral or tertiary referral centres.  Nevertheless, we consider our study group a reflection 
of the current worldwide situation and believe that declined impact on daily living is clinically 
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relevant for all patients. In contrast to malignant diseases, survival rates are not of interest for 
TGCT with its benign character. According to high recurrence rates, quality of life (prior and after 
treatment) is essential to evaluate.
Patient-Reported Outcome Measures
Patient reported outcome measures (PROMs) are increasingly used in health policy, patient-
centred care, and shared clinical decision making28. In the era of personalized medicine, patient 
involvement is increasing in shared decision making for different treatment strategies with 
functional outcome and quality of life. In our study, members of the largest online TGCT community 
were involved in establishing the questionnaire Evaluation of TGCT on daily living.
Functional outcome and health-related quality of life are only spars reported for TGCT. Four studies 
have reported on standardized PROMS4, 9, 29, 30. Currently, validated PROMS for TGCT patients do 
not exist. In accordance with Gelhorn et al.4, VAS for worst pain and stiffness and PROMIS-PF 
questionnaires were used. Conform van der Heijden et al.9, 29 and Verspoor et al.30, the SF-12, a 
quality of life questionnaire, was included, known as the shorter version of the SF-36. One study 
identified a high health care burden with a significant increase in health care costs, ambulatory 
costs, and physical therapy in 9328 TGCT patients8.
In benign diseases, including TGCT, death is not an outcome variable. Besides tumour reduction, 
critical endpoint measures are clinical relevance and impact of treatment. Currently, clinical 
TGCT studies lack specific and validated PROMs to document treatment-induced symptomatic, 
functional, and economic (back to work) improvement31. To obtain an impression of physical 
function and quality of life in TGCT patients, participants in our study were requested to complete 
different validated questionnaires. In our experience, PROMIS-PF was most useful in determining 
these functional factors. To minimize the multitude of questions and include the most important 
components for clinical TGCT studies, we would propose a combination of PROMIS-PF and a short 
quality of life questionnaire, for instance EQ5D5L, in clinical practice.
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Risk Factors for Deteriorated Outcome
Risk factors for deteriorated outcome in our study were diffuse-type TGCT, recurrent disease, 
and ≥2 surgeries performed. This is in concordance with current literature on risk factors for a 
high recurrence rate. According to the necessity of mutilating surgeries to treat recurrences, we 
considered risk factors for recurrent disease comparable to risk factors for deteriorated outcome.
Higher recurrence rate in diffuse TGCT compared with localized TGCT is exuberant described1, 5-7, 30, 
32-34. Bruns et al.34 described 173 patients treated in 10 orthopaedic departments in Germany and 
Austria and reported higher recurrence rates in institutions treating less than 20 cases for TGCT, in 
diffuse disease, in the hip joint and after arthroscopy. Schwartz et al.35 described 99 patients with TGCT 
in the knee, hip, elbow, or shoulder. They concluded that localization in the knee, previous surgical 
procedures, and incomplete synovectomy were related significantly to higher number of subsequent 
recurrences. On the basis of current literature and to investigate possible risk factors for recurrent 
disease thoroughly, gender, age at time of diagnosis, TGCT localization, initial surgery, presence of 
recurrence, total number of surgeries, and time since last treatment for TGCT, were compared.
conclusions
TGCTs have major impact on daily living in a relatively young, working population (median age at 
diagnosis, 33 years). Majority of symptoms improve after treatment, however, symptoms remain 
in about half of the TGCT patients; especially in patients with diffuse type, recurrent disease, and 
≥2 surgeries. The high recurrence rate in diffuse TGCT results in clinically important deteriorated 
outcome in physical function and health-related quality of life. In preventing recurrent disease, and 
its deteriorated outcome, an extensive mutilating surgery might be necessary. Physicians should 
be aware that TGCT patients frequently experience symptoms and limitations in daily life and 
societal participation (work, sports, and hobbies), even after treatment(s). We deem it important 
for future research to evaluate treatment, including its effectiveness on improving quality of 
daily living. With this study, we hope to increase knowledge on TGCT among treating physicians, 
highlight the importance of quality of life, and to offer research-based information to patients.
Supplementary data
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In Tenosynovial Giant Cell Tumours (TGCT), previously named Pigmented Villonodular Synovitis 
(PVNS), a distinction is made between a single nodule (localized-type) and multiple nodules 
(diffuse-type). Diffuse-type is considered locally aggressive. Onset and extermination of this 
orphan disease remain unclear. Surgical resection is the most commonly performed treatment. 
Unfortunately, recurrences often occur (up to 92%), necessitating reoperations and adjuvant 
treatments. Once all treatments fail or if severe complications occur; limb-amputation may become 
unavoidable. We describe four cases of above knee amputation after TGCT diagnosis. 
Background
Tenosynovial Giant Cell Tumour (TGCT) is considered an orphan, mono-articular, locally aggressive 
neoplasm1. TGCT patients complain of continued pain, swelling and a decreased range of motion 
of the affected joint2. Typically, younger patients (below the age of 40 years) are affected. Time 
to definitive diagnosis usually takes several years1. TGCT develops along the synovial lining of 
joints, tendon sheaths and bursae1, 3. Two extremes along a continuum of one disease process 
are described: a single nodule (localized-type) and multiple nodules (diffuse-type)1, 2, 4. These two 
subtypes differ in their clinical and radiological presentation, response to treatment and prognosis. 
Histologically, no differences are detected1, 5. Exact onset remains unclear. Current findings are 
pleading for both a reactive inflammatory disorder and a clonal neoplastic proliferation, provoking 
a CSF1 overexpression; suggesting the tumour-landscaping effect6. The localized-type (Giant Cell 
Tumour of Tendon Sheath) is defined as a demarcated benign mass, most commonly occurring 
in fingers (85%). Lesions are small (between 0.5 and 4 cm), typically lobulated and white to grey 
along with yellow and brown areas1, 2, 4. Reported recurrences ensuing surgical treatment are 
relatively low: 0-6%4. On the contrary, the diffuse-type (Diffuse-type Giant Cell Tumour (Dt-GCT), 
previously named Pigmented VilloNodular Synovitis (PVNS)), shows extensive involvement of the 
entire synovial membrane and tends to have the capability to grow infiltrative through adjacent 
structures2, 4. Dt-GCT affects mostly weight-bearing joints: predominantly the knee-joint (75%), 
followed by the hip-joint (15%). At present, surgery remains the gold standard, while systemic 
targeted treatments are only available in trial-settings7. Recurrence rates for Dt-GCT is 14% (up-to 
67) after open synovectomy and 40% (up-to 92) after arthroscopic synovectomy4. Recurrent or 
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resistant disease, frequently necessitate multiple mutilating surgeries, end occasionally inevitably 
in total joint arthroplasties8. Once all treatments fail or severe complications occur: limb-amputation 
may become unavoidable. To our knowledge, current literature lacks reports of limb-amputation 
in TGCT patients, but patient groups often discuss the possibility on online fora (“PVNS is pants” 
closed Facebook community; https://www.facebook.com/groups/91851410592/?ref=ts&fref=ts)9. 
To underline potentially aggressiveness of TGCT, four patient history scenarios are described.
Case presentation
Case 1
A female, aged 46, was diagnosed with TGCT. Initial TGCT treatment consisted of three arthroscopic 
synovectomies. First synovectomy was supplemented with low-dose radiation, consecutive two 
synovectomies with intra-articular 90Yttrium. Fourteen years later, an Magnetic Resonance Imaging 
(MRI) scan revealed recurrent TGCT, including bone-involvement. A total knee replacement (TKR) 
was performed. Four years later, her knee started to hurt and swell again. Infection parameters were 
elevated, MRI showed extensive synovitis and a PET-CT showed enhancement around her TKR, suspect 
for recurrent TGCT. Her range of motion was impaired, with a flexion-extension of 50-20-0. Twenty-
three years after initial diagnosis, she was referred to our tertiary orthopaedic oncologic centre. TGCT 
re-excision was not an option, as a result of extensive tumour growth (Figure 1a, Figure 1b). Imatinib (a 
tyrosine kinase inhibitor with activity against CSF1R) was started for four months. Besides the tumour 
growing outwards from her operation-scar, a nearby fistula revealed and started leaking. She was 
admitted with malaise, fever, elevated infection parameters, a red swollen right leg and not able to 
mobilize. During four weeks of admission she was treated with several blood transfusions attributed 
to persistent anaemia, intravenous antibiotics and analgesics. After an investigational tyrosine-
kinase-inhibitor (TKI) in compassionate use was started, she was discharged. After a fall, a few days 
after she was discharged, her condition worsened. She was readmitted and treated with intravenous 
antibiotics for an acute Staphylococcus aureus infection, provoked by TGCT growing outside the 
operation scar composing a direct connection to the TKR. To avoid septic shock: an urgent above 
knee amputation seemed a live-saving procedure. Within one month, signs of osteomyelitis revealed. 
Treatment with debridement, antibiotics and irrigation stabilized the patient. At one year follow-up, 
there were no signs of local recurrence or infection and her phantom pain was decreasing.
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Figure 1a  Sagittal T1-weighted 
MR image, turbo spin echo, after 
intravenous contrast injection in 
a 69 year old female patient with 
recurrent, end stage TGCT on the 
right side. Extensive tumour growth 
around her total knee replacement 
(TKR), involving the entire knee-
joint: anterior and posterior, ranging 
from high up supra-patellar pouch 
to below tibia-fibular joint, including 
bone-involvement.
Figure 1b  Sagittal Short-TI Inversion 
Recovery metal clear MR image of 
the posterior part of the right knee, 
revealing extensive tumour growth, 
also growing outside the body. 
Characteristic TGCT blooming effect 
is seen attributed to scattered areas 






Figure 2a Left knee sagittal 
T1-weighted MR image after 
intravenous contrast injection with 
fat suppression in a 61-year old male 
patient with extensive recurrent 




Figure 2b Sagittal turbo-spin echo 
proton density-weighted MR image 
presents Dt-GCT located intra- and 
extra-articular, posterior a large 
Baker’s cyst including tumour 
involvement.




A 63-year old male was referred to our tertiary hospital with recurrent Dt-GCT of his left knee. 
Two years prior to referral, Dt-GCT was diagnosed and (partial) arthroscopically removed 
elsewhere. MRI showed a diffuse TGCT growth-pattern involving all compartments of the entire 
knee-joint, including a Bakers cyst (Figure 2a, Figure 2b). Consequently, a two-staged anterior 
and posterior synovectomy in two tempi was performed; macroscopically all pathological tissue 
was removed. There was chondromalacia grade 3-4. A few months later, the patient suffered 
progressive knee pain again. Recurrent Dt-GCT lesions, including bone-involvement and 
progressive osteoarthritis were seen on X-ray and MRI. A transarticular distal femoral resection 
and resection of all Dt-GCT tissue was performed. The knee joint was reconstructed using an 
EndoProsthetic-Reconstruction (EPR). Thereafter patient’s knee function seemed to improve. 
However, several months later, swelling and increasing knee pain developed. C-reactive protein 
(CRP) and erythrocyte sedimentation rate were elevated, nevertheless cultures of aspirated 
knee fluid were negative. Along with general deterioration of the patient, wound debridement, 
antibiotics, irrigation, and retention (DAIR) was performed. Two out of six cultures, showed 
coagulase negative staphylococci without a sign of recurrent TGCT. Despite the DAIR procedure, 
his EPR had to be replaced with a gentamicin loaded spacer. Because of the difficulty to treat the 
low-grade infection, his spacer was replaced with a gentamicin and vancomycin loaded spacer. 
Thereafter, patient’s condition improved, his infection parameters declined and cultures of an 
open biopsy were negative. The EPR was re-implanted. Unfortunately the low grade infection 
recurred again. After two additional DAIR procedures the patient preferred an above-knee 
amputation over another DAIR procedure, life-long antibiotics or a third 2-stage revision. At 





A 67 year old male had a TKR after years of indistinct progressive knee-pain. Peroperatively a 
benign tumour with few giant cells was diagnosed as a coincidental finding. A few months later 
a supra-patellar biopsy showed a mixed malignant appearance, including TGCT components. 
Unexpectedly, lymphadenopathy on his groin, did not show malignant cells, but reactive 
cells. The patient suffered of systemic symptoms: night sweats, weight loss and infection like 
symptoms (not specified). Both for the lymphadenopathy and his painful right knee he received 
radiotherapy (70 Gy on both locations, treatment for uncontrollable pain). Histopathologic 
revision, by a tertiary specialized pathologist in a reference centre, showed a Dt-GCT. Aggressive 
tumour progression, including bone-involvement provoked TKR failure (Figure 3, Figure 4a, Figure 
4b). Within one year, several histologically proven Dt-GCT lung metastases were discovered. 
Molecular research revealed a t(1;6)(p13;q27) translocation (Supplementary materials), this is 
not the typical t(1;2)(p13,q33) translocation, however literature shows different variants on this 
translocation. Final diagnosis through FISH technique confirmed Dt-GCT. Discomforting pulmonal 
symptoms expressed multiple lung, pleural and costal metastases. Inside the thorax, numerous 
suspected lymph nodes were seen. When he developed pulmonary symptoms; an investigational 
TKI was started, which had an effect on his lung-metastases, but not on his irradiated painful 
lymphademic leg (Figure 5a, Figure 5b). Complaints of tiredness, disguise, a very oedematous right 
leg with a leaking protuberance and persisting anaemia provided discomfort. Attributed to the 
TKI, pulmonary symptoms disappeared and his lung metastases stabilized. However, a hospital 
admission due to pneumonia on both sides and pulmonary embolisms caused a repercussion. As 
a last resort, the primary-tumour was resected by amputation, complicated with 4 Litres blood loss 
and desaturation (until 90%), necessitating admission to the intensive care unit. Histopathology 
confirmed Dt-GCT without malignant cells, however margins were not disease free. Residual and 
recurrent disease was seen on MRI three months post-operatively and clinically observed. After 
six months, a debulking procedure was performed on his amputated stump. The TKI did not show 
effect on the metastases anymore and was discontinued after one year of compassionate use. 
Currently, his phantom pain is acceptable.
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Figure 3  Metal artefact reducing 
sequelae sagittal T2 weighted turbo 
inversion recovery MR image of the right 
knee of a 67 year old male patient, with a 
TKR in situ. Extensive tumour progression 
around TKR and bone invasion is shown. 
Figure 4 a & b  X-rays (anterior-posterior and sagittal) of failing total knee replacement, attributed to aggressive 




Figure 5 a&b  PET CT-scan showing extensive TGCT around the right knee-joint and multiple lung, pleural and 
costal metastases. When pulmonary symptoms developed; an investigational tyrosine-kinase-inhibitor (TKI) 
was started (a. prior to treatment, b. after treatment), which had an effect on his pulmonary-metastases, but 
not on his irradiated painful lymphademic leg.  




After years of indistinct knee-complaints, a biopsy proved Dt-GCT in a 17 year old male. Intra-
articular 90Yttrium was not effective. After a partial open synovectomy, Dt-GCT recurred. A two-
staged anterior and posterior synovectomy in two tempi (complicated by haemorrhage) was 
performed at a tertiary oncology centre. During the following 13 years, the patient underwent a total 
of seven surgeries in an effort to treat Dt-GCT, including a knee-arthrodesis using a compression 
plate and screws (Figure 6). Osteosynthesis was removed several years later because of a low 
grade osteomyelitis and persisting anaemia. Subsequently, a two-staged anterior and posterior 
debulking synovectomy was performed (Figure 7 shows MRI prior to debulking). After another 
debulking procedure, local tumour control did not seem feasible. An above knee amputation was 
performed at the age of 30. Histopathological revision proved Dt-GCT, without malignant cells. 
After several years of painless walking with an external prosthesis, pulmonary symptoms occurred. 
Imatinib, an investigational TKI, chemotherapy and radiotherapy had no effect on pulmonary and 
lymph node metastases. Despite all efforts, deterioration of the patient seemed  irreversible. The 
patient deceased at the age of 35 years.
Figure 6 Knee-arthrodesis after multiple 
Dt-GCT surgeries in a 26 year old man, 
using a compression plate and screws.
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Figure 7  Sagittal T1 weighted Spectral Presaturation with Inversion Recovery MR 
image after intravenious contrast, of a 28 year old male patient revealing a large, 
extra-articular TGCT tumour mass.  Patients history describes multiple surgical 
treatments, including removal of osteosynthesis material for a knee arthrodsesis. 




TGCT onset is typically slow and patients present with unspecified complaints1. Pain, swelling and 
stiffness in the involved joint might be misinterpreted as osteoarthritis, rheumatoid arthritis, a 
meniscal tear or other ligamentous injury2. Because of the rarity of the disease, definitive diagnosis 
may take several years and patients present with extensive disease. Frequently, patients are referred 
to a tertiary hospital, after several arthroscopic or open synovectomies and even radiotherapy 
(case number 1)10, 11. Besides declined functional outcome and quality of life10, these patients are 
at risk of repeated recurrences and extensive resistant disease7. Multiple surgeries increase the risk 
of infection. Continued inflammation, joint usuration and bone involvement may lead to articular 
destruction that might worsen (pre-existing) osteoarthritis2. A total joint replacement or even an 
endoprosthetic-reconstruction may become inevitable8, 12. Occasionally, total joint arthroplasty 
is the primary procedure performed in TGCT8. Only seldom, an above-knee amputation as a last 
resort in treatment of TGCT is mentioned13-16.
Is an above knee amputation justified in an essentially benign, but locally aggressive disease? After 
(major) complications, for example periprosthetic infections, in primary total knee arthroplasties, 
above knee amputations are performed17, 18. Our amputation cases also attributed to severe 
prosthetic infections (case 1 and 2). Radiotherapy, applied in case 1 (in a non-specialized hospital) 
and 3 (in order to decrease severe pain-complaints), increases risk of prosthetic failure, infection 
and wound healing. The overall prevalence of above-the-knee amputation after TKA is estimated 
at 0.36%17. When severe pain, a swollen joint, limited range of motion and stiffness impair range 
of motion: an above-knee amputation might increase patients mobility17, 19. Therefore, we feel 
amputation is justified in extreme TGCT cases.
TGCT is a heterogeneous disease. Some cases are instantly diffusely spread intra- and extra-
articular or even show malignant characteristics. Metastases in histologically benign TGCT are 
extremely rare, called an implantation phenomenon and conservatively treatment is suggested14. 
Symptomatic free metastases in case 3 were conservatively treated. Physicians should be aware 
of the potentially aggressive course of TGCT. Multiple mutilating surgeries decline functional 
outcome and quality of life10. Expert centres need to cooperate on these rare cases to understand 
the biology underlying these different clinical behaviours. 
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West et al. discovered a central role for CSF1 in the pathogenesis of TGCT6. Multiple trials with 
systemic therapies targeting CSF-1 receptor, show promising results as novel treatment method 
for diffuse-TGCT7. Emactuzumab (RG7155) (a monoclonal antibody against CSF1R) showed an 
objective response in 26 of 28 (86 %) TGCT patients20. Prolonged tumour regression is described 
in patients, treated with tyrosine kinase inhibitor PLX339721. (Serious) adverse events in 
emactuzumab and PLX3397 are investigated. Currently, two studies are recruiting patients with 
recurrent or unresectable TGCT diffuse-type: MCS110 (a CSF1-directed monoclonal antibody, 
NCT01643850) and FPA008 (an anti-CSF1R monoclonal antibody, NCT02471716). In the near 
future, if these systemic treatments are approved, multiple surgeries and final limb amputation, 
hopefully, will become obsolete.
To our knowledge, this is the first case-series focussing on limb-amputation after multiple 
treatments of TGCT. In order to prevent extensive final treatments, like amputations, further 
investigation of TGCT risk factors for recurrences is essential in proper primary-treatment planning. 
In the orphan TGCT, knowledge of disease impact can be improved. Patients suffering extensive 
disease including patients after multiple mutilating surgeries, might experience higher quality of 
life once they feel in control of their own life again. Performing an above-knee amputation may 
therefore be considered in extreme and extensive TGCT cases.
conclusion
Frequently, TGCT is successfully treated with radical surgical excision. In a substantial percentage 
of cases, it presents as an aggressive and extensive disease that requires complex treatments, 
and, in extreme cases, can even lead to limb-sacrificing surgery. Quick diagnosis and adequate 
treatment of this rare condition are important factors for outcome. Therefore, it is essential that 
these patients get referred to specialized centres at an early stage. We described four extensive 
Dt-GCT cases, treated with an above-knee amputation as final treatment.  
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Both localized- and diffuse-type tenosynovial giant cell tumours (TGCT) are defined a benign 
disease as metastases or lethal outcome very rarely occur. Diffuse-type TGCTs are regarded 
more challenging to treat because they have an infiltrating growth pattern and lack anatomical 
boundaries which make complete resection difficult and at times technically impossible or 
undesirable with joint function preservation and health-related quality of life in mind. Within 
this present era of systemic targeted and multimodality therapies (available in trial settings), 
standalone surgical resection cannot be regarded as the gold standard anymore for all cases. 
This thesis aims to unravel the heterogeneity of TGCT, to improve oncologic results and maintain 
joint functionality and health-related quality of life, by addressing several disease aspects. 
Patient selection for different treatment options is improved by translational research, risk factor 
identification, treatment outcome evaluation and disease severity stratification.
Up to date incidence calculations are necessary for diagnostic purposes. Therefore, chapter 2 
determined worldwide incidence rates in TGCT affecting digits, TGCT localized-extremity and 
TGCT diffuse-type. Previous incidence rate calculations originated from 1980, in which a US county 
study calculated an incidence rate of 9 and 2 per million person-year in localized- (including digits) 
and diffuse-TGCT, respectively (Myers 1980). By use of PALGA, the non-profit nationwide network 
and registry of histo- and cytopathology in The Netherlands, a search was performed for TGCT in 
a 5-year time frame. Subsequently these data were clinically verified in the corresponding Dutch 
hospitals. Dutch TGCT incidence calculations were converted to world population incidence rates. 
Finally, incidence rates of TGCT affecting digits was 29, localized-type extremity TGCT 10 and 
diffuse-type TGCT 4 per million person-years. All three groups showed a female predilection and 
highest number of new cases in age-category 40 to 59 years. The knee was most often affected: 
localized-extremity (46%) and diffuse-type (64%), mostly treated with open-resection: localized 
(65%) and diffuse (49%). Reoperation rate due to local recurrence for localized-extremity was 9%, 
diffuse-TGCT 23%. Compared to the initial US-county study, our study showed a 5-fold higher 
incidence rate in localized-type (combining localized-digits and localized-extremity), and a more 
than 2.6 fold higher incidence rate in diffuse-type. This difference could be attributed to our 
nationwide coverage and because of increased awareness about the disease.
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The controversy that localized- and diffuse-type TGCT are clinically and radiologically two different 
types, while histopathologically they seem indistinguishable is evaluated in chapter 3. Abundant 
expression of Colony Stimulating Factor1 (CSF1), due to genomic rearrangements, is believed to 
be the driver mechanism in tumour formation. This study aimed to correlate CSF1-expression 
and CSF1-rearrangement with the biological behaviour of different TGCT-types and with clinical 
outcome (recurrence). Along a continuum of extremes, therapy naïve knee TGCT patients with 
>3-year follow-up, mean age 43 (range 6-71) years, 56% female were selected. Nine localized- (two 
recurrences), 16 diffuse-type (nine recurrences) and four synovitis as control were included. The 
use of CSF1 split-apart FISH, consecutive to mRNA ISH, showed to be an auxiliary diagnostic tool, 
with 76% of TGCT harbouring CSF1-gene rearrangement. A clear association was not revealed 
between CSF1 over-expression or CSF1 rearrangement and the biological behaviour of different 
TGCT-characteristics (e.g. localized-/diffuse-type and clinical outcome (recurrence)) of the knee. 
Since localized- and diffuse-TGCT differ clinically, chapter 4 established a severity classification 
to stratify different disease severity stages. This classification may aid to identify eligible patients 
for systemic targeted therapy or trials for novel agents. Parameters were defined by field-experts 
to assess disease extension on MR images. Type of TGCT, articular involvement, involvement of 
muscular/tendinous tissue and ligaments showed good inter- and intra-rater agreement (Kappa 
≥0.66), had adequate number of presence (minimum of 20%) and yielded positive association 
on first recurrence. Ranging from highest to lowest hazard ratios these four MR parameters 
constructed the TGCT severity classification for all large joints, including four distinct severity-
stages. Recurrence free survival at 4 years (log rank p<0.0001) was 94% in mild localized, 88% in 
severe localized, 59% in moderate diffuse and 36% in severe diffuse. The TGCT severity classification 
informs physicians and patients on disease extent and risk for first local recurrence after surgical 
treatment.
As the clinical behaviour of TGCT is very heterogeneous and probably multifactorial, chapter 5 
evaluated the unexplored influence of female sex hormones on symptoms in TGCT. Female sex 
hormones (oestrogen and progesterone) elevate during pregnancy. Since an increase in TGCT-
related symptoms during pregnancy is observed in the outpatient clinic and on online TGCT 
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patient fora, we hypothesized that these increased symptoms were influenced by female sex 
hormones. Fifty-six percent of pregnant patients reported an increase in TGCT-related symptoms, 
predominantly swelling of the affected joint. Influences of sex specific hormones and female 
fertile life phase specific hormones were determined by comparing recurrence free survival 
rates between the sexes and pre- versus post-menopausal women. No differences were found 
in recurrence free survival rates, between both sexes, (localized- (p=0.206 ≤50 years, p=0.935 
>50 years); diffuse-type (p=0.664 ≤50 years, p=0.140 >50 years)), neither in pre- versus post-
menopausal women (localized- (p=0.106); diffuse-type (p=0.666)). This makes a causal relation 
with female sex hormones unlikely. Finally, presence of female sex hormonal receptor-status in 
available tumour tissue was assessed. In all examined localized- and diffuse-TGCT tissue-samples, 
oestrogen or progesterone hormone-receptor staining was negative and could therewith not be 
linked to the increased TGCT-related symptoms. 
Many case-series in adults are described, whereas only 76 pediatric patients with TGCT were 
reported, according to our systematic review, presented in chapter 6. This study compared TGCT 
in children with TGCT in adults, calculated incidence rate and evaluated clinical behavior of TGCT 
in children. The standardized pediatric TGCT incidence rate of large joints was 2.42 and 1.09 per 
million person-years in localized and diffuse types, respectively. In 57 children diagnosed and 
treated between 1995 and 2015, in one of the four tertiary sarcoma centers in The Netherlands, 
symptoms were swelling, pain, and limited range of motion with a median time before diagnosis 
of 12 (range 1-72) months. With the numbers available, differences in presentation between 
children and adults were not observed in terms of sex, symptoms before diagnosis, first treatment, 
recurrent disease, follow-up status, or median time to follow-up. The 2.5-year recurrence-free TGCT 
survival rate after open resection was similar between children and adults: 85% (95%CI 67%-100%) 
versus 89% (95%CI 83%-96%) in localized, respectively (p=0.527) and 53% (95%CI 35%-79%) 
versus 56% (95%CI 49%-64%) in diffuse type, respectively (p=0.691). Although the incidence of 
pediatric TGCT is low, it should be considered in the differential diagnosis in children with chronic 
mono-articular joint effusions. Recurrent disease after surgical treatment of this orphan disease 
was comparable between children and adults. 
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In the literature, chapter 7 and chapter 8 presented the largest series of both localized- and 
diffuse-type TGCT. Two-thousand one-hundred and sixty-nine (941 localized-, 1192 diffuse-, 36 
unknown-type) histologically proven TGCT cases of large joints were included, treated between 
1990-2017 in one of 31 collaborating sarcoma centers globally. 
In localized-TGCT (chapter 7), 62% was female with median age at first treatment of 39 years and 
median follow-up of 37 months. 67% affected the knee and primary treatment at tertiary center 
was one-staged open resection in 71%. Total number of recurrent disease was 13% with local 
recurrence free survival at 3, 5 and 10 years of 88%, 83% and 79% respectively. The largest risk 
factor for recurrent disease was prior recurrence (p<0.001). Complications were noted in 4% after 
surgical treatment of localized-TGCT. Initial symptoms of pain and swelling improved after surgical 
treatment(s) in 71% and 85%. Only including therapy naïve cases, tumour size ≥5 cm versus 
<5cm HR 2.50(95%CI 1.32-4.74;p=0.005) and initial treatment with arthroscopy versus open HR 
2.18(95%CI0.98-4.84;p=0.056) yielded positive association with local recurrence in both univariate 
and multivariate analyses. Relatively low complication rates and good functional outcome warrant 
an open approach with complete resection in localized-TGCT, to reduce recurrence rates in high 
risk patients.
In diffuse-TGCT (chapter 8), 58% was female, median age 35 years and median follow-up 54 
months. 64% affected the knee and in 53% primary treatment was one-staged open synovectomy. 
45% had first local recurrence, accompanied with local recurrence free survival at 3, 5 and 10 years 
of 62%, 55% and 40%, respectively. Largest risk factor for recurrent disease was prior recurrence 
(HR 3.5 95%CI 2.8-4.4, p<0.001) with a 5 years RFS in therapy naïve patients compared with 
patients treated elsewhere of 64% and 25%, respectively. Complications were noted in 12%. 
Initial symptoms of pain and swelling improved after surgical treatment(s) in 59% and 72% of 
patients respectively. In a subgroup analyses including therapy naïve cases affecting the knee, 
neither sex (male;female), age (≤35years;>35years), bone-involvement (present;absent), surgical 
technique (open;arthroscopic) nor tumour size (<5cm;≥5cm) yielded an association with first local 
recurrence. Since complete resection of diffuse-TGCT could be regarded as nearly impossible and 
recurrence rates are unacceptably high after both arthroscopy and open synovectomy in the knee, 
even in specialized centres, standalone surgical resection cannot be regarded the gold standard 
anymore in the era of multimodality therapies.
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Chapter 9 described long term effects of imatinib mesylate, a non-selective CSF1 inhibitor, in 
TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States used 
imatinib as treatment. Thirty-nine patients were female (63%), median age at treatment start was 
45 years, with a median time from diagnose to treatment of 3.5 years. Median follow-up after 
treatment start was 52 months. Four patients with metastatic TGCT progressed rapidly on imatinib 
mesylate and were excluded for further analyses. Seventeen (29%) of 58 evaluable patients 
achieved complete or partial response. One- and five-year progression-free survival rates were 
71% and 48%, respectively. Thirty-eight (66%) patients discontinued imatinib after a median of 7 
months. Reported adverse events in 45 (78%) patients were mostly grade 1-2 (89%) (e.g. edema 
(48%) and fatigue (50%)). Five patients experienced grade 3-4 toxicities, including neutropenia, 
acute hepatitis, facial edema, skin toxicity and fatigue. This study confirmed the known efficacy 
of imatinib in TGCT. In responding cases, prolonged activity of imatinib on TGCT symptoms 
was confirmed, even after discontinuation, but with high rates of treatment interruption and 
additional treatments. Limitations of this study are related to the retrospective study design, 
the lack of a control group and the absence of patient reported outcome measures. To evaluate 
patients reported outcome measures, chapter 10 focused on joint function and health-related 
quality of life outcome after surgical treatment in a prospective cohort study. Patient-reported 
outcome measures (Short Form (SF)-36, Visual Analogue Scale (VAS) and Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC)) were assessed in a homogeneous group 
of 206 consecutive patients with localized- (N=108) and diffuse-type (N=98) TGCT of large joints, 
initially treated with (arthroscopic/open) synovectomy at either Leiden University Medical 
Center or Radboud University Medical Center. In particular, the physical component of SF-36 
subscales showed significant and clinically relevant deteriorated scores preoperative- and direct 
postoperative compared with general population means, in both localized- and diffuse-TGCT. Six 
months after surgery, SF-36 scores improved to general population means and continued fairly 
stable the following years. Median pain (VAS) scores, for both-subtypes, showed no clinically relevant 
difference pre- or postoperatively. Pain experience differed tremendously between patients and 
over time. Mean function (WOMAC) scores, for both TGCT subtypes, showed no clinically relevant 
differences (effect size < MCID 20) pre- versus postoperatively. However, in diffuse-type patients 
WOMAC pain and physical function scores showed a trend toward improved preoperative versus 
postoperative scores. To conclude, patients report a significant better health-related quality 
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of life after surgery in TGCT whereas joint function showed a trend towards improvement. To 
evaluate patient reported outcomes in an even larger group of patients, chapter 11 conducted a 
crowdsourcing study in the largest TGCT patient support group. To evaluate the impact of TGCT 
on daily living; physical function, daily activities, societal participation (work, sports and hobbies) 
and overall health-related quality of life was assessed. Secondary aim was to define risk factors 
for deteriorated outcome in TGCT with the use of validated questionnaires (VAS for worst pain 
and stiffness, Patient Reported Outcomes Measurement Information System-physical functioning 
(PROMIS-PF), SF-12 and EuroQoL (EQ-5D-5L)). In a timeframe of six months, TGCT patients were 
invited to complete the online questionnaire. To confirm disease presence and TGCT-type, patients 
were requested to share histological- or radiological-proof of TGCT. Three-hundred thirty-seven 
questionnaires (32% with disease confirmation), originating from 30 countries, were completed. 
Median age at diagnosis was 33 (IQR 25-42) years, majority was female (80%), diffuse-TGCT (70%) 
and affected lower extremities: knee (71%) and hip (10%). In 299 lower extremity TGCT-patients, 
recurrence-rate was 36% and 70% in localized- and diffuse-type, respectively. Due to TGCT, 13% 
of localized- and 11% of diffuse-type was unable to (fully) perform their employment and 58% 
of localized- and 64% of diffuse-type was unable to practice sport-activities. For both types, pain 
and swelling decreased after treatment, but stiffness worsened and range of motion decreased. 
This could be attributed to (multiple) surgical treatments, inducing scar tissue, cartilage wear 
and adhesions. Compared with general United States population, all patients showed declined, 
clinically relevant, PROMIS-PF scores, SF-12 physical and mental scores and EQ-5D-5L utility-score. 
When comparing localized- and diffuse-TGCT, diffuse-type scored almost 0.5 standard-deviation 
lower for PROMIS-PF (p<0.001) and 5% lower for EQ-5D-5L (p=0.03). In localized-TGCT, recurrent 
disease and ≥2 surgeries negatively influenced scores of VAS-pain/stiffness, SF-12 physical and EQ-
5D-5L (p<0.05). In diffuse-type, recurrence resulted in lower score for VAS-pain/stiffness, PROMIS-
PF, SF-12 mental and EQ-5D-5L (p<0.05). In both types, patients with treatment ≤1 year ago scored 
significantly lower on SF-12 physical. This study demonstrated that TGCT has major impact on 
daily living in a relatively young and working population. Physicians and other relevant health 
care providers (e.g. physiotherapists) should be aware that TGCT patients frequently continue to 
experience declined health-related quality of life and physical function and often remain limited 
in daily activities, employment and sports, even after treatment(s).
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Extreme final treatment measures in TGCT, an above knee amputation, are presented in chapter 
12. High recurrence rates are known in diffuse-TGCT (up to 92%), necessitating reoperations and 
adjuvant treatments. Once all treatments fail or if severe complications occur, limb amputation 
may become unavoidable. Four cases treated with this last resort treatment for TGCT, an above-
knee amputation, were described.
Conclusions, clinical implications and future perspectives for the subject of this thesis are discussed 
in chapter 14.

























In the 2013 WHO classification of tumours of soft tissue and bone, giant cell tumour of the tendon 
sheath and pigmented villonodular synovitis (PVNS) were unified in one overarching name: 
tenosynovial giant cell tumours (TGCT)1, 2. To date, among most treating physicians, the disease 
still remains best known with the term PVNS3. With this thesis, we want to create disease awareness 
and update knowledge on disease and treatment outcome.
TGCT is a rare heterogeneous disease (chapter 2) with a wide clinical spectrum; patients of all ages 
are affected (chapter 5 and 6), including different joints (both small and large), various disease 
stages and severities. This heterogeneity challenges research initiatives, as current literature mainly 
consists of relatively small single centre observational case-series that often compare apples to 
oranges. Frequently, series have a retrospective design and level of evidence is not exceeding level 
III-IV. To achieve solutions on unmet medical needs, we need to set up research projects that reach 
higher levels of evidence through thorough (inter)national, multicentre collaborative studies.
1. Translational research
The translocation (1;2)(p13;q35) that is responsible for overexpression of Colony Stimulating Factor 
1 (CSF1), is thought to be the driver mechanism of this disease4, 5. It remains unclear when and 
why this translocation forms, but it remains a ‘local problem’ as TGCT is a mono-articular disease. 
An unravelled clinical question is how to differentiate the biological behaviour of different TGCT-
types with clinical outcome (recurrence). All TGCT cases show CSF1 over-expression. By the use of 
correlative microscopy for CSF1 mRNA ISH and consecutive CSF1 split-apart FISH, we were able to 
detect CSF1-gene rearrangement in 76% of the TGCT cases; 77% for localized-TGCT and 75% for 
diffuse-TGCT. The relatively high percentage of rearrangement in our study could be attributed to 
our scoring on preselected areas, based on high CSF1 expression. In addition, our DNA FISH analysis, 
using bacterial artificial chromosome (BAC) clones (RP11-354C7 and RP11-96F24) bracketing 
CSF1 locus, identified not only a translocation, but also an inversion for CSF1 rearrangements. In 
diagnosing TGCT, CSF1 mRNA-ISH in combination with CSF1 split-apart FISH; using digital correlative 
microscopy, is an auxiliary diagnostic tool to identify rarely occurring neoplastic cells. Although this 
helps the diagnostic process, in chapter 3 we were unable to use this technique and differentiate for 
biological behaviour of TGCT by evaluating CSF1 over-expression or rearrangement. 
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2. Individually tailored treatment
Physical joint examination is generally nonspecific in the clinical diagnosis of TGCT. A specialized 
musculoskeletal radiologist can however diagnose TGCT on magnetic resonance (MR) imaging, 
which is the most distinctive imaging technique6-10. MR imaging can also be a differentiating tool 
to determine tumour severity staging and for evaluation of disease extent during follow-up. The 
TGCT severity classification in chapter 4 defines TGCT extension on MR imaging to classify disease 
severity. This classification, including four distinct severity-stages, could attribute to a treatment 
strategy flowchart and improve the homogeneity in clinical studies. Definitive diagnosis however 
is established by histopathology, either by biopsy or surgical resection.
The fundamental question whether curation is necessary in a locally aggressive disease often 
arises in literature. Debilitating symptoms and (progressive) joint destruction commonly 
result in treatment of the diseased tissue. At present, the choice of treatment is established by 
preference of the patient, treating physician and might differ per centre. Most common performed 
treatment is surgical excision, aiming for local tumour control. Localized-TGCT presents as a well 
circumscribed lesion and recurrence rates after arthroscopic and open synovectomy are reported 
similar (6% after arthroscopic and 4% after open synovectomy)11. Surgical treatment for the 
locally aggressive diffuse-TGCT is more challenging, as pathologic tissue can be widely spread 
and technically difficult to reach. In extensive disease (chapter 4, severe diffuse stage), irradical 
resection could be preferred with joint preservation in mind. However, higher rates of recurrences 
are described after macroscopically incomplete resections12-15. As primary treatment for diffuse-
TGCT, either an arthroscopic- or (one- or two staged) open synovectomy or a combination of these 
two treatments is performed. Physicians in favour of arthroscopic resection claim fast recovery, 
a lower complication rate and less joint morbidity13, 16-22. However, frequently at the cost of 
inadequate excision, high recurrence rates (on average 40% in diffuse-TGCT) and a theoretical risk 
of joint seeding and portal contamination11, 23. A complete synovectomy is generally impossible 
with traditional arthroscopy, therefore Blanco et al. and Mollon et al. used multiple portals in 
arthroscopic synovectomy24, 25. Chin et al. stated that knee arthroscopy is an inferior treatment 
for extra-articular TGCT26. Nowadays, open synovectomy, either one- or two-staged, is the 
preferred surgical therapy in most centres, because of clear tumour visibility and lower short term 
recurrence rates (on average 14% in diffuse-TGCT)11, 27, 28. The disadvantage of a one- or two-staged 
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open resection, could be deteriorated joint function accompanied with decreased health-related 
quality of life (chapter 9)29. A combined anterior arthroscopic- and posterior open synovectomy 
in the knee is only incidentally reported. Mollon et al. described the combined approach of an 
anterior arthroscopy and posterior open synovectomy (N=15 patients), with low recurrence 
rates25. Colman et al. retrospectively subdivided 48 diffuse-TGCT patients in three groups; either 
treatment with an arthroscopy, the combined approach or an open approach. They concluded 
that the combined approach is a feasible option because of relatively low short term recurrence 
rates (9%)30. Chapter 7 revealed that the longer the follow-up, the higher the recurrence rates. 
Localized-TGCT had a recurrence rate of 21% and diffuse-TGCT 69% after initial surgical resection 
at a tertiary oncology centre with a follow-up of more than 10 years. The suspicion arouses that 
most patients will develop a recurrence when you wait long enough. The main question remains: 
is the recurrent disease accompanied by debilitating symptoms or joint destruction?
In general, all surgical treatments harbour the risk of complications. Literature frequently lacks 
descriptions of complications. Chapter 7 reports a complication rate of 4% in localized-TGCT and 
12% in diffuse-TGCT after initial surgical treatment at a tertiary centre. Most common complication 
in diffuse-TGCT was joint stiffness, which might be difficult to prevent in surgical treatment of 
extensive disease.
In extensive diffuse disease, radical excision is next to impossible as residual tumour cells (micro- R1 
or macroscopically R2) may persist. In diffuse-TGCT, joint destruction and secondary osteoarthritis 
is frequently present. When chronic symptoms persist, joint arthroplasty might become inevitable, 
especially in large joints with tight capsules including a higher risk of bone involvement, such as 
the hip and ankle29, 31, 32. 
A combination of surgery and external beam radiation is considered in extensive or recurrent 
diffuse-TGCT. Radiotherapy may kill residual tumour cells, but possibly at the cost of increased 
(delayed) complications, especially in re-operation, and impaired functional outcome15, 33-35. Blanco 
et al. reported that partial arthroscopic synovectomy of the knee combined with external beam 
radiation might reduce the risk of recurrence (N=22 patients)24. A meta-analysis suggested that 
open synovectomy (N=19 studies) or synovectomy combined with perioperative radiotherapy 
(N=11 studies) is associated with a reduced rate of recurrence34. Mollon et al. reserved additional 
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external beam radiation for patients at high risk for local recurrence, if they had the following 
characteristics: multiple recurrent intra-articular disease, extra-articular extension, or gross 
residual disease remaining following surgery25. Currently, sufficient data including adequate 
patient numbers is lacking to support the additional value of external beam radiation in primary 
cases and should only be performed in specific extensive or recurrent diffuse-TGCT cases. 
Additional reported treatment modalities include radiation synovectomy with 90yttrium36 and 
cryosurgery37, 38, for which the therapeutic value is inconclusive and their long-term side effects 
and complications are unknown. Bickels et al. treated seven patients with diffuse-TGCT of the 
ankle with subtotal synovectomy and intra-articular 90yttrium and warned not to use 90yttrium 
as additional treatment because of unacceptable high rate of serious complications39. Gortzak et 
al. reported no significant differences in residual disease, complication rate and overall physical 
and mental health scores between patients surgically treated for TGCT of the knee with (N=34) or 
without (N=22) adjuvant 90Yttrium, after a mean follow-up of 7.3 years36. Chin et al. subdivided 
patients, after surgical resection without disease eradication, into three groups: group I 
combined arthroscopic and open synovectomy (five patients), group II combined synovectomy in 
combination with intra-articular radiation synovectomy (dysprosium-165) (30 patients), and group 
III combined resection and three months postoperatively external beam radiation (five patients). 
They concluded that group I and Group II showed similar increases in postoperative flexion 
compared with group III15. Verspoor et al. evaluated 12 patients treated with surgical synovectomy 
and additional cryosurgery. They did not find better results compared to surgical resection alone37.
Diffuse-TGCT grows locally aggressive. Therefore, systemic therapy, with possible (severe) side 
effects, seems justified in this benign but debilitating disease. Colony Stimulating Factor1 (CSF1), 
due to genomic rearrangements, is believed to be the driver mechanism in tumour formation. By 
a paracrine loop, the CSF1 excreting tumour cells, attract non-neoplastic cells, carrying the CSF1 
receptor. Interruption of this pathway is the aim of systemic targeted therapies. Targeted therapy 
might be used as treatment independently or to primarily down-stage the disease and facilitate 
consecutive surgical resection. Non-selective CSF1 inhibitor therapies with nilotinib40 or imatinib 
(chapter 8) and newer, more potent selective CSF1 inhibitors such as pexidartinib41, emactuzumab42, 
cabiralizumab43; or a monoclonal antibody such as MSC110 (clinicaltrial.gov) seem promising. 
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Results are usually tumour-centric presented, using Response Evaluation Criteria in Solid Tumors 
(RECIST); complete response, partial response, stable disease and progressive disease; and patient 
centric, using symptom improvement evaluation. In a randomized, placebo-controlled phase 3 
study, pexidartinib showed an improved overall response rate (complete response and partial 
response merged) of 39% in the pexidartinib-group (N=61) and 0% of placebo-group (N=59), after 
median six months follow-up. PROMIS physical function, worst stiffness and pain response was 
significantly better in patients treated with pexidartinib41. Emactuzumab (N=29) had an overall 
response rate of 86% and a rate of disease control of 96%, including a significant functional and 
symptomatic improvement (median follow up 12 months)42. Preliminary results of cabiralizumab 
showed partial response in 5 out of 11 patients and positive functional status improvements by 
Ogilvie-Harris score (from 2 to 7)43. Ogilvie-Harris score combines pain, synovitis, range of motion 
and functional capacity on a scale of 0 to 12.
Complete response was reported in a total of four patients; two patients treated with 
emactuzumab42 and two patients treated with imatinib, presented in chapter 8.
Reported mild side effects include edema, change of hair colour, fatigue, nausea and skin rash/
dermatitis, but also moderate to severe side effects such as neutropenia, acute hepatitis, facial 
edema, skin toxicity and fatigue. Despite these side effects, in selected patients with extensive and 
recurrent diffuse-TGCT, CSF1 inhibitors might offer a solution. Treatment optimization is yet to be 
established; optimal agent, therapy duration, timing of surgery, toxicity profile and mechanism of 
resistance.
A challenging rare subgroup of soft tissue sarcoma patients, comprises multifocal, malignant or 
metastatic disease resembling TGCT (four patients with metastatic TGCT in chapter 8 and two 
patients in chapter 11). These patients are incidentally reported in case-series44. The largest series 
of Li et al. included seven patients with malignant TGCT and concluded that these tumours should 
be regarded as a distinct sarcoma with considerable morphologic variability, metastatic propensity, 
and lethality45. As specialized centres see these patients extremely rare, upcoming research should 
reveal whether TGCT is capable of malignant transformation or whether this malignant tumour 
should be regarded a different (malignant) entity.
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To summarize, several treatment modalities in the heterogeneous disease TGCT are available. 
Current literature fails to specify patient characteristics per treatment modality and lacks 
randomized controlled trials, impeding definitive treatment of choice for each individual, based 
on efficacy and safety. A solution for the difficulty of performing a randomized controlled trial 
might be the so called stepped wedge cluster design. This is a special form of a randomised study 
in which an intervention at group level is implemented in stages46. To contribute to personalized 
treatment, careful evaluation of health-related quality of life and functional outcome (chapter 9 
and 10), not just local recurrence and complications, should be included in patient follow-up. In 
addition, large scaled studies based on individual participant data meta-analysis provide a higher 
form of evidence in comparison with small heterogeneous case series. Advantages include that 
missing data can be accounted for at the individual level, subgroup analyses can be performed 
(e.g. per affected joint) and up to date disease status or follow-up information can be updated 
continuously (chapter 7)47.
3. Centralized treatment in a multidisciplinary team
TGCT onset is typically slow and patients present with unspecified symptoms1, 2, 48, 49. Pain, swelling, 
and stiffness of the involved joint might be misinterpreted as osteoarthritis, rheumatoid arthritis, a 
meniscal tear, or other ligamentous injury50. Because of the rarity of the disease, definitive diagnosis 
may take several years and patients present with extensive disease11, 51, 52. After several (arthroscopic 
or open) synovectomies and even radiotherapy, patients are still referred to a tertiary hospital. 
Besides declined functional outcome and health-related quality of life, these patients are at risk 
of repeated recurrences, therapy resistant disease and higher risk of complications29. Continued 
inflammation, joint usuration and bone involvement may lead to articular destruction that might 
worsen (pre-existing) osteoarthritis50. By creating more public awareness, involving relevant 
dedicated health care providers (e.g. rheumatologists, general practitioners, physiotherapists), 
delay of diagnosis should be reduced by referring patients to specialized centres at an early 
stage to provide optimal treatment(s)53. Specialized centres treat multiple patients with TGCT 
and this rare disease is considered daily practice. Therefore, all members of the multidisciplinary 
team are highly trained to recognize disease specifics. Members of the multidisciplinary TGCT 
team include dedicated physicians with experience in musculoskeletal oncology in the field of 
pathology, radiology, orthopaedic oncology, arthroscopic orthopaedics, radiotherapy, medical 
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oncology and if necessary paediatric orthopaedics. To prevent end stage treatment options, such 
as limb amputation (chapter 11), centralization of treatment should become state of the art. 
Two examples of advantages of centralization of treatment are provided by the tertiary oncology 
centre in Leiden (LUMC). Every half year a patient centred newsletter is send to all patients with 
TGCT. This newsletter includes information on recent literature and (new) studies at patient level. 
In addition, the TGCT-team of the LUMC is active on Facebook, with their own up to date Facebook 
page (‘TGCT study’) and within the closed Facebook-group ‘PVNS is pants’ (chapter 10).
4. Patient-centred outcome measures
Outcome of TGCT treatments should be measured on how the patient is feeling. The mantra 
for patient-centred treatment is: don’t make the treatment worse than the problem. Perhaps a 
debilitating operation costs more than the disease itself in the view of health-related quality of life and 
joint function preservation. Taking the factor time into account is necessary, as short term satisfying 
results could emerge into deteriorated outcome in the long run. Defining specific treatment options 
for each individual patient is of utmost importance. Would this individual patient benefit more from 
conservative treatment or side effects of targeted therapy? Mild side effects might be considered 
acceptable, however moderate to severe side effects seem less justifiable in a non-lethal disease.
Assessment of health-related quality of life and functional outcome in TGCT is necessary. However, 
specific patient reported outcome instruments have yet to be defined. A few studies, including 
chapter 9 and 10, have reported disease outcome from a patient perspective15, 25, 29, 36, 48, 54, 55. Used 
validated questionnaires included worst pain and worst stiffness numeric rating scale (NRS), short 
form (SF) health survey-12 and SF-36, Euroqol 5 (EQ5D5L), knee-injury osteoarthritis outcome 
score (KOOS), hip disability osteoarthritis outcome score (HOOS), Toronto extremity salvage score 
(TESS), musculoskeletal tumour society (MSTS) score, patient reported outcomes measurement 
information system physical function (PROMIS-PF) and Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC). None of these patient reported outcome instruments are specifically 
designed for rarely lethal, but morbid musculoskeletal tumours. Gelhorn et al. performed research 
interviews regarding symptom experience to test the relevance and content validity of several 
existing patient reported outcome instruments. They recommended PROMIS-PF as most suitable 
questionnaire48. PROMIS-PF is subdivided in an upper- (11 questions) and lower-extremity part (13 
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questions). Since TGCT affects all joints, measurements eligible for all these locations would be the 
aim. In addition, general health-related quality of life measures are important to compare TGCT 
with other musculoskeletal disorders.
A major disadvantage of standardized questionnaires is that they include questions not applicable 
for each individual participant. Therefore, the item response theory (IRT) and Computer Adaptive 
Testing (CAT) are developed. IRT examines the response characteristics of individual items and 
the relationship between responses to individual items and the responses to each other item 
in a domain. By using IRT, CAT is a method that selects subsequent questions (from the item 
bank) based on the responses until predetermined termination criteria are met. Hereby only 
relevant questions are asked and the amount of questions is greatly reduced. This ensures a 
higher amount of patients willing to complete the questionnaire56. Relevant questions could be 
extracted from the PROMIS databank, including over 300 measures of physical, mental, and social 
health for use with the general population and with individuals living with chronic conditions
(http://www.healthmeasures.net). For future self-reported outcome evaluations in TGCT, we 
would propose the CAT method by use of the PROMIS item bank.
Besides well-defined subjective outcome measures, objective outcome measures also need to be 
determined to structure clinical evaluation. The timed up and go test provides information on 
physical strength by measuring the time (seconds) to rise from and return to a chair with three 
meters walking in between57. Another functional measure is the six-minute walk test, not just 
determining joint range of motion, but looking at performance of the individual58.
5. Limitations
This thesis consists of multiple cohort studies. At times, patients are present in several cohorts. 
Patients treated in the RadboudUMC or LUMC, were also present in the PALGA search to calculate 
the incidence (chapter 2). In the evaluation of impact on daily living (chapter 11), a Facebook 
cohort is used in which Dutch patients were present, which were also registered with the PALGA 
search. This overlap of patients in the cohort studies could have influenced the results. However, 
since each study had a unique research question to evaluate different aspects of the disease, this 
influence is considered minimal.
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To conclude, TGCT is a chronic debilitating illness with large impact on daily living. It is a challenge 
for physicians to provide optimal personalized treatment, since TGCT patients present as a 
heterogeneous group, trials with targeted therapies are ongoing and a standardized treatment 
algorithm is lacking. Based on our experience, literature and the TGCT severity classification 
on MR imaging* (chapter 4), we propose a treatment algorithm for TGCT of all large joints as 
a foundation to build upon and to evolve (figure 1 and figure 2). In addition to the physical and 
financial burden for the patient, TGCT also involves a high healthcare burden with rising costs after 
diagnosis59. Current developments are promising: increasing disease awareness, centralization 
of care, several targeted therapy trials, evaluation of personalized follow-up questionnaires and 
ongoing prospective international collaboration studies. These initiatives should be expanded to 
achieve new insights in TGCT.
*The TGCT severity classification on MR imaging contains four distinct severity stages:
1. Mild localized contains localized-type, either intra- or extra-articular involvement 
without involvement of muscular/tendinous tissue/ligaments.
2. Severe localized includes localized-type, either intra- or extra-articular lesions and 
either or both involvement of muscular/tendinous tissue/ligaments.
3. Moderate diffuse comprises diffuse-type with intra- and/or extra-articular disease 
without involvement of muscular/tendinous tissue/ligaments.
4. Severe diffuse is diffuse-type including intra- and extra-articular involvement and 
involvement of at least one of the three structures (muscular/tendinous tissue/ligaments) 





The driver mechanism in TGCT tumour formation seems to be over-expression of CSF1. Only 
a minority (2-16%) of cells in the tumorous tissue harbour the CSF1 rearrangement4, 5. Despite 
the few tumour cells, they disrupt the entire surrounding area in different degrees of extent. We 
expect the neoplastic cell to be a synovial like mononuclear cell, as was proposed by West et 
al.4 They reported that CSF1 expressing cells also express CD68, without CD163 co-expression, 
and therefore expect CSF1 expressing neoplastic cells to be derived from synovial-lining cells. 
Identification of this neoplastic cell could attribute in investigations of new treatment modalities.
Dynamic contrast-enhanced MR imaging and histopathology research revealed high vascularization 
in both localized- and diffuse-TGCT, showing marked enhancement on T1-weighted images with 
a delayed wash-out60, 61. Angiogenesis is induced by CSF1 through vascular endothelial growth 
factor (VEGF)62. Formation of blood vessels is fundamental for tumour development. A possible 
therapeutic target would be to control this increased vascularity by inhibiting VEGF, for example 
with Bevacizumab (Avastin)63.
2. Individually tailored treatment
It is unclear whether curation of diffuse-TGCT is possible at present, since residual tumour cells 
(micro- R1 or macroscopically R2) remain after surgical resection, optimal targeted therapy is 
under investigation and treatment with other therapies is inconclusive. A common question 
arises: is wait and see or conservative treatment justified in the locally aggressive diffuse-TGCT? 
Forthcoming research should provide answers on degree of joint destruction and (impaired) 
health-related quality of life in a wait and see or conservative treatment course.
Currently, data on tumour progression after quitting targeted therapy treatment is lacking. Future 
investigations should focus hereon. Also, several experimental studies with targeted therapy can 
be thought of, for example investigation of intermittent use (drug holidays), the possibility of intra-
articular injection and the option of isolated limb perfusion with CSF1 blockers/inhibitors. 
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Figure 2 (right page)  Proposed treatment algorithm for diffuse-TGCT of large joints to be 
discussed in a multidisciplinary soft tissue tumours team. Treatment proposal should balance 
between disease severity and potential treatment morbidity and should be individually 
tailored for each patient. Wait and see and conservative treatment are considered similar, 
but should include a (2-)yearly MR imaging for follow-up to evaluate possible progressive 
disease (T1- and T2-weighted fast spin echo, possibly other fluid sensitive sequences, and 
preferably a scan after administration of contrast). Excision for functional improvement and 
joint preservation should be proposed in symptomatic patients. An open synovectomy could 
be preferred above an arthroscopic synovectomy in extra-articular disease (chapter 7), to 
reduce the risk of recurrence. External beam radiation therapy can only be advised in recurrent 
or severe diffuse cases and might be succeeded by targeted therapy in the near future. If 
arthroplasty is anticipated, radiotherapy should not be considered lightly. As the preferred 
dosage of radiotherapy is unknown, a moderate dose is recommended. Since targeted 
therapy trials are ongoing, no specific targeted therapy is advised. The timing and duration 
of (neo)adjuvant targeted therapy around surgery should be subject of future research.
Figure 1  Proposed treatment algorithm for localized-TGCT of large joints. Balance between disease severity 
and potential treatment morbidity should be individually tailored for each patient. Wait and see and 
conservative treatment are considered similar. Open resection could be preferred above an arthroscopic 
resection to potentially reduce the risk of recurrence, but arthroscopic resection should not be excluded as a 






















































































































































































































































Future treatment studies should combine current knowledge into new studies to improve 
treatment modalities. Recurrent disease, (short- and long-term) complications, health-related 
quality of life and joint function should be evaluated as outcome. Patients could be stratified by the 
TGCT severity classification (chapter 4), that may be improved by using biological differentiation 
using next generation sequencing or new MR imaging techniques. In a prospective cohort study, 
several different treatment groups could be evaluated and compared:
	 Wait and see/conservative treatment in case of mild symptoms
	 Surgical treatment (open versus arthroscopic resection, one versus two-staged 
synovectomy)
	 Neoadjuvant targeted therapy + surgical treatment
	 Surgical treatment + adjuvant targeted therapy
	 Neoadjuvant external beam radiation + surgical treatment
	 Surgical treatment + adjuvant external beam radiation
The intervention at group level could be implemented in stages, by use of the stepped wedge 
cluster design46. Best modality to monitor response of tumour activity is yet to be established. 
There might also be a role for dynamic contrast-enhanced MR imaging or fluorodeoxyglucose-
positron emission tomography (FDG-PET), as TGCT shows high FDG update64.
Evaluation of different treatment modalities, patient characteristics, disease severity and biological 
behaviour could result in a prediction model. This prediction model should predict individual risk 
profiles, that can then be linked to recommended treatment strategies and should take patient 
characteristics, affected joint, volume of disease, disease extent, performed treatment(s) and 
possibly histopathologic or genetic features into account.
3. Centralized treatment in a multidisciplinary team
The current trend in rare diseases is centralization of treatment that necessitates (highly) specialized 
expertise. Diffuse-TGCT treatment should sail along this trend. In addition, centralization of diffuse-
TGCT treatment could be realized by creating more public awareness and easy available reliable 
information.
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4. Patient-centred outcome measures
For future self-reported outcome evaluations in TGCT, the CAT method by use of the PROMIS item 
bank could be used. Preferably in the form of an easy accessible application on a mobile device. A 
new feature could be to not only link the application to the electronic patient dossier, but to also 
provide feedback to each individual patient personally, on how they are performing in the field of 
physical, mental and social health compared with themselves at specified time periods previously. 
As TGCT is known with recurrent disease developing years after initial surgical treatment, patients 
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Tenosynoviale reusceltumoren (tenosynovial giant cell tumours, TGCT) zijn zeldzame goedaardige 
tumoren. Deze aandoening werd voorheen pigmented villonodular synovitis (PVNS) genoemd. 
De tumoren ontstaan vanuit het synoviale membraan van een gewricht – het membraan 
dat de gewrichtsvloeistof aanmaakt, vanuit de peesschede of de slijmbeurs. Een TGCT kan 
gewrichtsklachten geven als pijn, zwelling, stijfheid of bewegingsbeperking in verschillende mate 
van ernst. Hierdoor kan de tumor een hoge morbiditeit veroorzaken in een relatief jonge, werkende 
populatie. Op grond van klinische en radiologische kenmerken worden twee typen onderscheiden: 
het gelokaliseerde type dat zich uit als een goed afgrensbare nodus, en het diffuse type dat lokaal 
invasief is. TGCT kan behandeld worden met een operatie, een medicijn in onderzoeksverband en 
eventueel aanvullend radiotherapie. Het is nog niet bekend welke behandeling het meest effectief 
is. Het vaststellen van de meest geschikte behandeling is uitdagend doordat de tumor zo zeldzaam 
is, patiënten erg van elkaar verschillen en elke behandeling andere nadelen (bijwerkingen, 
recidieven, complicaties) kent. 
Het doel van dit proefschrift was de kennis te verbeteren van de pathofysiologie en het biologisch 
gedrag van TGCT, van het diagnostisch proces bij deze aandoening en van de kwaliteit van leven 
bij TGCT-patiënten, om betere behandelmethoden te vinden. Door bewustzijn te creëren en 
publiciteit te genereren, wordt bijgedragen aan de verbetering van de medische behandeling 
van TGCT. In dit proefschrift worden verscheidene kennishiaten gedicht op het gebied van de 
incidentie, histopathologische en hormonale karakteristieken, stratificatie van ziekte-ernst en 
ziektelast bij kinderen. Daarnaast zijn de langetermijneffecten van systemische doelgerichte 
therapie en de kwaliteit van leven na chirurgische behandeling onderzocht. Tenslotte wordt in 
dit proefschrift de grootst bekende, wereldwijde studie gepresenteerd met individuele data van 
patiënten met gelokaliseerde of diffuse TGCT.
Actuele incidentieberekeningen zijn noodzakelijk voor het diagnostisch proces. In hoofdstuk 
2 is het wereldwijde incidentiecijfer berekend voor TGCT in vingers en/of tenen, gelokaliseerde 
TGCT van de grote gewrichten, en voor diffuse TGCT. De tot nu toe gehanteerde TGCT-incidentie, 
gebaseerd op een provinciale Amerikaanse studie uit 1980, is 9,2 voor het gelokaliseerde type 




Door middel van het Pathologisch Anatomisch Landelijk Geautomatiseerd Archief (PALGA) 
werden alle mogelijke TGCT-patiënten in Nederland geïdentificeerd, die in een periode van vijf 
jaar waren gediagnosticeerd. De diagnose werd geverifieerd op basis van de klinische data in de 
lokale ziekenhuizen. De Nederlandse incidentiecijfers zijn op basis van leeftijdsopbouw omgezet 
naar wereldwijde incidentiecijfers. De hiermee berekende  incidentie is voor TGCT van vingers en 
tenen 29, voor het gelokaliseerde type van grote gewrichten 10, en voor het diffuse type 4 per 
miljoen persoonsjaren. In alle drie de groepen waren vrouwen oververtegenwoordigd en was de 
incidentie het hoogst in de leeftijdscategorie 40 tot 59 jaar. De knie was het vaakst aangedaan: bij 
65% van de patiënten met gelokaliseerd type TGCT en bij 49% van de patiënten met diffuus type. 
Het aantal heroperaties vanwege een lokaal recidief was 9% bij gelokaliseerde en 23% bij diffuse 
TGCT. Vergeleken met de oorspronkelijke incidentiestudie uit Amerika, toont deze studie een 5 keer 
verhoogde incidentie voor gelokaliseerde type (vingers, tenen en grote gewrichten gecombineerd) 
en een 2,6 keer zo hoge incidentie voor diffuus type TGCT. Deze hogere incidentie zou verklaard 
kunnen worden door onze landelijke dekking en vanwege groeiende bekendheid met de ziekte.
Het onderzoek beschreven in hoofdstuk 3 is gericht op de tegenstrijdigheid dat gelokaliseerd 
en diffuus type TGCT klinisch en radiologisch verschillend zijn, maar histopathologisch niet 
te onderscheiden zouden zijn. De belangrijkste stimulans voor tumorformatie in TGCT is 
een overvloedige expressie van de Colony Stimulating Factor 1 (CSF1), veroorzaakt door een 
genetische translocatie. Deze studie onderzocht of er een correlatie bestond tussen de expressie 
en genetische herstructurering van CSF-1, en het biologisch gedrag en klinische uitkomst van 
beide TGCT-subtypes – waarbij klinische uitkomst werd gedefinieerd als lokaal recidief. Langs 
een continuüm van uitersten werden patiënten geselecteerd die niet eerder behandeld waren 
voor TGCT van hun knie en een follow-up van minstens 3 jaar hadden. Negen patiënten met 
gelokaliseerde (2 recidieven), 15 met diffuse TGCT (9 recidieven) en 4 patiënten met synovitis (als 
controle) werden geïncludeerd. De gemiddelde leeftijd was 43 (spreiding 6-71) jaar en 56% was 
vrouw. De combinatie van de technieken CSF1-split apart-FISH (fluorescence in situ hybridization) 
na mRNA-in situ hybridization bleek een diagnostisch hulpmiddel. Hiermee werd in 76% van 
de tumoren genetische herstructurering van CSF-1 gedetecteerd. Concluderend, er werd geen 
duidelijk verband gevonden tussen CSF1-expressie en CSF1-herstructurering met biologisch 
gedrag en klinische uitkomst. 
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Binnen het gelokaliseerde en diffuse type TGCT bestaat een grote verscheidenheid in ziekte-ernst. 
Daarom is in hoofdstuk 4 een classificatie ontwikkeld gebaseerd op ziekte-uitgebreidheid, om 
te kunnen stratificeren tussen verschillende ziektestadia. Als eerste hebben experts parameters 
gedefinieerd om de uitgebreidheid van ziekte te beschrijven op basis van een MRI scan. Vier 
parameters kwamen vaker dan 20% voor op MRI, toonden goede overeenkomst binnen en tussen 
beoordelaars (kappa ≥0.66) en toonden een positieve correlatie met een lokaal recidief: 1. het 
TGCT-type, 2. betrokkenheid van het gewricht, 3. betrokkenheid van spier- of pees-weefsel; en 
4. betrokkenheid van ligament(en). Vervolgens werd de TGCT severity classificatie voor grote 
gewrichten geconstrueerd. Op basis van hazard ratio’s van de vier genoemde parameters, 
aflopend van hoog naar laag, werd een classificatie met vier onderscheidende ziektestadia 
gemaakt. De recidiefvrije overleving na 4 jaar (log rank p<0.0001) was 94% voor het mild localized-
stadium, 88% voor severe localized, 59% voor moderate diffuse en 36% voor het severe diffuse-
stadium. Met deze TGCT severity classificatie wordt zowel de arts als de patiënt geïnformeerd over 
ziekte-uitgebreidheid en het risico op een eerste, lokaal recidief na chirurgische behandeling. 
Deze classificatie kan bijdragen aan de identificatie van geschikte patiënten voor systemische 
doelgerichte therapie of voor trials met nieuwe medicijnen. Daarnaast kan het toepassen van deze 
classificatie, door de data meer objectiveerbaar te maken, de uitkomsten van wetenschappelijk 
onderzoek naar TGCT vergelijkbaarder maken. 
Patiënten rapporteren een toename van TGCT-gerelateerde klachten tijdens zwangerschap, zowel 
bij polikliniekbezoeken als op online TGCT-patiëntenfora. Onze hypothese was dat dit veroorzaakt 
wordt door veranderingen in vrouwelijke geslachtshormonen. Geslachtshormonen (oestrogeen 
en progesteron) stijgen tijdens de zwangerschap. Hoofdstuk 5 beschrijft het eerste onderzoek 
naar de invloed van vrouwelijke geslachtshormonen op symptomen van TGCT. Vijfenzestig procent 
van de onderzochte zwangeren rapporteerden middels een vragenlijst een toename van TGCT-
gerelateerde symptomen, voornamelijk zwelling van het aangedane gewricht. De invloed van 
geslachtspecifieke hormonen en van de vrouwelijke vruchtbare leeftijdsfasen werden beoordeeld 
door het vergelijken van de recidiefvrije overleving tussen mannen en vrouwen, en tussen pre- 
en  postmenopauzale vrouwen. Er werd geen verschil gevonden in recidiefvrije overleving voor 
geslacht (gelokaliseerd type TGCT (p=0.206 ≤50 jaar, p=0.935 >50 jaar; diffuse type (p=0.664 ≤50 




type (p=0.106); diffuse type (p=0.666)). Dit resultaat maakt een causale relatie tussen vrouwelijke 
geslachtshormonen en lokaal recidief erg onwaarschijnlijk. Daarnaast werd de oestrogeen- en 
progesteronreceptor status onderzocht in TGCT-weefsel van zowel het diffuse als gelokaliseerde 
type. Deze receptoren bleken afwezig. Dus ook op histopathologisch niveau werd geen verband 
gevonden tussen toename van vrouwelijke hormonen en de toename van de TGCT-gerelateerde 
klachten tijdens zwangerschap.
Medische publicaties over TGCT bij kinderen zijn zeldzaam: na onze systematische review blijkt 
slechts over 76 kinderen met TGCT gepubliceerd te zijn. In hoofdstuk 6 worden de klinische 
kenmerken en beloop van TGCT bij kinderen vergeleken met die bij volwassenen. Daarnaast wordt 
de incidentie op de kinderleeftijd berekend. De gestandaardiseerde pediatrische TGCT-incidentie 
van grote gewrichten was 2,42 en 1,09 per miljoen persoonsjaren in respectievelijk gelokaliseerde 
en diffuse TGCT. In vier tertiaire sarcoom-centra in Nederland zijn 57 kinderen gediagnosticeerd 
en behandeld tussen 1995 en 2001. Gerapporteerde symptomen waren pijn, zwelling en beperkte 
bewegingsuitslag met een mediane duur van symptomen van 12 (range 1-72) maanden. Er 
was geen verschil tussen kinderen en volwassenen ten aanzien van geslacht, symptomen voor 
diagnose, gelokaliseerde of diffuse type, eerste behandeling, percentage lokaal recidief, follow-
upstatus of follow-upduur. De 2.5 jaar recidiefvrije overleving na open resectie was vergelijkbaar 
tussen kinderen en volwassenen: respectievelijk 85% (95%CI 67%-100%) versus 89% (95%CI 83%-
96%) bij het gelokaliseerde type (p=0.527) en respectievelijk 53% (95%CI 35%-79%) versus 56% 
(95%CI 49%-64%) bij het diffuse type (p=0.691). Ondanks de lage pediatrische incidentie zou TGCT 
in de differentiaaldiagnose moeten staan bij kinderen met langdurige zwelling van één gewricht. 
De kans op recidief-ziekte na chirurgische behandeling van deze aandoening is vergelijkbaar voor 
kinderen en volwassenen.
In hoofdstuk 7 en hoofdstuk 8 wordt de tot nu toe grootste serie patiënten beschreven met 
gelokaliseerd of diffuus type TGCT. Er werden 2169  patiënten geïncludeerd (941 gelokaliseerd, 
1192 diffuus en 36 onbekend type) met histologisch bewezen TGCT van grote gewrichten, 
behandeld tussen 1990 en 2017 in één van de 31 deelnemende internationale sarcoomcentra. 
Van de patiënten met gelokaliseerd type TGCT (hoofdstuk 7) was 62% vrouw, met een mediane 
leeftijd tijdens eerste behandeling van 39 jaar, en een mediane follow-up van 37 maanden. De 
312
Chapter fifteen
knie was aangedaan in 67% en de initiële behandeling in een tertiair centrum was open resectie 
in 71% van de patiënten. In totaal kreeg 13% van de patiënten een recidief, met een recidiefvrije 
overleving op 3, 5 en 10 jaar van respectievelijk 88%, 83% en 79%. De grootste risicofactor voor 
een lokaal recidief was het hebben van een eerder recidief (p<0.001). In 4% van alle chirurgisch 
behandelde patiënten met gelokaliseerde TGCT werd een complicatie geregistreerd. Initiële 
symptomen van pijn en zwelling verbeterden na chirurgische behandeling bij respectievelijk 71% 
en 85% van de patiënten. Wanneer alleen niet eerder behandelde patiënten werden geïncludeerd, 
werd een positieve associatie gevonden met een lokaal recidief bij een tumor grootte ≥5 cm (versus 
<5cm [HR 2.50(95%CI 1.32-4.74;p=0.005)]) en na behandeling met arthroscopie (versus open 
[HR 2.18(95%CI0.98-4.84;p=0.056)]). Deze associatie bleek zowel uit univariate als multivariate 
analyses. Het relatief lage complicatierisico en de goede functionele uitkomsten ondersteunen de 
keuze voor een open, complete resectie bij patiënten met een gelokaliseerde TGCT en een hoog 
risico op recidieven, met als doel recidiefpercentages verder te verlagen.
Van de patiënten met een diffuus type TGCT (hoofdstuk 8) was 58% vrouw, met een mediane 
leeftijd van 35 jaar en een mediane follow-up van 54 maanden. Het kniegewricht was aangedaan 
in 64%; en 53% van de patiënten onderging als initiële behandeling een one-staged open 
synovectomie in een tertiair centrum. In totaal kreeg 45% van de patiënten een lokaal recidief, 
met een recidiefvrije overleving op 3, 5 en 10 jaar van respectievelijk 62%, 55% en 40%. Het 
eerder hebben gehad van een recidief bleek de grootste risicofactor voor recidief van de ziekte 
(HR 3.5 95%CI 2.8-4.4, p<0.001), met een 5 jaar recidiefvrije overleving van 64% in niet eerder 
behandelde patiënten, vergeleken met 25% bij patiënten die elders behandeld waren en met een 
recidief naar een tertiair centrum werden verwezen. 12% van de patiënten had een complicatie 
als gevolg van de chirurgische behandeling. Initiële symptomen van pijn en zwelling verbeterden 
na operatie bij respectievelijk 59% en 72% van de patiënten. In een subgroepanalyse van niet 
eerder behandelde patiënten met TGCT in de knie, behandeld in een tertiair centrum, werd geen 
verband gevonden tussen het optreden van een lokaal recidief en de volgende factoren: geslacht, 
leeftijd (jonger dan 35 jaar of 35 en ouder) bot-betrokkenheid (wel of niet), chirurgische techniek 
(open of arthroscopisch) en tumor grootte (kleiner dan 5cm of 5cm en groter). Onze conclusie 
is dat een op zichzelf staande chirurgische behandeling niet langer de gouden standaard moet 




van multimodale therapieën. De onmogelijkheid van het uitvoeren van een radicale resectie van 
diffuse TGCT, verklaart waarschijnlijk het onacceptabel hoge recidief percentage na zowel open als 
arthroscopische resectie, zelfs in gespecialiseerde centra.
Hoofdstuk 9 beschrijft de lange termijneffecten van het gebruik van imatinib mesylaat, een niet-
selectieve CSF1-remmer, bij patiënten met diffuus type TGCT. In totaal 62 patiënten uit 12 centra 
in Europa, Australië en de Verenigde Staten van Amerika gebruikten imatinib als behandeling. In 
deze groep waren 39 patiënten vrouw (63%), met een mediane leeftijd van 45 jaar ten tijde van de 
start van de behandeling en een mediane duur vanaf diagnose tot start van de behandeling van 
3,5 jaar. De mediane follow-up vanaf start van de behandeling was 52 maanden. Vier patiënten 
met metastasen van TGCT werden geëxcludeerd uit de analyses wegens ernstige ziekteprogressie, 
ondanks behandeling met imatinib. Van de overgebleven 58 patiënten bereikten 17 gehele of 
gedeeltelijke respons (29%). De progressievrije overleving van de gehele groep na 1 en 5 jaar 
waren respectievelijk 71% en 48%. 38 patiënten stopten met gebruik van imatinib na 7 maanden 
(66%). Gerapporteerde bijwerkingen in 45 (78%) patiënten waren voornamelijk graad 1-2 (89%) 
(zoals oedeem (48%) en moeheid (50%)). Vijf patiënten ervaarden graad 3-4 toxiciteit, inclusief 
neutropenie, acute hepatitis, gezichtsoedeem, huidtoxiciteit en moeheid. 
Deze studie bevestigt de werkzaamheid van een tyrosinekinaseremmer zoals imatinib in 
TGCT. Zelfs na staking van de behandeling werd effect gezien, echter met hoge percentages 
behandelonderbrekingen en additionele behandelingen (zoals operaties). Deze resultaten geven 
richting aan het effect van imatinib, met als beperking het retrospectieve studie karakter, het 
ontbreken van een controlegroep en het ontbreken van patiëntgerapporteerde uitkomstmaten.
Hoofdstuk 10 beschrijft een prospectieve cohortstudie naar gewrichtsfunctie en 
gezondheidgerelateerde kwaliteit van leven-uitkomsten na chirurgische behandeling, om de 
patiëntgerapporteerde uitkomstmaten te evalueren. In totaal 206 opeenvolgende patiënten 
met gelokaliseerd (N=108) en diffuus type (N=98) TGCT van grote gewrichten, behandeld met 
arthroscopische of open synovectomie in het Leids Universitair Medisch Centrum of Radboud 
Universitair Medisch Centrum, werden geïncludeerd. Patiënten rapporteerden middels het 
Short Form 36 (SF-36), de Visual Analogue Scale (VAS) en de Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC). Bij zowel gelokaliseerde als diffuse TGCT scoorden 
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de patiënten vooral op de fysieke component van de SF-36-subschalen significant en klinisch 
relevant slechter pre-operatief en direct postoperatief vergeleken met de algemene bevolking. 
Zes maanden na chirurgische behandeling verbeterden de SF-36 scores naar de gemiddelden 
van de algemene populatie; deze bleven de volgende jaren tamelijk stabiel. Mediane pijnscores, 
gemeten middels de VAS, vertoonden geen klinisch relevant verschil pre- of postoperatief, in geen 
van beide subtypes. Pijnbeleving verschilde enorm tussen patiënten en in de tijd. Gemiddelde 
functiescores (WOMAC) vertoonden in beide subtypes geen klinisch relevant verschil (effect size 
< MCID 20) pre- versus postoperatief. Echter, bij diffuse TGCT-patiënten toonden pijnscores en 
fysieke functiescores uit de WOMAC een trend richting verbetering pre- versus postoperatieve 
scores. Op alle drie de onderzochte schalen rapporteerden patiënten een significant betere 
gezondheidgerelateerde kwaliteit van leven na chirurgie voor hun TGCT, en een trend richting 
verbetering van gewrichtsfunctie. 
In de grootst bekende TGCT-patiënten groep werd in hoofdstuk 11 de impact van TGCT op het 
dagelijks leven onderzocht. De volgende aspecten werden geëvalueerd: fysieke functie, dagelijkse 
activiteiten, sociale participatie (werk, sport en hobby’s) en gezondheidgerelateerde kwaliteit 
van leven. Een tweede doel was het definiëren van risicofactoren voor verslechterde uitkomsten 
bij TGCT, door middel van vier gevalideerde vragenlijsten: VAS worst pain and stiffness; Patient 
Reported Outcomes Measurement Information System for Physical Function (PROMIS-PF); SF-12 
en EuroQoL (EQ-5D-5L). Gedurende zes maanden werden TGCT-patiënten uitgenodigd om de 
online vragenlijsten in te vullen. Patiënten werden verzocht om histologisch of radiologisch bewijs 
van TGCT te delen om ziekteaanwezigheid en TGCT-subtype te bevestigen. In totaal werden 337 
vragenlijsten volledig ingevuld (32% met ziektebevestiging), door patiënten afkomstig uit 30 
landen. De mediane leeftijd tijdens de diagnose was 33 (IQR 25-42) jaar, en de meerderheid was 
vrouw (80%) en had een tumor van het diffuse type (70%) in een van de onderste ledematen: knie 
(71%) en heup (10%). Het recidiefpercentage was 36% bij gelokaliseerde en 70% bij diffuse TGCT, 
van in totaal 299 patiënten met TGCT in een onderste extremiteit. Ruim 1 op de 10 patiënten was 
door de TGCT niet in staat om zijn of haar werk (volledig) uit te voeren (gelokaliseerde 13%, diffuse 
type 11%). Meer dan de helft van de patiënten was niet in staat om sportactiviteiten te beoefenen 
(gelokaliseerde type 58%; diffuse type 64%). In beide subtypes verminderden pijn en zwelling na 




kraakbeenslijtage en verklevingen, veroorzaakt door (meerdere) chirurgische behandelingen, 
kunnen de toegenomen stijfheid en bewegingsbeperking verklaren. Vergeleken met de algemene 
Amerikaanse bevolking toonden alle patiënten een klinisch relevant lagere PROMIS-PF-scores, 
fysieke en mentale scores op de SF-12 en EQ-5D-5L-utiliteitscores. Wanneer het gelokaliseerde 
en het diffuse type met elkaar vergeleken worden, scoorden patiënten met het diffuse type bijna 
0,5 standaarddeviatie lager op de PROMIS-PF (p<0,001), en 5% lager op de EQ-5D-5L (p=0,03). 
Bij patiënten met het gelokaliseerde type had de aanwezigheid van een recidief en 2 of meer 
operaties een negatieve invloed op de pijn- en stijfheidscores op de VAS, fysieke scores op SF-12 
en EQ-5D-5L-scores (p<0,05). In diffuse-type resulteerde recidief ziekte in lagere VAS-pijn/stijfheid, 
PROMIS-PF, SF12 mentaal en EQ-5D-5L scores (p<0,05). In beide types scoorden patiënten met 
behandeling korter dan 1 jaar geleden significant lager op de fysieke component van de SF-12. 
Deze studie toont aan dat TGCT een grote impact heeft op het dagelijks leven in een relatief 
jonge werkende patiëntenpopulatie. Artsen en andere betrokken zorgverleners, bijvoorbeeld 
fysiotherapeuten, dienen zich ervan bewust te zijn dat TGCT-patiënten frequent een verminderde 
kwaliteit van leven en beperkingen in hun fysiek functioneren ervaren en dat ze gehinderd blijven 
in dagelijkse activiteiten zoals werk en sportactiviteiten, zelfs na behandeling(en).
Hoofdstuk 12 beschrijft een extreme, definitieve behandelingsmaatregel bij TGCT: een 
bovenbeenamputatie. Bij diffuse TGCT is er zeer vaak sprake van recidieven (tot wel 92% 
beschreven), die heroperaties en aanvullende behandelingen noodzakelijk maken. Als alle 
behandelingen falen of ernstige complicaties optreden, kan amputatie onvermijdelijk zijn. Dit 
hoofdstuk beschrijft vier ziektegeschiedenissen waarin een amputatie van het bovenbeen het 
laatste redmiddel bleek.
Concluderend, TGCT is een chronische ziekte met een grote impact op het dagelijks leven. Voor 
artsen is het uitdagend om de optimale gepersonaliseerde behandeling te bewerkstelligen, omdat 
TGCT patiënten erg van elkaar verschillen, trials met doelgerichte therapie nog gaande zijn en er 
geen gestandaardiseerd behandel algoritme bestaat. Als fundament en om verder te ontwikkelen 
wordt een behandel algoritme voorgesteld voor TGCT van alle grote gewrichten in hoofdstuk 
14. Dit algoritme is gebaseerd op onze ervaring, de literatuur en de TGCT severity classificatie op 
MRI scans (hoofdstuk 4). Naast de fysieke en financiële last voor de patiënt zorgt TGCT ook voor 
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stijgende medische kosten na diagnose. Huidige ontwikkelingen zijn veelbelovend: groeiend 
bewustzijn, centralisatie van zorg, verscheidene doelgerichte therapie trials, evaluatie van 
gepersonaliseerde follow-up vragenlijsten en lopende prospectieve internationale samenwerking 
studies. Deze initiatieven moeten uitgebreid worden om nieuwe inzichten te krijgen in TGCT.
De discussie, klinische implicaties en toekomstperspectieven over het onderwerp van dit 
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